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 ABSTRACT 
An epidemic that has had profound impact on humanity both culturally and health-wise in recent 
decades is the Acquired immunodeficiency syndrome (AIDS) triggered by the Human 
immunodeficiency virus (HIV).  The developments of drugs, impeding specific enzymes essential 
for the replication of the HIV-1 virus, has been a breakthrough in the treatment of the virus.  These 
enzymes include the HIV-1 protease (PR), which is a significant degrading enzyme necessary for 
the proteolytic cleavage of the Gag and Gag-Pol polyproteins, needed for the maturation of viral 
protein.  The catalytic mechanism of the HIV-1 PR of these polyproteins is a major subject of 
investigation over the past decades. 
Most research on this topic explores the HIV-1 PR mechanism of action on its target as a stepwise 
general acid-base mechanism with little or no attention to the concerted process.  Among the 
limitations of the stepwise reaction model is the presence of more than two transition state (TS) 
steps and this led to different views on the precise rate-determining step of the reaction as well as 
the protonation state of the catalytic aspartate in the active site of the HIV-1 PR.   Likewise, 
consensus on the exact recognition mechanism of the natural substrates by HIV-1 PR is not 
forthcoming. The present study investigates the recognition approach and mechanism of reaction 
of the HIV-1 PR with its natural substrate by a means of computational models.  It is intended to 
explain the cleavage mechanism of the reaction as a concerted process through the application of 
in-silico techniques.  This is achieved by computing the activation energies and elucidating the 
quantum chemical properties of the enzyme-substrate system.  An improved understanding of the 
mechanism will assist in the design of new HIV-1 PR inhibitors.  
The molecular dynamics (MD) technique with hybrid quantum mechanics and molecular 
mechanics (QM/MM) method that includes the density functional theory (DFT) and Amber model 
were utilized to investigate the concerted hydrolysis process.  Based on previous studies in our 
group involving concerted TS modeling, a six-membered ring TS pathway was first considered.  
This was achieved by employing a small model system and QM methods (Hartree-Fock and DFT) 
for the enzymatic mechanism of the HIV-1 PR.  A general-acid base (GA/GB) model where both 
catalytic aspartate (Asp) groups are involved in the mechanism, and the water molecule at the 
active site attacks the natural substrate synchronously, was utilized.  A new perspective arose from 
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the study where an acyclic concerted computational model offered activation energies closer to 
experiment observations than the six-membered ring model.  Hence, the proposed concerted 
acyclic mechanism of the HIV-1 natural substrate within the entire protease was investigated using 
both multi-layered QM/MM “Our own N-layered Integrated molecular Orbital and molecular 
Mechanics” (ONIOM) theory and QM/MM MD umbrella sampling method.   
A comprehensive review about experimental and theoretical results for the interactions between 
HIV PR and its natural substrates was presented.  An important output in the present study is that 
the acyclic TS model barrier with one water molecule at the HIV-1 PR active site (DFT study), 
provides marginally, the most accurate activation energies.  Similarly, the computational model 
demonstrated that optimum recognition specificity of the enzyme depends on structural details of 
the substrates as well as the number of amino acids in the substrate sequence (minimum P5-P5ʹ 
required).  By modelling the entire enzyme—substrate system using a hybrid ONIOM QM/MM 
method, it was observed that although both subtype B and C-SA HIV-1 PR recognize and cleave 
at the scissile and non-scissile regions of the natural substrate sequence, the scissile region has a 
lower activation free energy.  In all cases we found activation free energies that are in good 
agreement with experimental results.  Also, the free energy profiles obtained from the umbrella 
sampling model were in absolute agreement with experimental in vitro HIV-1 PR hydrolysis data.  
The outcome of this investigations offers a plausible theoretical yardstick for the concerted 
enzymatic mechanism of the HIV-1 PRs that is pragmatic to related aspartate proteases and 
possibly other enzymatic processes. 
Future studies on the reaction mechanism of HIV-1 PR and its natural substrate should encompass 
the use of advanced theoretical techniques aimed at exploring more than the energetics of the 
system.  The prospect of integrated computational algorithms that does not involve 
cropped/partitioning/constraining or restraining model systems of the enzyme—substrate 
mechanism to accurately elucidate the HIV-1 PR catalytic process on natural substrates/inhibitors 
will be undertaken in our group.  Computational investigations on the enzymatic mechanism of 
the HIV-1 PR—natural substrate involves fine-tuning the scissile amide bond strength through 
steric and electronic factors.  This may lead to the development of potential substrate-based 
inhibitors with better potency and reduced toxicity.   
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 ISIQEPHU 
Ubhubhane olube nomthelela omkhulu ebuntwini bobabili ngokwemvelo nangokuqonda 
kwezempilo emashumini eminyaka amuva nje yi-Acquired immunodeficiency syndrome (AIDS) 
okubangelwa yi-Human immunodeficiency virus (HIV). Ukuthuthuka kwezidakamizwa, okufaka 
amandla ama-enzyme athile abalulekile ekuphindaphindweni kwegciwane le-HIV-1, kube 
yimpumelelo ekwelashweni kwaleli gciwane. La ma-enzyme afaka i-HIV-1 proteinase (PR), 
okuyi-enzyme ebalulekile eyonakalisayo edingekayo ekuhlanzeni kwe-protein ye-Gag ne-Gag-
Pol, edingeka ekuvuthweni kweprotheni yegciwane. Indlela ebusayo ye-HIV-1 PR yalezi zi-
polyprotein iyinto enkulu ephenywayo emashumini eminyaka edlule. 
Ucwaningo oluningi ngalesi sihloko luhlola indlela esebenza ngayo ye-HIV-1 PR kulokho 
okukuhlosile njengenyathelo elisisekelo le-acid-base elisebenzayo ngaphandle kokunaka noma 
lengenayo inqubo ehlanganisiwe. Phakathi kokukhawulelwa kwemodeli yokusabela esezingeni 
eliphansi kukhona ubukhona bezinyathelo ezingaphezu kwezimbili zokuguqula isimo (TS) futhi 
lokhu kuholele ekubukweni okuhlukile esilinganisweni esinqunyiwe sokulinganisa sokuphendula 
kanye nesimo sokuhlasela sethonya elishukumisayo kulowo osebenzayo indawo ye-HIV-1 PR. 
Ngokunjalo, ukuvumelana mayelana nendlela ngqo yokuqashelwa kwezakhi zemvelo nge-HIV-1 
PR akusondeli. Ucwaningo lwamanje luphenya indlela yokuqashelwa kanye nendlela yokusabela 
kwe-HIV-1 PR ngesakhiwo sayo esingokwemvelo ngezindlela zamamodeli wokuncintisana. 
Kuhloswe ukuchaza indlela ye-cleavage yokusabela njengenqubo ekhonjiwe ngokusebenzisa 
amasu we-in-silico. Lokhu kutholakala ngokuhlanganisa amandla we-activation amandla kanye 
nokucacisa izakhiwo zamakhemikhali we-quantum wohlelo lwangaphansi lwe-enzyme. 
Ukuqonda okungcono kwendlela ezokusiza ekwakhiweni kwama-inhibitors amasha we-HIV-1 
PR. 
Indlela esetshenziswayo yama-molecule (i-MD) ene-hybrid quantum mechanics kanye ne-
molecule mechanics (QM / MM) efaka inqubo yokusizakala yokusebenza kwe-density theory 
(DFT) kanye ne-Amber model ukuphenya inqubo ekhonjiwe ye-hydrolysis. Ngokusekelwe 
kwizifundo zangaphambili eqenjini lethu ezibandakanya ukumodelwa kwe-TS ekhonjiwe, indlela 
eyindilinga eyisithupha yomgwaqo eyi-TS yaqala ukubhekwa. Lokhu kutholwe ngokusebenzisa 
uhlelo olusha lwemodeli nezindlela ze-QM (Hartree-Fock ne-DFT) ngomshini we-enzymatic we-
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HIV-1 PR. Imodeli ejwayelekile ye-acid-(GA / GB) lapho amaqembu womabili we-catalytic 
aspartate (Asp) abandakanyeka khona emshinini, futhi i-molecule lamanzi esakhiweni 
esisebenzayo lihlasela i-substrate yemvelo ngokuvumelanisa, lalisetshenziswa. Kuqhamuke 
umbono omusha ocwaningweni lapho imodeli ye-acyclic ekhonjiwe yokuhlinzekwa kwamandla 
inika amandla okusebenzisa eduze nokuhlolwa okubonwayo kunasekuqaleni kwendandatho 
eyindandatho eyisithupha. Ngakho-ke, indlela ehlongozwayo ekhonjwe ngendlela ekhanyayo ye-
HIV-1 substrate yemvelo kuyo yonke iprotease iphenyisisiwe kusetshenziswa ama-QM / MM 
amaningi ahlukaniswe ngama-Mechanics”(ONIOM) kanye ne-QM / MM MD isampula 
isambulela indlela. 
Ukubuyekezwa okuphelele mayelana nemiphumela yokulinga kanye nemibhalo theory 
yokuxhumana phakathi kwe-HIV PR nezakhi zayo zemvelo kwalethwa. Umphumela obalulekile 
ocwaningweni lwamanje ukuthi isithintelo se-acyclic TS imodeli nge-mocule eyodwa yamanzi 
kwisiza esisebenzayo se-HIV-1 PR (i-DFT), sinikela ngamandla, amandla anembe kakhulu 
okusebenza. Ngokufanayo, imodeli yokuhlanganisa ibonise ukuthi ukuqashelwa okuphelele kwe-
enzyme kuncike kwimininingwane yokwakheka kwama-substrates kanye nenani lama-amino acid 
ngokulandelana kwe-substrate (ubuncane be-P5-P5'). Ngokumodela yonke i-enzyme — uhlelo 
olusebenzisa uhlelo lwe-hybrid ONIOM QM / MM, kwaqapheleka ukuthi yize zombili izifunda 
ezingaphansi kwe-B ne-C-SA ye-HIV-1 PR zibona futhi zinamathele ezindaweni ezibucayi 
nezingasontekile zendlela yokulandelana engokwemvelo. isifunda esinomswakama sinamandla 
aphansi we-activation mahhala. Kuzo zonke izimo sithole amandla we-activation mahhala 
avumelane kahle nemiphumela yokuhlolwa. Futhi, amaphrofayili wamandla wamahhala 
atholakala kusampuli yesampuli ye-umbrella ayesesivumelwaneni ngokuphelele nedatha 
yokuhlolwa kwe-vitro HIV-1 PR hydrolysis. Umphumela walolu phenyo uhlinzeka 
ngokungenaphutha kwethiyori eyingqophamlando ye-enzymatic mechanism ye-HIV-1 PRs 
edlulele kumaphrotheni ahlobene ne-aspartate kanye nezinye izinqubo ze-enzymatic. 
Izifundo zesikhathi esizayo mayelana nendlela yokusebenza kwe-HIV-1 PR kanye nengxenye 
yayo yemvelo kufanele ifake phakathi ukusetshenziswa kwamasu athuthukile we-theorytical 
okuhloswe ngawo ukuthola ngaphezu komfutho we-system. Ithemba lama-algorithms 
ahlanganisiwe wokubandakanya okungabandakanyanga okuhlanganisiwe / ukwahlukanisa / 
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ukuphoqelela noma ukuvimba izindlela eziyimodeli ze-enzyme-inqubo engaphansi yokwengeza 
ukucacisa ngokunembile inqubo yokulwa ne-HIV-1 PR kuzakhi zangaphansi zemvelo / 
ezinqandweni kuzokwenziwa eqenjini lethu. Uphenyo lwe-computational mayelana ne-enzymatic 
mechanism ye-HIV-1 PR-substrate yemvelo ifaka phakathi ukulungisa kahle amandla e-bond 
ayisihlanganisi nge-steric ne-elekthronikhi. Lokhu kungaholela ekwakhiweni kwama-inhibitors 
angaphansi komhlaba angaphansi nge-potency engcono nokunciphisa ubuthi. 
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 CHAPTER ONE 
 INTRODUCTION 
1.1 Background 
A prolific epidemic that has had a profound health impact on humanity in this 21st century is the 
Acquired immunodeficiency syndrome (AIDS) caused by the Human immunodeficiency virus 
(HIV).1  Since it was first recognized in the 80s,2 HIV has grown from a single infection report to 
a global pandemic and remains one of the severest health challenges.2  The HIV virus has two 
strains the HIV type 1 (HIV-1) and type 2 (HIV-2), where the former is the most predominant and 
virulent across the globe, the latter more common in West and Southern Africa.1, 3  As a result of 
the number of people living with this infection both worldwide4 and especially in South Africa 
(7.1 million individuals),5 the quest for managing and treating this disease is therefore a high 
priority. 
HIV attacks the host’s immune system, which makes an individual vulnerable to opportunistic  
infection.6  An intensive study of its structure and lifecycle led to the development of unrivaled 
anti-viral drugs inhibiting the three vital retroviral enzymes; protease (PR), reverse transcriptase 
(RT) and integrase (IN), necessary for replicating the virus.7  The hydrolytic action of the protease 
on the natural amino acids substrate sequences results in processing the corresponding mature 
virion.  The Gag proteolysis delivers substrates necessary for the processing of matrix (MA), 
nucleocapsid (NC), capsid (CA), spacer peptide 1 (p1), spacer peptide 2 (p2) and p6gag.8  While 
Gag-Pol proteolysis delivers substrates that is required for RNAse H (RH), integrase (IN) and 
reverse transcriptase (RT).9 
The HIV-1 protease (HIV-1 PR) is a degrading enzyme necessary for the proteolytic cleavage of 
the Gag and Gag-Pol polyproteins, which is required for the development of mature virion 
proteins.10-12  One of the most active family of anti-retroviral drugs that is presently used in the 
treatment of HIV infection is the PI.  These inhibitors are developed to mimic the Gag and Gag-
Pol natural substrates of the HIV protease, which prevents the proteolytic activity of the enzyme 
and exert an inhibitory effect on replicating the HIV virus both in vitro and in vivo.13, 14  A 
combination of antiretroviral therapy that includes PIs has resulted in a notable recovery of 
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immunodeficiency in patients and decreased AIDS related mortality.15, 16  Nevertheless, failure to 
completely suppress the HIV replication leads to the development of viral resistance, this 
resistance to PIs does not only arise for the protease but also in some natural substrates of the 
protease.13  Also, the long term use of the commercially available PIs causes adverse effects on 
the HIV patients.17, 18  It is therefore necessary to develop new inhibitors with reduced side effects 
and toxicity, improved potency, long-lasting viral suppression and better oral bioavailability.  
Hence, the mechanism of action of the protease (proteolysis) on the Gag and Gag-Pol natural 
substrate is an important phenomenon.  
Much research has focused on the mode of action of the HIV-1 PR on its natural substrates using 
various theoretical methods such as molecular dynamics (MD),19-21 empirical valence bond 
(EVB),22 a hybrid quantum mechanics/molecular mechanics (QM/MM),23-26 MD QM/MM.27, 28  
Several experimental studies were also reported,29-31 however, the exact mechanism of action still 
remains a subject of debate over to date. 
Herein, the reaction mechanism and recognition of the Gag and Gag-Pol natural substrates 
sequence towards two HIV-1 PR subtypes (B and C-SA) was studied.  This was carried out using 
computational tools in which an advance molecular simulation (Umbrella Sampling),32  MD19-21 
and a multi-layer QM/MM ONIOM33, 34 methods were harnessed to understand some related 
questions on the recognition of natural substrates and enzymatic catalysis of HIV-1 protease.  The 
HIV-1 PR and its natural substrates which form the major focus of this research are discussed 
herein and theoretical tools/perspectives are introduced in the next chapter. 
1.2 The HIV virus and lifecycle 
The human immunodeficiency virus belongs to a family of retroviruses (lentivirus)35 and can infect 
multiple cells in the human system such as dendritic cells and macrophages, however its major 
cell target is the CD4 lymphocyte also called the CD4+ or T cells.36, 37  The HIV virus genes consist 
of specialized enzymes; protease, reverse transcriptase, integrase and two lone ribonucleic acid 
(RNA) strands that facilitate replication38 (Figure 1).   
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Figure 1. Diagrammatic representation of the HIV genome, (Reprinted with permission from ref 39. 
Copyright © 2014 S. Thomas).39  
Once the HIV virus is manifested in the CD4+ cell, the infection can be classified into three steps: 
first the RNA strands are converted into deoxy-ribonucleic acid (DNA) by the viral reverse 
transcriptase.40  By means of the integrase enzyme the newly formed viral double-stranded DNA 
genome is inserted into the host cell’s DNA and this triggers the formation of new RNA, which is 
further transcribed into long protein chains that includes env, Gag and Gag-Pol precursors.35, 41  
Lastly, the protease cleaves the non-functional polyproteins into functional viral protein and 
together with the new immature RNA are assembled into viral particles, which then form the 
mature virus cells42, 43 (Figure 2). 
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Figure 2. Schematic illustration of the HIV-1 life cycle. (Reprinted with permission from ref 44. 
Copyright © 2016 International Association of Providers of AIDS Care).44 
1.3 The HIV-1 protease 
HIV-1 PR belong to the family of aspartyl proteases45 and as stated earlier, plays a vital role in the 
maturation of the HIV virus.13, 46  Hence it serves as an important target for the development of 
anti-retroviral drugs.10-12  HIV-1 protease is an identical C2-symmentric homodimer, which 
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normally contains 99-amino acids in each dimer in its active form47 (Figure 3).  However, variants 
of the subtype C-SA HIV-1 PR exist, for example, 100 (I36T↑T) and 101 (E35D↑G↑S) amino acid 
residues, that have been reported by our group.48  The active site of the HIV-1 PR consist of a 
catalytic triad (Asp25-Thr26-Gly27) at each dimer, these are well conserved and similar in all HIV 
subtypes, the triads are enclosed by two β-sheet flaps.49, 50  The catalytic aspartates interact directly 
with inhibitors and substrates and this has been associated with the enzymatic catalysis.47  The PR 
enzyme has three regions/domain as shown in Figure 3 and are known as the dimerization or 
terminal domain, the flap and the core or active site domain. 
 
Figure 3. Structure of the HIV-1 PR showing its three domains.51  
1.3.1 The HIV-1 PR regions 
The dimerization or terminal domain is crucial in the dimer formation and stabilization of the 
active sites, this domain consists mainly of the termini of four stranded β-antiparallel sheets 
residues 1-4 and 95-99, a turn surrounding residue 4-9 and the helix residues 86-94 of each 
monomer.52, 53 
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The flap region comprises of two β-hairpin motifs with residues 43-58 of both monomers 
following the exposed loop 33-43 amino acid residues of each monomer.  The HIV-1 PR flap 
exhibit structural rearrangement from closed to semi-open and wide-open form which encloses the 
active site and provides an important ligand/substrate binding interaction.52, 54 
The active site cavity is also known as the core domain and is composed of four β-strand structures, 
this helps in stabilizing the dimer and the catalytic site.16  The domain sequence comprises of 
compact 10-32 and 63-85 residues from each dimer.  The conserved catalytic tripeptide Asp25-
Thr26-Gly27 is positioned at the interface of the core domains of each monomer, the interface 
between the terminal and core regions is primarily composed of small hydrophobic residues.52, 54 
1.4 HIV-1 natural substrate and substrate binding 
The active site of the HIV-1 PR is composed of well-defined subsites where the substrates side 
chains can be accommodated while binding.  The distinct subsites for each dimer are labelled S1 
to Sn and S1ʹ to Snʹ, and the corresponding amino acid side chains of the substrate cleaved during 
hydrolysis are labelled P1 to Pn and P1ʹ to Pnʹ starting from the scissile bond.
55  However, due to 
the C2 symmetric nature of the HIV-1 protease, the subsites S1 and S1’ are similar and this is the 
same for all other subsites in the protease (Figure 4).13, 47 
 
Figure 4. A representation of the PR substrate binding.  P1—Pn, P1'—Pn' is a standard nomenclature used 
in representing amino acids of peptide residues, while protease binding sites are represented by S1—Sn, 
S1'—Sn' (Open access).
35, 47 
The hydrolytic cleavage of certain sections (scissile bond) in the Gag and Gag-Pol natural substrate 
precursors by HIV-1 PR leads to the release of specific functional polypeptide products, which are 
then processed into separated viral peptide units.  HIV-1 PR recognizes and cleaves nine sites of 
these protein precursors which produces corresponding peptide segments of the natural substrates 
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(Table 1).56-58  The mechanism of the natural substrate by the HIV-1 PR has been the premise of 
developing protease inhibitors for the treatment of HIV/AIDS for decades.6, 59-61  This current 
research focuses on the interaction of the HIV-1 PR and its natural substrate and this will be 
extensively discussed in subsequent chapters. 
Table 1. The non-homologous natural substrate gag and gag-pol polypeptides cleaved by the HIV-1 
protease.56, 57 
Peptide sequences cleavage domain Natural substrate 
Cleavage sites in Gag  
Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-Asn MA-CA 
Lys-Ala-Arg-Val-Leu*Ala-Glu-Ala-Met-Ser CA-p2 
Pro-Ala-Thr-Ile-Met*Met-Gln-Arg-Gly-Asn p2-NC 
Glu-Arg-Gln-Ala-Asn*Phe-Leu-Gly-Lys-Ile NC-p1 
Arg-Pro-Gly-Asn-Phe*Leu-Gln-Ser-Arg-Pro p1-p6 
Cleavage sites in Gag-Pol  
Val-Ser-Phe-Asn-Phe*Pro-Gln-Ile-Thr-Leu TF-PR 
Cys-Thr-Leu-Asn-Phe*Pro-Ile-Ser-Pro-Ile PR-RT 
Gly-Ala-Glu-Thr-Phe*Tyr-Val-Asp-Gly-Ala RT-RH 
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile RH-IN 
The asterisk (*) denotes the scissile bond.  Matrix-capsid; MA-CA, capsid-p2; CA-p2, p2-nucleopsid; p2-NC, 
nucleopsid-p1; NC-p1, trans frame peptide-protease; TF-PR, protease-reverse transcriptase; PR-RT, reverse 
transcriptase-RNAseH; RT-RH, RNAseH-integrase; RH-IN.
56, 57
 
1.4.1 Scissile bond/cleavage domains 
The cleavage sites within the Gag and Gag-Pol polypeptides that are recognised by the HIV-1 PR 
are provided in Figure 5.  The ability of the HIV-1 protease to specifically recognize the natural 
substrates has been associated with the conserved shape of the peptide, substrate modulation, and 
the conformational adaptability of both substrate and protease that is interdependent.24, 56, 57, 62, 63  
A different opinion is that the HIV-1 PR recognises its natural substrate based on the 
conformational specificity of the PR for the Gag and Gag-Pol polyproteins sequence.21 
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Figure 5. Recognition and reaction mechanism of the HIV-1 PR, each illustration is based on the PDB 
structures indicated: the apo HIV-1 PR; 1LV1,64 substrate-bound HIV-1 PR; 1KJH57 and broken scissile 
bond (the product peptides) bound to HIV-1 PR; 2NPH.65  This structure was created using chimera.66 
The non-homologous polypeptide sequences of each cleavage site have a distinguishing scissile 
bond (asterisk in Table 1) and this is the point of the HIV-1 PR proteolytic action.  The design of 
the protease inhibitors (PIs) initiates from mimicking the scissile amino acids that occur within the 
cleavage domains especially the Phe*Pro scissile bonds (Table 1).67 
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The transition state (TS) modelling approach was utilized to better examine the natural substrate 
recognition pattern by HIV-1 PR (Chapter three and four).  This study explores the activation 
barrier at different peptide bond units within the natural substrate sequences.  This provided a 
comparative analysis of substrate specificity and recognition by the protease enzyme. 
1.5 HIV-1 PR mutations 
HIV-1 PRs have developed multiple mutations that show resistance to the commercially available 
anti-retroviral drugs over time.68  The high rate of viral replication and lack of proofreading or 
self-correcting of the reverse transcriptase contributes considerably to a build-up of drug resistance 
of this protease.68  Genome errors occur as the reverse transcriptase create the DNA virus from the 
RNA, coupled with the replication rate, new drug resistance generations of the virus can begin to 
outnumber the non-resistance virus.68, 69  Amino acids insertion, deletion and substitution that 
occur in the virus sequence is as a result of mutations that arise through resistance.70 The new 
mutant will also survive better in the presence of the same inhibitor/drug.  The structure of the 
HIV PRs are influenced by these mutations, which leads to conformational and steric hindrance of 
the existing PIs, hence the need to continuously design and synthesis new inhibitors.71-73 
HIV-1 subtype B differs structurally from the C-SA PR due to the eight-point mutations that occur 
away from the active site of the wild-type subtype B.70  In addition, other mutations were 
discovered to occur from the C-SA PR amongst them are I36T↑T (with 100 amino acids in each 
monomer) and E35D↑G↑S PRs (with 101 amino acids in each monomer).48  
1.6 HIV-1 PR catalytic mechanism 
In designing the HIV-1 PIs the first approach used, and still used today, is mimicking the natural 
substrate, but with a structural changes that inhibit or stop the protease function.35, 74  Hence, the 
HIV-1 protease interaction mechanism with its natural substrates is one of the most researched 
enzymes—substrate representatives for hydrolytic systems.75  Experimental studies have been able 
to show some factors like the protonation state of the catalytic Asp, the role of structural water and 
identification of the catalytic triad (Asp25-Thr26-Gly27).23, 41  Despite all that is known about the 
importance of the PR family and HIV-1 PR, its catalytic mechanism remains contentious, there is 
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no consensus on which is the correct/exact mechanism.49, 58  The HIV-1 PR hydrolysis is usually 
investigated as a stepwise general-acid general-base mechanism (GA/GB) and this involves a 
water molecule and both protonated and unprotonated catalytic Asp at the active site of the 
enzyme.27  Another proposed mechanism is the nucleophilic model whereby water molecule is 
absent in the calculations,25 this approach appears to be fading as researchers continue to unveil 
the important role of water in HIV-1 protease catalysis as discovered through X-ray 
crystallographic studies.64, 65, 76 
For the present study, both subtype B and C-SA HIV-1 PR enzymatic mechanistic pathways were 
investigated as a concerted general acid-base process (Chapters three to six).  Whereby, the 
nucleophilic attack of water as well as the general acid-base contributions of the catalytic aspartates 
occurs simultaneously.  This mechanism was initially proposed following an experimental study 
in 1991 by Jakólski31 et al., few computational studies19, 21, 23, 25 have also attempted to unravel the 
mechanism with little progress.  Since several enzymatic and chemical reactions that make use of 
a concerted mechanistic model were studied by our group,77-83 a concerted transition state model 
was also applied to describe the subtype B/C-SA PR—natural substrate catalytic interactions using 
different computational techniques.  Detailed results are presented in chapters three to six, the 
knowledge obtained during this research enable us to design new substrate-based inhibitors. 
Aim and objectives 
The overall scope of this study was to investigate the recognition mechanism of all the natural 
substrates by HIV-1 PR and subsequent catalytic interactions between them with the aid of 
computational applications. This is accomplished by the following objectives and are streamed 
down in ensuing chapters. 
• Chapter One: Introductory background of the study. 
• Chapter two: A computational background study. 
• Chapter three: Literature review on recognition and catalysis of natural substrates by 
HIV-1 PR. 
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• Chapter four: To elucidate the proposed concerted six-membered ring transition state 
mechanism of the natural substrate within the entire enzyme using hybrid ONIOM 
QM/MM method.  To analyze variations in relation to the earlier result (small model). 
• Chapter five: To compare the activation energies at different peptide bonds other than the 
scissile region within two natural substrate sequences each from the Gag and Gag-Pol 
polypeptide.  To investigate if the natural substrate recognition pattern is the same for both 
subtype B and C-SA HIV-1 PR using the hybrid QM/MM ONIOM method. 
• Chapter six: To investigate the activation energies of all the natural substrates sequences 
for the same HIV-1 PR (subtype B and C-SA) using combine MD and ONIOM approach. 
• Chapter seven: To elucidate the proposed concerted six-membered ring transition state 
mechanism of the natural substrates by subtype C-SA HIV-1 PR using the Umbrella 
Sampling method. 
• Chapter eight: Overall conclusion of the research outcome. 
Thesis outline 
The dissertation is presented in a manuscript format and each chapter is directed in addressing one 
or more research questions.  The first and last chapters contain a general introduction and an overall 
conclusion for the whole study.  An outline is therefore highlighted below. 
Chapter one gives an introductory overview of the dissertation and the main direction of the study 
is emphasised. 
Chapter two introduces the different computational techniques accessible and the computational 
method used is highlighted.  
Chapter three presents the literature review on recognition pattern and hydrolysis of natural 
substrates by HIV-1 PR. 
Chapter four includes the application of ONIOM to investigate substrate hydrolysis by HIV-1 PR 
using an exact natural substrate. 
12 
 
Chapter five presents substrate recognition by both subtype B and C-SA HIV-1 PR using ONIOM 
approach, investigation of the recognition pattern and specificity of the PRs for cleavage at a 
specific amide bond was extensively explored. 
Chapter six presents the concerted hydrolysis of the HIV-1 natural substrates against subtypes B 
and C-SA through combine MD simulations and ONIOM technique. 
Chapter seven explores the concerted acyclic mechanism of the HIV-1 PR proposed through 
Umbrella sampling technique. 
Chapter eight presents the overall conclusion on the research outcome. 
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 CHAPTER TWO 
 Computational Background 
1.1 Computer-aided drug design 
Structure-based drug design has been a leading tool in HIV-1 protease inhibitors and has generated 
many positive results.1-3  Drug design with the aid of computer processes are proving valuable in 
this area, from modelling the interactions of potential drugs and drug targets to analysing 
experimental results.4, 5  Due to improved computer hard and soft-ware, computer-aided methods 
are supposed to be more cost effective and less time consuming than experimental methods, but 
caution against unrealistic expectations should be maintained.4  For highly mutative enzymes such 
as HIV, time is a significant factor and the computational approach has proven to be a useful 
complimentary tool to experimental methods.6-8  This technique utilizes computational chemistry 
in discovering new potential drugs and their targets and to give molecular insight into inhibitor-
enzyme interactions that are not readily accessible from experimental methods and. 6-8 
1.2 Computational chemistry 
Computational chemistry can be defined as the mathematical description of chemistry which 
covers a wide range of theoretical fields including; quantum mechanics, minimization of energy, 
molecular mechanics and dynamics and conformational analysis.9, 10  Primarily these approaches 
with other computer-based models are used to calculate the molecular interactions and behaviour 
of chemical as well as enzymatic systems.  These techniques have been coupled with 
chromatographic, spectroscopic and other experimental approaches to study drug action and 
inhibition such as; antimalaria,11-13 antiretroviral,4, 14 antituberculotic,15 anticancer16-19 and 
antibiotic drugs.20-22  Studies on the inhibition of pathogens predominantly antiretroviral drugs 
have been skilfully addressed in our research group.4, 23-27 
Computational approaches can be utilized to identify chemical processes using parameterized 
advanced software to solve challenges via quantum mechanics (QM), molecular mechanics (MM), 
hybrid QM/MM and or Molecular dynamic (MD) methods.28  Reaction mechanisms yet to be 
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established by experimental kinetic studies can be tested through a series of electronic structure 
calculations.  The combination of spectroscopic methods, molecular modelling and enzymatic drug 
design was extensively reviewed on recent advances of computational and theoretical chemistry 
and the rest of this chapter describes an overview of the computational methods applied in this 
study.4, 29 
1.3 Theoretical models 
Theoretical models are used to describe the chemical behaviour of molecular systems through a 
set of approximations, these algorithms are applied to atomic orbitals to compute energies, 
frequencies and perform geometry optimization of molecules.28-30  Computational methods 
employed in chemistry are basically classified as quantum and non-quantum mechanical 
methods.30 
1.3.1 Quantum mechanics 
The QM mechanics also known as electronic structure theories is aimed at solving the 1926 Erwin 
Schrӧndinger equation usually expressed in terms of a wave function31, 32 to understand the 
properties molecules (see equation 1).30  This theory is costly considering the computational 
resources and time but more accurate, hence, practical for smaller systems.4, 33, 34  There are several 
methods of QM theory available to researchers and these are summarized in the following 
paragraphs. 
−
ћ2
2𝑚
𝑑2
𝑑𝑥2
+ 𝑉(𝑥)𝛹 = 𝐸𝛹                                                              1 
Where ћ is the reduced planck constant 1.055 x 10-34 Js, V(x) represents the potential energy at x, 
and E represents the summation of both kinetic and potential energies. 
1.3.1.1 Semi-empirical methods 
These methods are currently utilized for large molecular systems such as biomolecules and protein 
to render results in an acceptable time frame.4, 29, 35, 36  Semi-empirical methods are based on 
quantum mechanics but only valence electrons are considered as a result of severe approximations 
employed in the method.  The common theoretical models in semi-empirical methods are; PM3, 
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PM6, AM1, INDO and ZINDO.29, 30, 37, 38  These different theoretical approximations are for 
specific series of atoms/molecules and their parametrizations include approximations from 
experimental data or high level of ab initio calculation results.39  Therefore, it is important to verify 
the suitability of a chosen method for specific chemical systems. 
1.3.1.2 Ab initio methods 
This method remains the most prevalent electronic structure method applied by both computational 
and theoretical chemist despite the demanding requirements in terms of computational resources 
and time.30, 40, 41  Ab initio methods are centred on quantum mechanics laws derived from 
theoretical principles and even though the methods grouped under this model have similar 
approaches, they vary in the implemented mathematically algorithm approximations.30, 35, 40, 41  
Molecular systems can be studied easily and the required time for such calculation depends on the 
computer hard and software with respect to the level of theory and basis set applied.  Ab initio 
methods includes Configuration Interaction (CI), Hartree-Fock (HF) and Moller-Plesset (MPn-
including electron correlation).39, 40  These methods systematically approach accuracy as the level 
of theory39, 40 and basis set39, 40 increases, which comes at a considerable computational cost in 
terms of time and resources.30   Reviews on ab initio methods have focused on specific studies or 
calculations as this approach is extensive.42-45 
1.3.1.3 Basis sets 
Basis sets are used to describe electronic wave functions mathematically,30 molecules are defined 
by molecular orbitals which are expressed in terms of atomic orbitals.46  Hence, the larger the basis 
set the more accurate the computational output.  A standard renown basis set for calculating 
organic molecule properties47, 48 is the 6-31+G(d,p)49, 50 and this was applied in three parts of this 
present study combined with the selected DFT methods.  Other examples of basis sets are: 
DGDZVP,51, 52 def2-TZVP,53, 54 MidiX,55, 56 LANL2DZ,57, 58 and aug-ccpVTZ59-61.  The 
performance, relevance and quality of the these basis sets has been studied62 and a comprehensive 
update by Frank47 and Grant48 on the various basis sets can be found in literature. 
1.3.1.4 Density functional theory methods (DFT) 
An alternative method was designed by Hohenberg, Kohn and Sham that uses density functional 
models for a more effective electronic structural method which computes energies using electron 
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density rather than wave function.63, 64  The DFT method can optimize molecular systems up to 
3000 atoms using large resources,65, 66  although the DFT and MP methods produces similar quality 
results, DFT theory is more cost effective (faster).66  Time-Dependent DFT is also an extension of 
DFT method and is extensively used to simulate optical properties of both organic and inorganic 
compounds,67 Salahub et al.68 and Laurent et al.,69 presented an update on this model in 2013. 
The DFT functionals are basically categorized as: PBE correlation, Dispersion,70 Becke one-
parameter hybrid, Becke three-parameter hybrid,71 revised B97, Minnesota and ԏ-dependent 
gradient-corrected correlational functional,  these is presented in Figure 1.  The hybrid method 
Becke3LYP by Becke72 and Lee et al.,73 is the most common among the DFT models particularly 
for organic molecules.  This model will be applied within the framework of this study using the 
Gaussian program.74  This model calculates correlation energies from electron density using exact 
exchange and gradient corrected density functional approximations.72, 73, 75  Although, poor 
estimation of barrier heights and weak exchange-correlations interactions has been noted,76-78 
B3LYP has shown to give relatively good geometries that agree with high level ab initio results 
of organic, molecular and organometallic compounds.9, 79-83  The M06 functionals are also now 
widely in use for calculating molecular properties and system modelling with a level of accuracy 
comparable to experimental results.62, 84  DFT methods are more attractive because they include 
electron correlation effects and better results are provided at a comparable cost.30 
 
Figure 6. Illustration of the DFT functionals with examples. 26 
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1.3.2 Molecular mechanics methods (MM) 
This method also known as non-quantum mechanical method uses classical physic laws to 
understand and predict structural behaviour and properties of a molecule or systems from a single 
geometry.32, 85  Large systems such as enzymes and other biological molecules can be modelled 
with MM methods, and this has an edge over quantum mechanics in terms of computational time 
and resources as they are characterized by force fields with specific empirical parameters.30, 86  
Universal Force Field (UFF),87 Merk Molecular Force Field (MMFF)88 and AMBER89 are all 
examples of the molecular mechanics force fields. 
For this study, AMBER force field in the Gaussian 16 package74 was applied which uses a simple 
harmonic model that includes bond stretch, angle bends, torsion, electrostatic interactions and 
standard functions for van der Waals.86, 90, 91   While the Gaussian package assigns the atom types 
automatically for UFF calculations, atom types needs to be clearly defined for AMBER 
calculations within the molecule specification section.30   
Though MM methods cannot be applied to study the bond formation/breaking reaction since it 
does not consider the electronic effect of a chemical system.30, 85  However, hybrid QM/MM 
methods are now being utilized in practical applications, such as; investigating enzymatic 
processes, the design of drug leads and catalysis, predicting drug metabolism and resistance.4, 92, 
93 
1.4 QM/MM hybrid methods 
To overcome the challenges in theoretical modelling of large systems such as proteins/enzymes 
and considering cost effectiveness, combining the QM with MM method was proposed.94-96  An 
extensive review96 was done on the principles and applications of these methods.  The basic 
concept of the hybrid QM/MM is to split a large system into either two or three parts as regard to 
research interest(s).  The QM part is associated with the reactive atoms that are involved in the 
catalysis and binding, bond forming/breaking process, while the MM region takes up the rest of 
the system and solvent.65, 94 
There are two forms of Hamiltonian QM/MM based on the partitioning strategy, and are known 
as the additive and subtractive forms,96  an example is 97, 98 Our own N-layered molecular Orbital 
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and molecular Mechanics (ONIOM)65, 99  method.  The combined QM/MM approach gives a 
unique approximation in which the QM accuracy and MM efficiency are both shared in molecular 
simulations.96  The QM/MM method was extensively used in this study to unravel the catalytic 
mechanism of both subtype B and C-SA HIV-1 PR.  
1.4.1 ONIOM technique 
The ONIOM QM/MM process allows the partitioning of an enzyme or molecular system into 
layers depending on the relevance of each part to the enzyme’s bioactivity and research aim, these 
parts are named; the model, the intermediate (in the case of a third layer) and the real/environment 
system.65  Using the Gaussian software74 and GaussView,100 the two- or three-layer segmentation 
of an entire system can be achieved.  For the present investigation, the HIV-1 PR—substrate was 
partitioned into two distinct layers.  The “model” part considers the catalytic site of the enzyme as 
well as the natural substrate and are treated at the QM; DFT level of theory, whereas the “real” 
portion consists of the remaining residues of the system and are treated with MM (AMBER 
forcefield101) (Figure 2).  The two and three-layer ONIOM calculations are performed in the same 
manner and are represented respectively as; 
𝐺𝑂𝑁𝐼𝑂𝑀 = 𝐺𝑟𝑒𝑎𝑙
𝑙𝑜𝑤 + 𝐺𝑆𝑀
ℎ𝑖𝑔ℎ
− 𝐺𝑆𝑀
𝑙𝑜𝑤                                                                              2 
𝐺𝑂𝑁𝐼𝑂𝑀 = 𝐺𝑟𝑒𝑎𝑙
𝑙𝑜𝑤 + 𝐺𝐼𝑀
𝑚𝑒𝑑𝑖𝑢𝑚 + 𝐺𝑆𝑀
ℎ𝑖𝑔ℎ
− 𝐺𝐼𝑀
𝑙𝑜𝑤 − 𝐺𝑆𝑀
𝑚𝑒𝑑𝑖𝑢𝑚                                   3 
This approach has been used to investigate the binding activities of known HIV protease inhibitors 
with two different HIV-1 PR subtypes and it displays a reasonable level of accuracy comparable 
with experimental data.24  Likewise, a review on the ONIOM method with detailed 
parameterization technique and extensive applications to different classes of molecules and 
systems is available in literature.65  
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Figure 2. Schematic representation of the two-layered ONIOM model (DFT: AMBER) of HIV-1 PR—
natural substrate complex.   
1.4.2 Umbrella sampling 
This technique in computational chemistry was first developed by Torrie and Valleau in 1977102 
is used to improve sampling of system(s) along a reaction coordinate from one thermodynamic 
state (reactant) to another (transition state or products).103  This can be described as a type of 
combined QM/MM MD method.102  Basically, an artificial restraint is added to sample some 
coordinates of a system in a range of values to bias it.98, 104   These potential biasing minima is 
moved to another range of coordinates of interest and more simulations are carried out, the various 
simulations (also known as windows) should have sufficient overlap.  The bias potential effect can 
then be removed, and the potential mean force (PMF) is constructed which is the free energy 
profile along the selected coordinate.98, 104  This approach has been widely used to calculate free 
energy differences in complex systems with AMBER105 and in the context of this work, this 
method will be adopted in computing the free energy difference of the natural substrates cleaved 
by HIV-1 subtypes C-SA. 
1.5 Computational software 
The computational software required for modelling, calculations and post analyses studies are 
discussed in the following sections. 
1.5.1 Graphical user interfaces (GUIs) 
MM Region 
 
QM Region 
	
Natural  
substrate 
HIV-1 Protease 
Asp dyad 
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GaussView,100 Visual Molecular Dynamics (VMD),106 Discover studio,107 UCSF Chimera108 and 
PyMOL109 are the pre- and post-processor GUIs program used in this present study.  All molecular 
complexes were modelled and viewed by means of these computational application packages. 
1.5.2 The Gaussian program 
Gaussian 16 Rev A.03110 and B.0274 (2016) are both an upgrade versions of the Gaussian program 
which started with Gaussian 70,92,94 and 03 versions.111  Accurate computational methods 
demand high computer resources, hence electronic structure calculations are usually carried out 
via shared processors.  The enzymatic interactions of HIV-1 PR (subtype and C-SA) with its 
natural substrates was investigated using Gaussian 16 Rev A.03110 that is installed on clusters at 
the Centre for High Performance Computing in Cape Town, South Africa (CHPC).  This package 
was used for all calculations including DFT and ONIOM. 
1.5.3 The AMBER suite 
The AMBER package112 is one of the common software for conducting MD simulations amongst 
the software package available.113  The AMBER 18105 which is the latest version (2018) has its 
root from AMBER 4 which represents 12 years of continuous development from version 9 by 
multiple research groups.113  AMBER program suite encompasses of numerous other programs 
working together to setup, perform and analyse MD simulations such as Umbrella sampling.104  
The parameterization of this software package allows the use of graphics processing units (GPUs) 
that offers more memory bandwidth and computational power which saves computational time 
and cost.105 Hence, the AMBER 18105 suite extension in CHPC (www.chpc.ac.za) was used in our 
MD simulations and Umbrella sampling for investigating the enzymatic interactions of HIV-1 PR 
(subtype and C-SA) with its natural substrates.   
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Abstract: Current investigations on the human immunodeficiency virus protease (HIV-1 PR) 
as a druggable target towards the treatment of AIDS require an update to facilitate further de-
velopment of promising inhibitors with improved inhibitory activities.  For the past two dec-
ades, up to 100 scholarly reports appeared annually on the inhibition and catalytic mechanism 
of HIV-1 PR.  A fundamental literature review on the prerequisite of HIV-1 PR action leading 
to the release of the infectious virion is absent.  Herein, recent advances (both computation-
ally and experimentally) on the recognition mode and reaction mechanism of HIV-1 PR in-
volving its natural targets are provided.  This review features more than 80 articles from repu-
table journals.  Recognition of the natural Gag and Gag-Pol cleavage junctions by this enzyme 
and its mutant analogs was first addressed.  Thereafter, a comprehensive dissect of the enzy-
matic mechanism of HIV-1 PR on its natural polypeptide sequences from literature was put 
together.  In addition, we highlighted ongoing research topics in which in silico methods 
could be harnessed to provide deeper insights into the catalytic mechanism of the HIV-1 pro-
tease in the presence of its natural substrates at the molecular level. Understanding the recog-
nition and catalytic mechanism of HIV-1 PR leading to the release of an infective virion, 
which advertently affects the immune system, will assist in designing mechanism-based in-
hibitors with improved bioactivity. 
Keywords: HIV-1 PR, natural substrates, recognition pattern, reaction mechanism, transition state modeling. 
1. INTRODUCTION  
Aspartate proteases (Asp PRs) form a distinct class  
of hydrolytic enzymes with two characteristic aspartate  
residues acting as the major catalyst in their active  
sites, and these Asp PRs cleave specific proteins or  
polypeptides [1-3]. Notable amongst this class of en- 
zymes are beta-secretase 1 (BACE 1; EC 3.4.23.46), 
 [4] cathepsin D (Cat D; EC 3.4.23.5), [5-7] human  
immunodeficiency virus type 1 protease (HIV-1 PR;  
EC 3.4.23.16) [8] and plasmepsin II (Plm II; EC 
 3.4.23.39) [9]. These proteinases are currently receiv- 
ing extensive attention as potential drug targets in a 
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number of serious infections and diseases, which in-
clude Alzheimer’s disease (AD), acquired Immunode-
ficiency Syndrome (AIDS) and malaria [10]. HIV-1 PR 
is an indispensable drug target moiety towards the 
treatment of HIV/AIDS [11]. 
HIV-1 PR is a typical lentivirus proteinase, which is 
homodimeric with normally a total number of 99 amino 
acid residues in each monomer. However, variants of 
100 (I36T↑T) [12] and 101 (L38L↑N↑L) [13] amino 
acid residues were recently reported by our research 
group. HIV PR is an important degrading enzyme nec-
essary for the proteolytic cleavage of the Gag and Gag-
Pol polyproteins, required for the development of ma-
ture virion proteins [11, 14]. The hydrolytic action of 
the PR on these asymmetric natural polyprotein sub-
strate sequences results in the processing of the corre-
2    Current Medicinal Chemistry, 2019, Vol. 26, No. 00 Lawal et al. 
sponding mature virion: Gag proteolysis leads to capsid 
(CA), matrix (MA), spacer peptide 1 (p1), nucleocapsid 
(NC), spacer peptide 2 (p2) and p6gag [15]. Gag-Pol 
leads to reverse transcriptase (RT), RNAse H (RH), 
and integrase (IN) [16]. The mechanism of action of 
PR on these polyproteins has been a subject of research 
over the past three decades and discussed herein. When 
HIV-1 PR cleaves these sites, nine cleavage domains 
are produced (Fig. 1 and Table 1).  
In 2000, a three-dimensional (3-D) structure of 
HIV-1 PR complexed with a natural substrate (corre-
sponding to CA-p2) was deposited by Prabu-Jeyabalan 
et al. [17] in the Protein Data Bank (PDB) with a reso-
lution of 2.0 Å (PDB code 1F7A [18], Fig. 2). The sub-
strate polypeptide sequence, containing ten amino acid 
residues, is long enough to cover the whole binding 
epitope of the protease which makes this result differ-
ent from the other 19 HIV-1 PR—substrate bound crys-
tal structures deposited in the PDB earlier [17]. Those 
structures are relatively short covering P3-P3ʹ epitope 
and most of which are not a close representation of the 
actual natural substrate segments [17]. Since the incep-
tion of this study [17], about 80 research articles (Web 
of Science Database, accessed on 29 September 2017) 
have focused on the natural substrate and HIV-1 PR 
demonstrating the importance of this topic. The cleav-
age sites of the HIV-1 PR corresponding to the Gag 
and Gag-Pol proteins precursor are represented in  
Table 1. 
Experimental investigation on the interactions be-
tween HIV-1 PR and the natural substrate include: how 
this homodimeric enzyme recognizes asymmetric sub-
strates, [17, 19] natural substrates mimics for the de-
sign of potent HIV-1 PR inhibitors, [20, 21] crystalliza-
tion of HIV-1 PR—natural substrate complexes, [17, 
19] mutations at cleavage sites, [22] and the determina-
tion of the enzyme processing rate of its substrates 
[23]. The application of in silico methods that better 
reveal the interaction between natural substrates and 
the HIV-1 PR including the reaction mechanism have 
been reported [10, 24-29]. Despite a vast number of 
such contributions from across the globe, a comprehen-
sive review on experimental as well as theoretical un-
derstanding of substrate specificity (in terms of natural 
target cleavage domains) and the substrate-PR reaction 
mechanism (Table 1) is lacking.  
A review that covers substrate sequences recogni-
tion and catalytic reaction mechanism of HIV-1 PR is 
required to provide tenable answers to pertinent ques-
tions on this perspective. Some of these questions are: 
what is the recognition pattern of HIV-1 PR—natural 
substrate system? What are the possible mechanistic 
models for the catalysis of natural substrates by HIV-1 
PR? Can a single protonation pattern be sufficient for 
the description of all the natural substrates catalysis? 
What is the most suitable representation of HIV-1 
PR—natural substrate complex in computational 
modeling of the cleavage mechanism? Can the struc-
tural moieties along the reaction coordinate (observed 
in theoretical simulations) be captured through experi-
mental method(s)? Is the mechanistic route of drug-
resistant and the native HIV-1 PRs catalysis of sub-
strates the same? 
Meanwhile, we found a number of review articles 
where HIV-1 PR—natural substrate reaction process 
was highlighted [11, 30-32]. In their 2000 report, Gul-
 
Fig. (1). Illustration of Gag and Gag-Pol cleavage process by HIV-1 PR. 
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nik et al. [30] wrote a review in which two subsections 
were dedicated to substrate specificity, cleavage 
mechanism, as well as protonation state of the catalytic 
aspartates. In addition to summarizing the enzymatic 
function of HIV-1 PR, these reviewers [30] provided a 
vivid description of the enzyme, documented the bio-
chemical and biophysical properties, highlighted the 
kinetic constants of the natural substrates and discussed 
mutations arising from HIV-1 PR drug resistance.  
Table 1. The nine recognition non-homologous natural 
substrate polypeptides segments cleaved by the 
HIV-1 protease [17, 19]. 
Peptide Sequences Cleavage Domain	   Natural  
Substrate	  
Cleavage sites in Gag	   	  
Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-Asn	   MA-CA	  
Lys-Ala-Arg-Val-Leu*Ala-Glu-Ala-Met-Ser	   CA-p2	  
Pro-Ala-Thr-Ile-Met*Met-Gln-Arg-Gly-Asn	   p2-NC	  
Glu-Arg-Gln-Ala-Asn*Phe-Leu-Gly-Lys-Ile	   NC-p1	  
Arg-Pro-Gly-Asn-Phe*Leu-Gln-Ser-Arg-Pro	   p1-p6	  
Cleavage sites in Gag-Pol	   	  
Val-Ser-Phe-Asn-Phe*Pro-Gln-Ile-Thr-Leu	   TF-PR	  
Cys-Thr-Leu-Asn-Phe*Pro-Ile-Ser-Pro-Ile	   PR-RT	  
Gly-Ala-Glu-Thr-Phe*Tyr-Val-Asp-Gly-Ala	   RT-RH	  
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile	   RH-IN	  
The asterisk (*) denotes the scissile bond. Matrix-capsid; MA-CA, capsid-
p2; CA-p2, p2-nucleopsid; p2-NC, nucleopsid-p1; NC-p1, trans frame pep-
tide-protease; TF-PR, protease-reverse transcriptase; PR-RT, reverse tran-
scriptase-RNAseH; RT-RH, RNAseH-integrase; RH-IN, auto proteolysis; 
AutoP [17, 19]  
 
In 2003, Brik and Wong [33] presented a perspec-
tive on the HIV-1 PR mechanism and its implications 
for drug design. The overview spans studies on the 
mechanism of HIV-1 PR, drug design and PR resis-
tance. With respect to the natural substrate, three plau-
sible catalytic models were enumerated (Schemes S1–
S3; Supporting Information, SI) based on the reviewed 
literature. The authors proposed the following research 
questions: [33] where is the exact location of the proton 
on the carboxyl groups of the catalytic Asps and what 
is the role of the flaps in the enzymatic reaction of 
HIV-1 PR?  
Rodríguez-Barrios and Gago in 2004 [31] also gave 
a brief description of this proteolytic enzyme and pro-
vided a summary of the HIV-1 PR hydrolytic mecha-
nism. In 2013, in vitro and in silico studies on the pro-
tonation states of the reactive Asp moieties of this ho-
modimeric enzyme were reviewed [34] alongside other 
aspartyl protease families. This contribution [34] pro-
vided details of experimental and computational cataly-
sis with respect to inhibitors, protonation states induced 
by inhibitors, probing the electronic state via pH meas-
urement of the titratable residues. An estimation of the 
pKa values for the acidic residues of HIV-1 PR-
inhibitor complexes was also reported. It was suggested 
that when screening potential ligands for this enzyme, 
protonation assignment on the ionisable Asp dyad 
should be based on the results of titration curves and 
protonation state at a given pH [34].  
Herein, we provide a detailed account on applicable 
research (since 2000) on the catalytic reaction mecha-
nisms of HIV-1 PR and its natural substrates; more 
than 100 references from the literature are cited. This 
review covers the basis for recognition and possible 
reaction pathways of the HIV-1 PR complexed with its 
natural substrates, the last part of the review provides a 
future perspective concerning this topic.  
2. RECOGNITION OF THE ASYMMETRIC 
SUBSTRATE BY HOMODIMERIC HIV-1 PR  
For an enzyme to carry out its bioactivity, molecular 
recognition of its substrates/inhibitors is imperative. 
Processing of the natural Gag and Gag-Pol polypro-
teins by HIV-1 PR is crucial for viral assembly and 
replication in the HIV life cycle [35]. In this section, 
we highlight the gained knowledge on the recognition 
of natural substrates by HIV-1 PR and mutant variants. 
2.1. The Natural Substrate 
The hydrolytic cleavage of certain segments in the 
natural Gag and Gag-Pol polyprotein precursors by 
HIV-1 PR (Fig. 1) leads to the production of specific 
polypeptide units, which are subsequently processed, 
into separated peptide units. Nine cleavage sites of the 
Gag and Gag-Pol proteins precursor are recognized and 
cleaved by HIV-1 PR to produce corresponding peptide 
segments of the natural substrates (Table 1) [17, 19]. 
The mechanism of substrate hydrolysis by this PR has 
remained a major backbone of inhibitor design [36-38] 
for the treatment of HIV/AIDS [11, 39].  
2.1.1. Cleavage Points 
Provided in (Fig. 1), are the cleavage domains 
within the Gag and Gag-Pol gene which are recognised 
by the HIV-1 PR. The recognition mechanism and 
specificity of HIV-1 PR is mostly associated with sub-
strate modulation, conserved substrate shape, interde-
pendence conformational adaptability of both HIV-1 
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PR and substrates [17, 19, 40-45]. A contrasting opin-
ion is that substrate recognition of HIV-1 PR seems to 
be based on the conformational specificity of the prote-
ase to the Gag and Gag-Pol polyprotein precursors 
[46]. The non-homologous peptide sequences of each 
cleavage domain have a characteristic scissile bond 
(C—N) which is the attacking point for the hydrolytic 
action of the HIV-1 PR. Mimics of the scissile amino 
acids within these cleavage domains form the basis of 
inhibitor design for this enzyme, most importantly the 
Phe*Pro scissile units (Table 1) [47]. 
2.2. Recognition of Natural Substrates by HIV-1 PR  
The processing and recognition of CA-p2 cleavage 
domain within the Gag polypeptide sequence by HIV-1 
PR was studied using a crystallographic approach [17]. 
The authors noted an extensive binding landscape in 
which the asymmetry peptide forms 24 hydrogen bonds 
which do not account for substrate recognition. They, 
however, linked the ability of HIV-1 PR to identify its 
substrate with the interdependence of the conforma-
tional changes. This fluctuation is mediated by six wa-
ter molecules forming hydrogen bonds that bridge the 
peptide chains as well as van der Waals (VDW) contact 
contributions from the protease’s amino acid residues 
[17]. An addendum to this, research provides another 
intriguing investigation where the same authors [17, 
19] determined the X-ray crystal structures of five 
HIV-1 PR—substrate complexes [19] (deposited in the 
PDB) [18]. The sequences of the investigated sub-
strates consist of ten asymmetric amino acid units, 
which cover about 1000 Å2 of the binding surface area. 
They reiterated that HIV-1 PR recognizes the shape of 
the non-homologous peptide substrate and not a par-
ticular amino acid sequence [17, 19]. 
Weber and coworkers [48] presented a comparative 
analysis between human T-cell leukaemia virus 
(HTLV-1) PR and HIV-1 PR through substrate binding 
site examination. An oligopeptide containing nine 
amino acids corresponding to the MA-CA cleavage 
domain (Table 1) was studied along with the CA-NC 
cleavage site of the former enzyme. Combining en-
zyme assays with molecular modeling methods, they 
observed a wide difference in the specificity of the 
HTLV-1 PR and HIV-1 PR. Variance of the substrate 
sequence at different positions reveals that most retro-
viral PRs, including HIV-1, preferentially enjoy large 
hydrophobic side chains at the P1 position. The amino 
acid in this position is located within the substrate 
pocket on the S1 subsite and seems to be highly con-
served [48] 
Light emitting holoprotein was also employed to de-
tect the proteolytic bond cleavage site of the MA-CA 
precursor [35]. This was revealed by a decrease in the 
bioluminescence generated by the aequorin fusion pro-
tein in the solid phase. The bioluminescence method 
yielded very sensitive detection limits (1 × 10-11 M) of 
 
Fig. (2). Structure of HIV-1 protease complexed with CA-p2.  PDB code 1F7A[17] (RCSB PDB accessed on 28 March 2017).  
Image created with UCSF Chimera [30.] 
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the substrate’s peptide bond cleavage by the HIV-1 PR 
[35]. Although the design of the study does not provide 
substantial input on how the HIV-1 PR recognizes its 
substrates, it is interesting to also mention that the use 
of this cysteine-free mutant of aequorin was harnessed 
to monitor the activities of two competitive and one 
non-competitive inhibitor for the HIV-1 protease [35]. 
In 2006, Schiffer and coworkers [42] presented a 
theoretical approach to evaluate the preferences of sub-
strate positions and correlations between them that 
might also identify which positions within known sub-
strates can likely tolerate sequence variability and 
which cannot. This was done using a biased sequence 
search threading (BSST) method [49]. The prediction 
of the eight non-identical amino acid sequences of the 
substrates was investigated using a probability function 
which is dependent on residue positions within the 
BSST generated sequence. This was done by employ-
ing three models; (1) each substrate position was con-
sidered independently, (2) interdependence between 
pairs was monitored and (3) triple-wise interdepen-
dency was tested [42]. Again, it was resolved that HIV-
1 PR identifies the substrate shape in its entirety with 
little or nil cognizance of its specific sequence [42].  
A closely related research initiative is an all-atom 
simulation study by Perez et al. [46]. CA-p2 cleavage 
domain (consisting of eight amino acid sequences) and 
a non-substrate was studied using molecular mechanics 
Poisson-Boltzmann surface area (MM-PBSA) and 
thermodynamic integration (TI) [50-52] to determine 
substrate detection in HIV-1 PR. The obtained binding 
free energies were drawn at 20 and 40 ns and the affin-
ity of non-substrate for the PR was found to be high 
[46]. The authors [46] estimated the free energy 
(∆Gbind) change between the non-substrate and studied 
natural substrate to be -4.4 kcal mol-1. Disputing both 
induced-fit and lock-and-key models as tenable de-
scriptions for substrate recognition, these authors 
adopted the following proposition to elucidate substrate 
recognition by HIV-1 PR [46]. (1) The PR preferen-
tially cleaves only natural substrates, with enough ex-
posure, for a given period of time. In other words, even 
with greater affinity, many non-substrates are not 
cleaved because they are concealed within the polypro-
tein pool and apparently unrecognizable by the PR. (2) 
From the adequately seen sequences, the detection is 
based on the conformational specificity of PR:Gag and 
PR:Gag-Pol polyprotein complexes that regulate which 
residues are within an accessible position to the active 
site [46].  
The distinctive binding scope of HIV-1 PR—
substrate complex (referred to as “the substrate enve-
lope”) was redefined [53] using molecular dynamics 
(MD) simulations [54]. This study was a sequel inves-
tigation from earlier reported work [40, 55-58] on the 
design of inhibitors against HIV-1 PR to test the hy-
pothesized substrate envelope. It was proposed that the 
conserved conformation with a characteristic overlap-
ping cavity in which the substrate sits within the active 
site, is the substrate envelope [40]. Özen et al. [53] car-
ried out MD simulations of seven natural substrates 
with HIV-1 PR at 11 ns to provide a clearer picture of 
the conserved 3-D geometry attained during HIV-1 
PR—substrate binding. The dynamic substrate enve-
lope was thereafter emphasized to be an exact represen-
tation of HIV-1 PR—substrate interactions [53].  
Schiffer and coworkers [59] attempted to initiate a 
model in which an engineered HIV-1 PR (induced mu-
tations) could be used to monitor substrate binding 
specificity via computational techniques. In simple 
terms, the investigation aimed at employing mathe-
matical, physicochemical, biochemistry and engineer-
ing processes to develop an improved computational 
algorithm that provides a comprehensive description of 
altered HIV-1 PR substrate recognition. It was ob-
served that substrate specificity was modified in mu-
tated HIV-1 PR, thereby facilitating alternate binding 
modes for the natural substrates. Rationalizing the 
weaknesses of the procedure and the output, these 
authors [59] emphasized that sound knowledge on the 
structural and conformational plasticity of the enzyme 
is vital to parameterizing such an algorithm. They pro-
posed that more accurate and advanced computational 
methods would probably be required to predict the con-
formational backbones of the remodeled proteins. For 
side-chain optimization, these authors have used Dun-
brack and Cohen-based backbone-dependent rotamer 
library [60] and the dead-end elimination (DEE) theo-
rem was used for the design of individual pockets [59].  
Related topics under this section include, analysis of 
the context surrounding the processing sites to deter-
mine the cleavage rate of Gag and Gag-Pol polyprotein 
precursors, [23, 61, 62] and identification of efficiently 
cleaved substrates of HIV-1 PR [63]. It was claimed 
that identification of substrate cleavable sites could 
serve as the best templates for the synthesis of the bet-
ter binding inhibitors [63]. An overall conclusion was 
also reached that the selection of processing sites and 
the order of precursor processing are defined partly by 
the structure of Gag-Pol itself and that this conforma-
tion assists in estimating the order of the initial cleav-
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age events [62]. Using fluorescein arsenical hairpin 
(FlAsH) reagent to label a natural substrate containing 
MA and the N-terminal domain of CA, Swanstrom’s 
group [23] studied the effect of substrate context on 
processing the HIV-1 PR Gag and Gag-Pol polypro-
teins. These authors [23] observed that complex sub-
strate interactions both beyond the active site of the 
enzyme and across the scissile bond contribute to de-
fining the rate of processing by the HIV-1 PR. The rate 
of cleavage by this viral protease can also be inhibited 
or enhanced through the replacement of the P1 residue 
of the Gag processing sites [61]. 
2.3. Natural Substrate Recognition by Drug-
Resistant HIV-1 PR Variants 
One of the major challenges in enzyme-based drug 
design is the development of drug resistance, of which 
the clinically approved antiretroviral drugs are not ex-
empted. HIV-1 PR drug resistance currently involves 
about 46 mutations, [64] and 69 HIV-1 PR mutant 
crystal structures are found in the RCSB PDB [18]  
With the observed high level of drug resis-
tance/multidrug resistance caused by HIV-1 PR mu-
tants, this overview will be incomplete without ad-
dressing how mutated protease recognizes the natural 
Gag and Gag-Pol polyproteins segments. The impact of 
mutated HIV-1 PR on the recognition of their natural 
substrate precursor (NC-p1 cleavage domain) was stud-
ied using GRASP software, [65] and it was observed 
that most active site mutations are rarely in contact 
with substrates, but are crucial to the binding of inhibi-
tors [40]. The Gag and Gag-Pol polypeptide precursors 
cleavage sites are recognized by this protein cleaving 
enzyme despite point mutation or insertion (such as 
HIV-1 subtype C-I36T↑T containing 200 amino acid 
residues [12]) due to the ability of the HIV-1 PR to de-
velop drug resistance to inhibitors at the active site, 
thereby recognizing the shape of its natural substrates. 
Hence, inhibitors designed for HIV-1 PR and their mu-
tants may easily undergo drug resistance, whereas the 
protease recognizes its polypeptide natural substrates 
and proceeds with its cleavage bioactivity [40].  
The output from this computational simulation [40] 
was followed by a crystallographic investigation con-
ducted at 1.44–2.10 Å resolution [41]. The main aim of 
this study was to describe the substrate recognition 
mechanism by drug-resistant HIV-1 PR with a co-
evolutional natural substrate (NC-p1) whose processing 
is not just the slowest, but also, the rate-limiting cleav-
age step in the maturation of Gag [41]. The NC-p1 
cleavage domain has been noted to coevolve with drug-
resistant V82A HIV-1 PR mutation whereby this sub-
strate’s P2 amino acid residue mutates from an alanine 
to a valine in response to this mutated variant (Fig. 3) 
[40]. Amazingly, their [41] maiden experimental study 
revealed that one of the HIV-1 PR flaps displayed a 
closed conformation while the other flap displays a dis-
crete intermediate conformation [41]. P3-P1 residues of 
the substrate were also observed to be of great impor-
tance in substrate recognition [40, 41].  
Tie et al. [66] carried out a high-resolution crystal-
lographic analysis to elucidate substrate recognition by 
wild-type HIV-1 PR, V82A and I84V variants at the 
molecular level. CA-p2, p2-NC, NC-p1, p1-p6 and 
p6pol-PR cleavage domains were co-crystallized with 
these two drug-resistant mutants and wild-type PR to 
examine their conformation changes and estimate ki-
netics. The substrate sequence was six to eleven amino 
acids long. The 3-D X-ray crystal structures, which 
were refined to 1.1–1.6 Å resolution, revealed that the 
binding affinity and recognition features of these mu-
tant PRs are partly dependent on the substrates’ con-
formational flexibility. The natural substrates have 
more adaptability to bypass new conformations in-
duced by drug-resistant mutants than potential inhibi-
tors.  
In order to confirm this coevolved substrate with 
mutant HIV-1 PR and to examine in detail their sub-
strate recognition pattern, Schiffer and coworkers [67] 
carried out another investigation at the molecular level. 
 
Fig. (3). Point mutation at P2 amino acid in NC-p1 natural Gag polyprotein cleavage domain.  The scissile bond is indicated 
with asterisk and mutated amino acid is in green. 
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Three coevolved HIV-1 PR––natural substrates were 
studied; AP2VNC-p1V82A, LP1ʹFp1-p6D30N/N88D and 
SP3ʹNp1-p6D30N/N88D in which two of these complexes 
have double mutations induced by nelfinavir treatment 
[68, 69]. The molecular modeling and dynamics analy-
sis revealed that the conserved envelope conformation 
is an important feature for the HIV-1 PR mutants to 
recognize and cleave their substrates [67]. Closely re-
lated research was again reported by the same group 
[70] using an Anisotropic Network Model (ANM) [71]. 
In addition to the substrate envelope theory with re-
spect to drug-resistant HIV-1 PRs and coevolved sub-
strates, these authors [70] proposed that the recognition 
of the asymmetric substrates by the HIV-1 PR and its 
known mutants may likely be a result of the flexibility 
in the flap regions, which control the intrinsic dynam-
ics. 
So far, all natural target sequences documented 
herein do not exceed P5 to P5ʹ. Using both in silico 
and in vitro techniques, Laco [72] put forward a novel 
analysis on substrate recognition by native, drug-
resistant and multidrug-resistant (MDR) HIV-1 PRs in 
an attempt to derive the significance of the substrate-
groove (S-groove) to natural target recognition by these 
PRs [72]. The natural substrate (with 24 amino acid 
residues) was employed for this study in which MA-
CA and NC-p1 cleavage domains were examined. 
From his numerous observations [72] a condensed 
summary is provided while focusing on substrate rec-
ognition of MDR3761 HIV-1 PR with seven protease 
inhibitor (PI) resistance mutations and four polymor-
phic changes with respect to the wild-type (WT) PR: 
[73]. (1) The S-groove can be described as an active 
pocket within the HIV-1 PR contributed by the two 
dimers, which allow the PR to bind up to 24-residues 
of a Gag and/or Gag-Pol cleavage sites. (2) The S-
groove can increase HIV-1 PR affinity for substrate 
recognition and cleavage process. (3) MDR PR is 
highly dependent on S-groove contacts for substrate 
recognition, binding and cleavage. (4) When Gag poly-
protein was used as the substrate, a similar bioactivity 
was observed for both native and MDR PRs [72]. In his 
recent investigation, Laco [72, 74] concluded that PRs 
interact with the Gag and Gag-Pol cleavage sites via 
the active-site and S-grooves [74].  
Lately, the nine cleavage domains of the natural 
Gag and Gag-Pol precursors were co-crystallized with 
MDR769 HIV-1 PR by Kovari and co-workers [73, 75-
77]. In one of their studies, a wide-open flap and an 
extended substrate pocket were observed in MDR769 
HIV-1 PR [75]. This MDR PR has ten of its residues 
mutated and each natural target has seven amino units 
from P3-P4ʹ [75]. It was argued that the enzyme rec-
ognizes its substrates through their preserved shape 
facilitated by conserved water molecules and hydrogen 
bonds [75, 77]. It was noted that the essential water 
molecule between the substrate and flap tips (Fig. 2) 
was absent in the reactive region of MDR769 HIV-1 
PR [75] These prompted the authors [77] to postulate 
the probability of variations in the enzymatic mecha-
nism of these mutant with respect to the WT PR.  
Deshmukh et al. [78] have associated the ability of 
the protease to naturally cleave known regions within 
the Gag polyprotein sequence with the conformational 
dynamics of the protease flaps that cover the active 
site. This was elucidated using chemical exchange-
based NMR spectroscopy approach and mutant prote-
ases. They [78] upheld that “the protease flaps are ac-
tively involved in substrate recognition and regulate the 
lifetime of productive complexes, allowing protease to 
differentiate between scissile and non-scissile se-
quences”. 
Understanding the recognition profile at the molecu-
lar level for the natural targets of HIV-1 PR and resis-
tant mutants is crucial to the development of more ac-
tive inhibitors. Many researchers have used computa-
tional techniques to provide a plausible description of 
this event in which more advanced in silico approach 
might likely yield better hypotheses.  
2.4. Thermochemistry and Kinetic Parameters for 
HIV-1 PR and its Natural Substrates 
Many in vitro analyses have been carried out to es-
tablish the kinetics parameters for HIV-1 PR and its 
natural substrate. These parameters are important fac-
tors in determining the catalytic activity of an enzyme 
and its substrate/inhibitor. Earlier kinetic constants 
found in the literature for HIV-1 PR and its natural tar-
gets were documented [30]. We therefore, present in 
Table 2, a summary of inhibition constants and binding 
free energies from literature. Kinetic constants for mu-
tated variants of HIV-1 PR are also included and all 
values presented are outputs involving sequences con-
sistent with natural targets.  
3. REACTION MECHANISMS OF HIV-1 PR AND 
ITS NATURAL SUBSTRATES 
In recent times, studies on reaction mechanisms 
have gone far beyond what happens when a mixture of 
constituents yields one or two distinct product(s). In-
vestigating the reaction mechanism is imperative to 
understanding enzyme catalysis, design of drugs and 
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Table 2. Experimental kinetic parameters for the proteolysis of natural Gag and Gag-Pol cleavage domains by HIV-1 
protease and its mutants. 
Cleavage Site	   Peptide Sequence	   HIV-1 PR	   ΔGbind 
kcal mol-1	  
Km (mM)	   Kcat  
(s-1)	  
Kcat/Km  
(mM-1.s-1)	  
Kd	  
MA-CA	   SQNY*PIVQ	   WT	   	   3.75 [79] 
0.78 [80]	  
23.00 [79] 
15.70 [80]	  
6.20 [79] 
20.10 [80]	  
	  
MA-CA	   VSQNY*PIVQ	   WT	   	   0.15 [81] 
 [48, 80]	  
6.90 [81] 
6.80 [48]	  
46.00 [81] 
45.30 [82]	  
	  
MA-CA	   QNY*PIVQ	   WT	   -8.33 [75]	   0.91 [80]	   1.60 [80]	   1.81 [80]	   8.20e-7 [75] 	  
MA-CA	   VSQNY*PIV	   WT	   	   0.12 [80]	   7.90 [80]	   65.80 [80]	   	  
MA-CA	   SQNY*PIV	   WT	   	   0.53 [80]	   13.50 [80]	   25.40 [80]	   	  
MA-CA	   QNY*PIV	   WT	   	   0.86 [80]	   1.00 [80]	   1.20 [80]	   	  
MA-CA	   VSQNY*PIVQ	   M46L	   	   0.56 [81]	   18.40 [81]	   32.90 [81]	   	  
MA-CA	   VSQNY*PIVQ	   V82S	   	   1.34 [81]	   13.40 [81]	   10.00 [81]	   	  
MA-CA	   VSQNY*PIVQ	   V82A	   	   0.42 [81]	   7.00 [81]	   16.70 [81]	   	  
MA-CA	   VSQNY*PIVQ	   I84V	   	   1.02 [81]	   93.50 [81]	   92.00 [81]	   	  
MA-CA	   VSQNY*PIVQ	   L90M	   	   0.64 [81]	   33.00 [81]	   51.60 [81]	   	  
MA-CA	   QNY*PIVQ	   MDR769	   -2.02 [75]	   	   	   	   3.40e-2 [75]	  
CA-p2	   ARVL*AEAM	   WT	   	   0.37 [79]	   2.60 [79]	   6.90 [79]	   	  
CA-p2	   RVL*AEAM	   WT	   -9.14 [75]	   	   	   	   2.10e-7 [75]	  
CA-p2	   RVL*AEAM	   MDR769	   -2.02 [75]	   	   	   	   3.40e-2 [75]	  
p2-NC	   ATIM*MQRG	   WT	   	   3.00 [79]	   41.00 [79]	   14.00 [79]	   	  
p2-NC	   TIM*MQRG	   WT	   -9.14 [75]	   	   	   	   2.10e-7 [75]	  
p2-NC	   TIM*MQRG	   MDR769	   -5.24 [75]	   	   	   	   1.50e-4 [75]	  
NC-p1	   ERQAN*FLGKI	   WT	   	   0.17 [81]	   0.15 [81]	   0.90 [81]	   	  
NC-p1	   ERQAN*FLGKI	   V82A	   	   	   	   0.70 [81]	   	  
NC-p1	   ERQAN*FLGKI	   I84V	   	   	   	   	   	  
NC-p1	   ERQAN*FLGKI	   M46L	   	   	   	   0.30 [81]	   	  
NC-p1	   ERQAN*FLGKI	   V82S	   	   	   	   0.40 [81]	   	  
NC-p1	   QAN*FLGK	   WT	   -6.74 [75]	   	   	   	   1.20e-5 [75]	  
NC-p1	   QAN*FLGK	   MDR769	   -3.83 [75]	   	   	   	   1.60e-3 [75]	  
p1-p6	   PGNF*LQSR	   WT	   	   >5.00 [79]	   <0.25 [79]	   0.05 [79]	   	  
p1-p6	   RPGNF*LQSRP	   WT	   	   1.20 [81]	   0.98 [81]	   0.80 [81]	   	  
p1-p6	   RPGNF*LQSRP	   V82A	   	   	   	   1.20 [81]	   	  
p1-p6	   RPGNF*LQSRP	   V82S	   	   	   	   1.20 [81]	   	  
p1-p6	   RPGNF*LQSRP	   I84V	   	   	   	   1.20 [81]	   	  
p1-p6	   RPGNF*LQSRP	   M46L	   	   	   	   0.60 [81]	   	  
p1-p6	   RPGNF*LQSRP	   L90M	   	   	   	   2.10 [81]	   	  
p1-p6	   GNF*LQSR	   WT	   -5.33 [75]	   	   	   	   1.30e-4 [75]	  
(Table 2) contd…. 
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Cleavage Site	   Peptide Sequence	   HIV-1 PR	   ΔGbind 
kcal mol-1	  
Km (mM)	   Kcat  
(s-1)	  
Kcat/Km  
(mM-1.s-1)	  
Kd	  
p1-p6	   GNF*LQSR	   MDR769	   -3.52 [75]	   	   	   	   2.70e-3 [75]	  
TF-PR	   FQF*PNIT	   WT	   -8.84 [75]	   	   	   	   3.50e-7 [75]	  
TF-PR	   FQF*PNIT	   MDR769	   -3.02 [75]	   	   	   	   6.30e-3 [75]	  
PR-RT	   LQF*PISP	   MDR769	   -3.42 [75]	   	   	   	   3.20e-3 [75]	  
RT-RH	   AETF*YVDG	   WT	   -6.91 [83]	   0.19 [79]	   1.80 [79]	   10.00 [79]	   6.21e-6 [83]	  
RT-RH	   ETF*YVDG	   WT	   -6.44 [75]	   	   	   	   2.09e-5 [75]	  
RT-RH	   ETF*YVDG	   MDR769	   -2.23 [75]	   	   	   	   2.40e-2 [75]	  
RH-IN	   RKIL*FLDG	   WT	   	   1.15 [79]	   5.10 [79]	   4.40 [79]	   	  
RH-IN	   KIL*FLDG	   WT	   -9.68 [75]	   	   	   	   6.40e-8 [75]	  
RH-IN	   KIL*FLDG	   MDR769	   -6.53 [75]	   	   	   	   1.70e-5 [75]	  
Note: PR is the protease, ΔGbind is the intrinsic binding free energy, Km is the Michaelis constant, Kcat is the catalytic constant, Kcat/Km is the rate of cataly-
sis, Kd and Ki denote the dissociation and inhibition constants, respectively. 
their metabolism. Here, we address the reaction 
mechanism of the native HIV-1 PR with natural Gag 
and Gag-Pol polyprotein cleavage domains. Contribu-
tions from the use of both experimental and theoretical 
techniques are presented on the mechanistic aspect of 
this enzyme with its substrates. Several key factors that 
contribute to the reaction mechanisms of HIV-1 PR and 
its natural substrates, such as, the protonation state of 
the aspartate dyad, the nature of the reaction, reaction 
process and conditions, role of water molecule(s) and 
finally, energetics are discussed. 
3.1. Effect of Protonation State on the Catalytic As-
partate Dyad 
Placement of proton(s) on the Asp dyad of HIV-1 
PR is crucial to understanding the reaction mechanism 
and is still a subject of debate [10, 84]. A review de-
scribing the protonation state of the ionizable group of 
aspartate proteases has appeared recently [34]. Experi-
mental techniques such as combined X‑ray/neutron 
crystallography, [85, 86] NMR spectroscopy, [87-89], 
calorimetric and binding kinetics [34] were used to de-
termine the protonation state in aspartic proteases. 
Similarly, theoretical methods have also been applied 
to understand the ionization state of these catalytic 
Asps. These methods include; QM/MM, [26, 90-92] 
MD simulations [93-95] and online software (such as 
PROPKA, [96] PDB2PQR [97] and H++ [98]). One of 
the latest theoretical reports on the detailed protonation 
pattern of the Asp dyad is from Roitberg and cowork-
ers, [99] where pH Replica-exchange MD (REMD) 
[95] was used to elucidate the pKa of both catalytic and 
titratable groups of apo and inhibitor-bound HIV-1 PR. 
It was observed in the substrate-free model that the 
protonation of Asp25 and Asp25ʹ are chemically in-
distinct while the bound model exhibited 
monoprotonation. It was remarked that the binding of 
an inhibitor rarely induces change in the ionizable 
states of the catalytic dyad. However, this former moi-
ety can invoke shifts in the pKa values of the Asp dyad 
as observed from neutral asymmetric inhibitors that 
were studied [99]. A correct understanding of the pro-
tonation state(s) of the HIV-1 PR—substrate complex 
catalytic aspartates is crucial for accurate QM 
modelling of the reaction mechanism.  
3.1.1. Possible C. of HIV-1 PR for Catalytic Function  
Evidence from both experimental and theoretical 
analyses has revealed that the catalytic process of HIV-
1 PR functions at pH of 2–7 [33, 34, 100]. This process 
usually occurs at the active site, which consists of two 
coplanar aspartate moieties and is usually stabilized by 
the catalytic triad Asp25(25ʹ), Thr26(26ʹ) and 
Gly27(27ʹ) peptide units [101]. The Asp 25(25ʹ) dyad 
of the free enzyme can exist in monoprotonated [99] 
(four possibilities, model A-D), an unprotonated [102, 
103] (model E) and diprotonated [104, 105] (four pos-
sibilities, model F-I) forms (Fig. 4).  
Piana and Carloni [100] reported the observation of 
a low barrier hydrogen bond (LBHB) within the apo 
HIV-1 PR of reactive Asp monomers (model J, Fig. 4). 
These researchers [100] utilised ab initio simulations at 
300 K to highlight the requirements for this enzyme to 
carry out its catalytic functions at the active site. These 
include, monoprotonation specifically on OD1 of 
Asp25ʹ, a catalytic water (WatC) molecule close 
enough to the carboxyl oxygen of the Asp moieties and 
the contribution of Thr26(26ʹ)–Gly27(27ʹ) to the sta-
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bility of the Asp dyad orientation [100]. Furthermore, 
the catalytic reactivity of HIV-1 PR—substrate com-
plex is dependent on the conformational flexibility of 
the enzyme [25, 106, 107]. The dynamics of the flap 
region of HIV-1 PR allows the inflow of the substrate 
and the release of the cleaved products. When investi-
gating these interactions with in silico methods, an ac-
curate theoretical level and large basis set are recom-
mended to obtain reasonable geometry orientation and 
energetics [1, 25]. 
 The catalytic core domain of the PR must attain a 
specific geometry before it can process its sub-
strate/inhibitor’s functionality, Okimoto et al. [93] 
termed this specific conformation the “active confor-
mation”. The proximity of the enzyme with the sub-
strate in the presence of WatC and protonated OD2 of 
the Asp25ʹ residue to form the enzyme-substrate (ES) 
complex should be within specific distances (Fig. 5). 
Using the Hartree-Fock (HF) [108] theoretical method 
and the 6-31G(2d) [109] basis set, these authors [93] 
determined the necessary conditions for an active con-
formation to enable HIV-1 PR to cleave its natural sub-
strates. These conditions are: (a) the two catalytic Asp 
dyad should hold WatC through formation of hydrogen 
bonds (Fig. 5: d1, d2, d3, and d4), (b) the interatomic 
distance between the oxygen of WatC and the scissile 
carbonyl carbon of the substrate should be maintained 
within 3.3 Å (Fig. 5: d5) and this was based on the 
VDW radii of the carbon and the oxygen in retrospect, 
[93] (c) and the oxygen of the cleavable carbonyl forms 
a hydrogen bond with the OD2 of Asp25ʹ (Fig. 5: d6).  
 The effect of conserved water molecules on the re-
active conformational state of the enzyme was also ad-
dressed therein [22, 110]. The 3-D arrangement of di-
poles from these structurally conserved water mole-
cules contribute to the favorable geometric of this en-
zyme required for its cleavage bioactivity [110] 
3.2. The Nature of the Reaction 
The mechanistic reaction of the HIV-1 PR has been 
extensively studied using both theoretical and experi-
mental techniques and categorized either as a nucleo-
philic [1, 111, 112] or a general acid-base [1, 111, 113-
 
Fig. (4). Proposed protonation models for the HIV-1 PR catalytic dyad [100, 105, 106, 109]. 
From Recognition to Reaction Mechanism Current Medicinal Chemistry, 2019, Vol. 26, No. 00    11 
120] reaction. The major distinction between these two 
mechanisms is the presence of a water molecule in the 
latter and absence in the former. Although the general 
acid-base mechanism is widely accepted, the nucleo-
philic reaction cannot be entirely ruled out. Within the 
context of this review, we highlight these two reaction 
mechanisms based on contributions from in silico and 
in vitro perspectives. 
 
Fig. (5). Interatomic distances obtained with ab initio HF/6-
31G(2d) for the ES complex, redrawn from literature.[94]  
Carbon, oxygen and nitrogen atoms are represented with 
grey, red and blue, respectively.  All distances are in Å, 
d1=3.28, d2=2.66, d3=2.96, d4=2.80, d5=2.91 and d6=2.97. 
3.2.1. Nucleophilic Reaction 
Earlier thoughts about the hydrolysis of natural sub-
strates by HIV-1 PR were that it most likely proceeds 
through a direct nucleophilic attack by an aspartate 
[111]. This direct nucleophilic attack process involves 
the catalytic aspartate group whereby the unprotonated 
Asp acts as the nucleophile rather than a water mole-
cule. The nucleophile generally attacks the carbonyl 
carbon of the scissile amide. This reaction has been 
studied to occur as a stepwise or a concerted nucleo-
philic reaction mechanism. 
 
3.2.1.1. The Stepwise Nucleophilic Mechanism 
The nucleophilic mechanism for HIV-1 PR catalysis 
was studied to be stepwise whereby the reaction pro-
ceeds through more than one TS structure and interme-
diates. The nucleophilic attack of the unprotonated Asp 
at the scissile carbonyl carbon produces an anionic in-
termediate that abstracts a proton from the protonated 
Asp (Scheme 1). The resulting acyl-enzyme intermedi-
ate is then hydrolyzed, with the unprotonated Asp act-
ing as a general base [111]. The stepwise nucleophilic 
mechanistic pathway was explored herein [1, 111, 112] 
using computational methods. Both quantum mechan-
ics (QM) and MD techniques have been harnessed to 
give a total account of the reaction process involved in 
this mechanism. In addition to their exploration of all 
possible mechanistic pathways for the enzymatic 
mechanism of HIV-1 PR, Park et al. [1] investigated 
the stepwise nucleophilic mechanism (Scheme 1) at 
MP2/6-31G(2d)//RHF/6-31G(2d) level of theory. The 
reaction steps involved the formation of a reactant 
complex, two TS structures, one intermediate and 
product complex. An overall ∆G‡ of 36.6 kcal mol-1 
was estimated for this mechanism. 
Approximate valence bond (AVB) [121] method 
was parameterized and tested on the cleavage of the 
natural substrate by the HIV-1 PR [122]. The AVB 
formalism was developed based on density functional 
theory (DFT) [123] approach and it allows partitioning 
of the exact atoms involved in the reaction and other 
surrounding amino acid residues and solvents. Atoms 
at the reaction center [122] were modeled using AVB 
while the rest of the system was treated with a classical 
MD [54] method. This computational method allows 
the authors [122] to investigate the stepwise nucleo-
philic mechanism in which protonation was assigned to 
the two Asp group (model I, Fig. 4). The first stage of 
the mechanism involves proton transfer between the 
inner oxygens (OD1) of both Asp and subsequent nu-
cleophilic attack by Asp25. As a result of the relatively 
short simulation time for AVB/MM technique em-
ployed by these authors, [122] it was impossible to es-
timate the energy barriers of the entire nucleophilic 
process. 
3.2.1.2. The Concerted Nucleophilic Mechanism 
The mechanistic pathway for HIV-1 PR catalysis of 
substrates could also be concerted nucleophilic, which 
proceeds with the formation of an enzyme-substrate 
complex leading to a concerted nucleophilic TS struc-
ture (Scheme 2). According to Park et al. [1] investiga-
tion, the concerted nucleophilic reaction involves the 
concurrent attack of the nucleophile (unprotonated 
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Scheme 1. A pictorial representation of the structures involved in stepwise nucleophilic mechanism for the hydrolysis of a sim-
plified peptide model by HIV-1 PR using MP2/6-31G(2d)//RHF/6-31G(2d).[1]  The legends are: SNR = stepwise nucleophilic 
reactant, SNTS1 = stepwise nucleophilic transition state 1, SNINT = stepwise nucleophilic intermediate, SNTS2 = stepwise 
nucleophilic transition state 2, SNP = stepwise nucleophilic product.  All distances are in Å. 
 
Scheme 2. Representation of the structures involved in concerted nucleophilic pathway for the hydrolysis of a simplified pep-
tide model by HIV-1 PR using MP2/6-31G(2d)//RHF/6-31G(2d).[1]  The legends are: CNR = concerted nucleophilic reactant, 
CNTS = concerted nucleophilic transition state, CNP = concerted nucleophilic product.  All distances are in Å. 
Asp) on the carbonyl carbon and transfer of a proton 
from the acidic Asp to the scissile nitrogen of the sub-
strate. The nucleophilic Asp bound tightly to the disso-
ciated scissile carbonyl in the concerted nucleophilic 
product (Scheme 2). In their study, Park et al. [1] used 
ab initio calculations including Møller-Plesset second-
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order perturbation (MP2) [124] and HF [108] theories 
coupled with the 6-31G(2d) [109] basis set, to describe 
the concerted nucleophilic mechanism. They used a 
model reaction where formamide represents the sub-
strate, while acetate and acetic acid represent the cata-
lytic Asp residues [1]. For this reaction, an activation 
free energy (∆G‡) of 25.8 kcal mol-1 was observed [1]. 
3.2.2. The General Acid-Base Mechanism 
The general-acid base mechanistic pathway for 
HIV-1 PR proteolysis of its substrates came into lime-
light in the early 1990s [125, 126] following previous 
experimental research on related proteolytic enzymes 
[127, 128]. Recent evidence weighs strongly in favor of 
the general acid-base catalysis through the use of com-
bined X‑ray/neutron crystallography, [85, 86] to detect 
notable reaction complexes along the PES of the HIV-1 
PR—natural target. This was earlier proposed to be 
rarely possible due to the reactive nature of the prote-
ase [1, 129]. In this mechanism, a water (WatC) mole-
cule acts as the nucleophile within the active site of the 
HIV-1 PR. The catalytic process has been proposed to 
either be stepwise or concerted. 
3.2.2.1 Stepwise General Acid-Base Mechanism 
The stepwise general acid-base (SG) mechanism is 
the most widely studied model for the catalysis of HIV-
1 PR. The reaction is quite diverse and puzzling opin-
ions continued to appear as researchers try to unravel 
the mechanism using both in silico and in vitro meth-
ods. Important research questions are: Can a single pro-
tonation pattern be sufficient for the proteolysis of all 
the natural substrates? How many TS structures are 
involved in SG mechanism and what is the rate-
determining step? 
Within the framework of this review, we have con-
sidered studies together based on the protonation pat-
tern (Fig. 4) used/proposed by different contributors 
from both computational and experimental investiga-
tions. This becomes a better approach due to the impor-
tance of protonation on the catalytic Asp group to en-
able HIV-1 PR enzymatic functions. It is quite interest-
ing to observe that most recent reports on HIV-1 PR—
substrate catalysis has adopted a monoprotonation 
mechanism (models A-D; Fig. 4).  
3.2.2.1.1. The Stepwise General Acid-Base Mechanistic 
Pathway of HIV-1 PR Involving Asp25 Protonation 
Protonation assignment to the catalytic Asp group 
has been studied to exist in a number of possible mod-
els (Fig. 4). On the active Asp25, two oxygens of the 
carboxyl group could either be protonated for HIV-1 
PR catalytic function. For ease of readability, the dis-
cussion is presented in the light of the applied in silico 
 
Scheme 3: Proposed mechanism for the substrate hydrolysis reaction catalysed by HIV-1 protease initiated by Asp25 protona-
tion.  Structures along the pathway are indicated as follows: (1) enzyme—substrate complex; (2) water attack TS; (3) tetrahe-
dral gem-diol intermediate; (4) scissile N-protonation TS; (5) protonated amide intermediate; and (6) cleavage of scissile C-N 
bond TS leading to separated product complex.  Redrawn from literature [26, 124, 132]. 
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and in vitro methods, the perspective of the study and 
major contributions towards describing the mechanism. 
To give a total account of the reaction process in-
volved in enzyme catalysis, the approximate valence 
bond (AVB) [121] method was parameterized and 
tested on the cleavage of the natural substrate by the 
HIV-1 PR [122]. Protonation of the catalytic groups 
was specifically on OD2 of Asp25 (model B, Fig. 4). 
Shown in Scheme 3 is the adopted reaction model by 
Trylska et al. [122]. Each reaction step was elucidated 
using HIV-1 PR—p2-NC cleavage mechanism with the 
scissile bond at Met*Met (Table 1). It was summarized 
that the AVB/MM technique would allow a detailed 
description of the enzymatic reaction. This reaction 
steps include; intermolecular proton transfers from wa-
ter to aspartate, nucleophilic attack of the reduced wa-
ter on the substrate scissile bond, conformational 
changes of the tetrahedral intermediate, two proton 
transfers between the intermediate and the Asp resi-
dues, and cleavage of the intermediate into reaction 
products [122]. As observed in the nucleophilic 
mechanism, the short simulation time hindered the pos-
sibility of estimating the energy barriers of the general 
acid-base mechanism using AVB/MM method [122] 
 Trylska et al. [112, 119, 122] continued their re-
search by providing a broader understanding on the 
enzymatic reaction of HIV-1 PR through the applica-
tion of AVB/MM MD simulations. Protonation pattern 
B (Fig. 4 and Scheme 3) was found to be the most suit-
able model for the general acid-base enzymatic cataly-
sis of HIV-1 PR on the N-acetyl-Thr-Ile-Met*Met-Gln-
Arg-amide sequence [112]. The role of hydrogen bond-
ing in the reaction mechanism of the enzyme and one 
substrate was also elucidated. The hydrogen bonds ob-
served were characterized as; [112] short and strong, 
weak and long, centred or asymmetric and single-well 
hydrogen bonds. It was observed that strong hydrogen 
bonds are peculiar to both mechanistic pathways (nu-
cleophilic and general acid-base) and assist in simulta-
neous proton transfers within the reactive field. A low 
barrier and central hydrogen bond were noted between 
the scissile NH and the OD2 of Asp25ʹ. OD1 of both 
Asp dyad formed an asymmetric-LBHB that facilitates 
the stability of the coplanar aspartates interchange be-
tween them. For the cleavage to occur, the nitrogen 
atom of the scissile bond should be protonated. Though 
computationally expensive, the authors [112] suggested 
a technique that explores the full conformational space 
such as umbrella sampling [130, 131]. This method 
gives an overt free energy profile capturing all possible 
moieties along the reaction coordinate.  
Over time, new improvements were put forward to 
establish a suitable mechanistic model for HIV-1 PR 
catalysis of its substrates. Taking into consideration the 
flexibility and electric field of the enzyme plus active 
site interaction with other residues as suggested herein, 
[106, 107] Rothlisberger and coworkers [25] offered a 
hybrid Car-Parrinello (quantum mechanics) and mo-
lecular mechanics (QM/MM) method [132] at 15 ps to 
describe the chemical steps involved in the cleavage of 
P3–P3ʹ sequence of p2-NC by HIV-1 PR. Using the 
BLYP hybrid exchange [133, 134] DFT formalism and 
the plane wave (PW) [135] basis set for the QM part, 
these authors [25] investigated two possible protona-
tion patterns (models B and J, Fig. 4) for the ionizable 
aspartates at the active site.  
Through this all-atoms simulation, the nature of 
each moiety along the reaction profile was discussed 
extensively with respect to reaction energies. Two 
plausible models were also explored for the formation 
of intermediate (INT); the gem-diol and the oxyanion 
(Fig. S1; SI), which was proposed to be possible 
through a tunnelling [136] effect. The required distance 
for tunnelling for the stability of an oxyanion INT was 
not achieved, but it was suggested that increasing the 
simulation time may yield a positive result [25]. The 
∆G‡ for the formation of gem-diol INTs was 18 kcal 
mol-1 via model B protonation mechanism. The data 
suggest that the catalytic reaction is more favorable 
when OD2 of Asp25 is protonated. Even when the re-
verse reaction was examined the same free energy bar-
rier was obtained, [25]. and including the catalytic triad 
in the QM part to monitor the reaction mechanism gave 
the activation free energy of 15 kcal mol-1 [25]. This 
lower energy difference in moving from ES to INT was 
rationalized with respect to the catalytic strength of 
HIV-1 PR which is partly driven by the polarity of the 
cleavage site surrounding [107]. When the alpha car-
bon (Cα) atoms of this enzyme were kept frozen, the 
calculated free energy for this same step was 25 kcal 
mol-1, [25] an indication of the vitality of flexibility for 
reactive catalysis [25, 107]. The theoretically predicted 
TSs energy value was 18 and 21 kcal mol-1 in which 
the second TS is 5 kcal mol-1 higher than experimen-
tally deduced value [137, 138]. These authors [25] also 
carried out QM calculations to rationalize this discrep-
ancy. 
Two of our hypothetical questions form part of 
Bjelic and Åqvist [110] aims when they analyzed the 
catalysis of Plm II, Cat D and HIV-1 PR on their re-
spective natural substrates. The reaction mechanism 
was studied with two natural substrate sequences 
namely; RH-IN and CA-p2 from the Gag and Gag-Pol 
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cleavage domains, respectively. The applied in silico 
method was a triple hybrid one in which empirical va-
lence bond (EVB) [139, 140] was coupled with free 
energy perturbation (FEP) [139, 141] and classical MD 
simulations. This integrated approach can be used for 
enzyme catalysis to dissect the reaction steps, elucidate 
the features of the structures along the reaction coordi-
nate and predict free energy values that are closer to 
experimental data [110]. After a detailed literature sur-
vey, protonation pattern B (Fig. 4) and the general 
acid-base stepwise mechanism (Scheme 3) were 
adopted for their [110] calculations. Elucidating the 
nature of each structure along the reaction coordinate, 
these authors observed a flat and almost similar in 
height tetrahedral INT structure between TS1 and TS2. 
The theoretical free activation energies for the enzy-
matic process on RH-IN were 17.2, 16.4 and 16.6 kcal 
mol-1 for TS1, INT and TS2, respectively, [110] in 
which the TS1 value is in agreement with the 
experimental value of 17.6 kcal mol-1 [113]. Apart 
from the active site WatC, a total of five water mole-
cules was observed to be crucial for stability and reac-
tivity, [110] which is supported by an earlier crystallo-
graphic study of this enzyme [22]. Despite not retain-
ing these water molecules in the enzyme preparation 
procedure, electrostatic interaction energy arising from 
them and the INT structures in both substrates amounts 
to -12 kcal mol-1 [110, 142-144]. A contrasting obser-
vation was put forward by these authors on the notion 
that the HIV-1 PR intrinsic conformational flexibility is 
substantial to the reduction of the free energy barrier in 
the catalytic process [25, 145].  
Kipp et al. [146] gave an answer to one of the 
research questions on the similarity between the 
mechanistic route of drug-resistant and the native HIV-
1 PRs catalysis of substrates. They [146] reported 
nearly identical TS structures in both complexes. Ex-
ploring enzymatic transition state analogues enables the 
development of better inhibitors, a powerful tool for 
drug discovery [147]. Kinetic Isotope Effects (KIEs) 
[126] and ONIOM methods were used to elucidate the 
chemical mechanism of native and I84V mutant HIV-1 
PR—Acetyl-Ser-Gln-Asn-Phe*Pro-Val-Val-NH2 sys-
tems. The reaction was proposed [146] to have oc-
curred in six phases (Scheme 3) and TS2 was noted as 
the rate-determining structure as earlier proposed in the 
literature [25, 113, 118]. This TS corresponds to the 
protonation process of the substrate scissile nitrogen 
atom.  
The relevance and implication of computational 
techniques in studying reaction mechanism can not be 
underestimated. Theoretical chemists can easily model 
a system and calculate the energetics in detail as well 
as locate the important moieties along the reaction co-
ordinate. Most recently is the use of an advanced com-
putational technique such as enhanced sampling that 
explores the full conformational space of the reaction 
process [112]. Recently, an investigation was done by 
Krzemińska et al. [120] on the catalytic reaction of 
HIV-1 PR with a non-natural substrate. The study util-
izes an intriguing model in which both electrostatic and 
dynamic contributions were accounted for. The applied 
methods are sophisticated with the observation of about 
14 reaction complexes that were revealed from the um-
brella sampling method, QM/MM/MD and 
QM/QM/MM approach (Fig. S1; SI). Although the 
modeled system is a 6-Alanine peptide sequence (not 
an exact natural substrate), some highlights from their 
[120] analysis are provided.  
Two mechanistic pathways involving OD2 protona-
tion of both Asp25 and Asp25ʹ were investigated. The 
mechanistic route that initiates through the protonation 
of the outer oxygen of Asp25 (model B; Fig. 4) leading 
to the formation of the gem-diol tetrahedral INT is the 
most plausible pathway. The breakdown of this INT 
into product fragments is likely the rate-determining 
step as earlier proposed through experiment [113] with 
∆G‡ of 15 kcal mol-1 [120]. This theoretical ∆G‡ is in 
agreement with experimental values within 15 and 17.9 
kcal mol-1 [125, 148]. A concerted process was ob-
served for the plausible rate-determining step, which is 
characterized by two proton transfers. The first in-
volves the transfer of hydrogen atom from Asp25ʹ 
OD2 to the substrate scissile nitrogen and the second 
hydrogen moves from a diol group of the tetrahedral 
INT to Asp25 OD2 (Scheme 3). 
These authors [120] also measured the enzyme ki-
netic isotope effects (KIEs) for the TS structures in-
volved in the mechanism and obtained values which 
are in reasonable agreement with experimental values. 
Contributions from dynamic effect (inherent through 
enzyme fluctuation with respect to the reacting moie-
ties [149]) on the activation barrier seem negligible 
compared to the electrostatic effect, which tends to be 
crucial for electronic reorientation of the geometry of 
molecules at the active site [120].  
3.2.2.1.2. The Stepwise General Acid-base Mechanistic 
Pathway of HIV-1 PR Involving Asp25ʹ Protonation 
The catalytic ability of HIV-1 PR was traced to its 
conformational adaptability by Piana et al. [107]. They 
[107] employed an integrated approach with ab initio 
Car-Parrinello MD simulation [132] (10.0 ps) and clas-
sical MD simulations (2.1 and 8.0 ns) at 300 K to in-
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vestigate the HIV-1 PR—N-acetyl-Thr-Ile-Met*Met-
Gln-Arg complex in which the substrate segments cor-
responds to six amino acid residues of p2-NC (Table 1) 
[107]. The computational method was used to deter-
mine the cleavage sites polarization, conformational 
fluctuations and the reaction mechanism of the com-
plex. The HIV-1 PR mechanistic interaction with its 
substrate was initiated as in Scheme 3, with more em-
phasis on the first TS modeling leading to the tetrahe-
dral intermediate formation [107] The authors [107] 
observed a mechanistic pathway which showcases OD1 
of Asp25ʹ protonation (model C; Fig. 4) as the 
energetically favorable compared to the rest of the 
models (A, B and D; Fig. 4). Acyclic TS (similar to 
TS1 Scheme 3) was observed from the ab initio 
calculations as a concerted process where the catalytic 
Asp dyad transfers a proton to the carbonyl substrate 
and accepts a proton from WatC. The ∆G‡ of 21.5 kcal 
mol-1 obtained [107] was 5.5 kcal mol-1 higher than 
experimentally estimated values [125, 126, 150]. These 
authors [107] however, attributed this large difference 
in the theoretically predicted energetics to their 
modeled complex (propionic acid/propionate as Asp 
dyad, substrate as N-methyl acetamide while 
Thr26/26ʹ and Gly27/27ʹ N-methyl formamide) and 
possibly the applied theoretical approximation [134, 
151]. It was concluded that the catalytic triad of the 
cleavage sites mainly induced the polarization of the 
reactants. The classical MD calculations revealed a 
large-scale protein fluctuation inherent from flaps and 
the cantilever, which modulates the conformational 
diversities of the substrates at the active site. They have 
also concluded that substrate residues further away 
from the active site may likely be vital to the substrate 
modulation [107] Weber and coworkers [152, 153] proposed a per-
spective on the hydrolysis of substrates by HIV-1 PR 
and mutants I54V, V32I and I47V. The investigations 
involved both theoretical and experimental techniques. 
An autoproteolytic peptide sequence cleavage mecha-
nism by WT, I54V, V32I and I47V HIV-1 PR mutants 
was investigated computationally after trapping notable 
moieties (through X-ray crystallography) along the re-
action pathway of these PRs—peptide systems [152, 
153] In both studies, the proposed mechanism of pep-
tide bond cleavage was described as represented in 
Scheme 4. The applied theoretical method, DFT; 
B3LYP/6-311++G(d,p), was used to provide more in-
sight into the nature of the amino-gem-diol INT [152]. 
Protonation on the Asp dyad was observed to be 
favorable on OD1 of Asp25ʹ (model C, Fig. 4). The 
PRs neither forms covalent bonds nor transfer its car-
boxyl hydrogen to the substrates [152] in contrast to 
Schemes 1-3 as revealed through experiment, [152] 
which will be discussed subsequently.  
The proposed mechanism proceed with the Asp 
group participating as anchoring moieties (Scheme 4) 
[152]. The reaction process involves formation of an 
enzyme—substrate complex (step A), nucleophilic at-
tack of WatC on the scissile carbonyl with formation of 
4-membered ring TS (step B), formation of gem-diol 
tetrahedral INT (step C), decomposition of the INT into 
product complex/protonation of scissile nitrogen (step 
D) and separation of the cleaved substrate from the en-
zyme (step E). The decomposition of the INT, which 
features protonation of the scissile nitrogen, was sug-
gested to be the rate-determining step [152] as pro-
posed from previous theoretical research [118].  
Okimoto et al. [93] investigated the mechanism of 
this enzyme with the natural substrate using MD [54] 
simulations. They elucidated the catalytic and stabiliz-
ing role of water molecules around the loop structures 
of the HIV-1 PR. Two possible general acid-base hy-
drolytic mechanisms were proposed, Schemes 3 and 5. 
The catalytic Asp dyad was monoprotonated in both 
mechanisms in which OD2 of Asp25ʹ (model D; Fig. 4 
and Scheme 5) was upheld to be ideal for the biological 
function of the PR. Simulating HIV-1 PR—PR-RT and 
HIV-1 PR—MA-CA complexes at 250 ps and 300 K in 
the presence of five characteristic water molecules, it 
was summarized [93] that the catalytic mechanism of 
HIV-1 PR initiates through the formation of enzyme—
substrate complex involving a protonated outer oxygen 
of the Asp25ʹ. The authors [93] suggested that the pro-
tonation state and water molecule(s) are crucial for the 
cleavage and processing of substrates to enable the rep-
lication of this virus. 
Next, the same group [93, 94] monitored the effect 
of specific substrate sequences on the reaction mecha-
nism of HIV-1 PR––substrate to identify efficient ca-
talysis with respect to substrate nature [94]. This was 
studied using MD simulations in two different ap-
proaches; the no cut-off and the Particle Mesh Ewald 
(PME) [154] methods in which analyses were drawn at 
300 K for 100 ps and 300 K for 250 ps, [94] respec-
tively. OD2 of the Asp25ʹ residue was protonated and 
MA-CA cleavage domain was studied as six, seven and 
nine asymmetric sequences (Table 1). An additional 
sequence in which Leu was substituted for Ser at P4 
position within the nonapeptide was also studied [94]. 
In all cases, the reaction was proposed to have passed 
through a stepwise mechanism in which the reactants 
come together to form an ES complex and later pro-
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Scheme 4. Proposed reaction mechanism of the peptide bond hydrolysis by HIV-1 PR devoid of the Asps bond sharing or atom 
exchange.  “Adapted with permission from literature [153]. Copyright (2007) American Chemical Society." 
 
Scheme 5. Summary of the mechanistic pathway involving Asp25ʹ OD2 protonation for the hydrolytic reaction of HIV-1 pro-
tease using an ab initio molecular orbital method.[94]. 
ceed to intermediate formation, substrate protonation 
and cleavage stages (Scheme 5) [93, 94]. However, the 
last substrate sequence with a point mutation at the P4 
position did not undergo catalysis due to its inability to 
fit in the active site [94] 
Amongst the nine natural substrate cleavage do-
mains, a scissile amidic bond is present at the Phe*Pro 
link in TF-PR and PR-RT cleavage junctions (Table 1). 
Altoè et al. [26] described the catalytic process of HIV-
1 PR—Phe*Pro complex to test the implementation of 
a novel QM/MM algorithm, tagged “Computations at 
Bologna Relating Ab-initio and Molecular Mechanics 
Methods” (COBRAMM). This approach is a hybrid 
model that acts as an interface within different pro-
grams through modularity. Through the combinations 
of programs, a user can easily design the desired com-
putational level based on the aim(s) of the investigation 
[26]. Two distinct pathways were observed for this 
mechanism using QM and QM/MM approach. In the 
first method, only the reactive atoms within the en-
zyme’s active site region and some neighbouring atom 
fragments were considered and apportioned into three 
layers. The applied DFT method involved B3LYP 
[108, 134] with DZVP, [155] 3-21G [156, 157] and 
STO-3G [158, 159] basis sets in the order high, me-
dium and low layers, respectively. In the second 
(QM/MM) method, the partitioning is also similar 
(high and medium) while the last layer contains atoms 
treated with STO-3G (third layer in QM) and the rest of 
the HIV-1 PR residues (Fig. 6) [26] which were as-
signed to AMBER force field (ff03) [160]. The proto-
nated ionisable group of the reactive aspartates was 
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noted to be Asp25ʹ OD2 (model D; Fig. 4 and Scheme 
5).  
From the QM calculation, four minima structures 
and two TS structures were observed along the PES for 
substrate hydrolysis [26]. One of the studied TS struc-
tures (corresponding to TS2 in Scheme 3) corresponds 
to an earlier experimentally [113] and theoretically 
[118] proposed rate-limiting step with a characteristic 
highest peak along the reaction coordinate [26]. The 
activation free energy of approximately 23 kcal mol-1 is 
comparable to experimentally deduced results [125, 
126]. The QM/MM model featured four different reac-
tion moieties along its path with just one TS structure. 
The free energy barrier of this TS was predicted to be 
21.4 kcal mol-1, which is slightly lower than the QM 
data. However, the total process leading to product re-
lease was exergonic in QM and endergonic in 
QM/MM. Rationalizing these discrepancies as detailed 
as possible, the authors [26] concluded that the contri-
bution of surrounding residues is crucial to product re-
lease. The proteolysis process was found to be more 
favourable in the QM method due to the smaller model 
system that was used (only the hydrolytic part was con-
sidered), while the QM/MM model system appeared to 
have restricted the system, i.e., the flexibility of 
part/entire protein was hampered [26] 
3.2.2.1.3. The LBHB Stepwise General Acid-Base 
Mechanistic Pathway of HIV-1 PR  
Northrop [136] described a general chemical reac-
tion process for the isomechanism of Asp proteases 
experimentally via the pH method. The mechanism was 
based on LBHB (model J, Fig. 4) in which seven pro-
ton transfers were proposed for the catalytic turnover 
using a chromophoric substrate (Scheme 6). Highlight-
ing other related observations [161, 162] to provide 
exclusive understanding of the purpose of the LBHB in 
Asp proteases, Northrop [136] hypothesized that 
LBHB facilitates the formation of a cyclic complex. 
Formation of cyclic moieties along the reaction coordi-
 
Fig. (6). A; The basis set adopted for the atoms of the QM system are shown using different colors.  B: Model system used to 
study the QM/MM reaction profile of the enzyme HIV-1 PR.  Pictures are adapted from literature [26] with permission “Copy-
right (2007) Springer-Verlag”. 
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nates in a given chemical process has been a subject of 
theoretical research in our group for over a decade [91, 
163-169]. In aspartate proteases, cyclic complexation 
allows the distribution of electron density which stimu-
lates the rate acceleration through reactant-state tunnel-
ing [136] 
In addition to studying other stepwise general acid-
base mechanism, Rothlisberger and coworkers [25] 
investigated the LBHB model. They studied the effect 
of protonation pattern on the formation of ES complex 
in which protonation model J (Fig. 4) was energetically 
more favourable than model B with a difference of 0.5 
kcal mol-1 [25]. However, an ∆G‡ of 36 kcal mol-1 was 
obtained for the gem-diol INTs via this (model J) pro-
tonation mechanism. This data suggests that the cata-
lytic reaction is less favourable as this value is much 
higher than experimental values [125, 148]. The 
mechanism takes the form of Scheme 4 [152] whereby 
the Asp group does not share bond with the substrate 
(Scheme 6). The process initiates from the introduction 
of substrate to the enzyme forming an ES complex go-
ing through three reaction steps to form the product 
complex (FʹPQ).  
3.2.2.1.4. Trapping Reaction Moieties Involved in HIV-
1 PR—Substrate Catalysis through Crystallization: The 
Stepwise General Acid-Base Mechanistic Pathway  
Experimental detection (with X-ray for example) of 
notable reaction complexes along the PES of HIV-1 
PR—natural target catalysis is rarely possible due to 
the reactive nature of the protease [1, 129]. An exact 
natural substrate is cleaved by the active HIV-1 PR 
before the crystals grow and data collection becomes 
difficult [129, 170]. However, efforts were made by 
Hosur and coworkers [129] to present the first crystal 
structure of an INT structure obtained from HIV-1 PR 
complexion with an oligopeptide sequence consisting 
of eleven amino acid units (Fig. 7). The trapped tetra-
hedral INT with the tethered HIV-1 PR was refined to 
2.03 Å resolution. The INT was prepared through the 
attachment of two oxygen atoms to the scissile carbon 
atom of the selected undecapeptide. A non-covalent 
association was observed between the transient INT 
and the tethered HIV-1 PR [129]  
These authors [129] proposed that the formation of 
INT and protonation of the scissile peptide nitrogen 
occur sequentially. A better insight on the nature and 
 
Scheme 6. Chemical and kinetic isomechanism of an aspartic protease redrawn from literature.[109]  E=Asp dyad and WatC at 
the enzyme’s active site held with LBHB, ES=enzyme—substrate complex, EʹS and FʹT=interaction within the ES complex, 
GʹZ=the initiation of the cleavage process of the substrate, FʹPQ=the cleaved peptide, F and G are resonance structures of the 
Asps leading to the formation E to initiate another cycle. 
20    Current Medicinal Chemistry, 2019, Vol. 26, No. 00 Lawal et al. 
 
Fig. (7). The tetrahedral peptidolysis intermediate. (a)–(c) Stereo diagrams of 2Fo–Fc maps (contoured at 0.8σ). (a) The sub-
strate is refined as a regular peptide. The region of the model between the P1 and P1′ residues, which does not fit properly in 
the density, is circled. (b) The substrate is refined as a cleaved peptide; (c) the substrate is refined as a reaction intermediate. 
Two orientations of the substrate are shown with magenta and green carbon atoms; sticks in the magenta model have been 
made thicker to allow easy tracing of the peptide chain. (d)–(f) Stereo diagrams of structural superposition of the reaction in-
termediate (yellow carbon) on to: (d) the regular peptide from the structure 1KJH (PDB code) (magenta carbon), (e) the re-
duced amide inhibitor MVT101 from the structure 4HVP (magenta carbon) and (f) the hydroxyethylene inhibitor U85548E 
from the structure 8HVP (magenta carbon). Only one orientation of the substrate is shown for the sake of clarity. Similar fea-
tures are also present in the other orientation. Only protein Cα atoms were used for superposition [131]. Image and details are 
taken from literature[131] with permission “Copyright (2005) Biochemical Society Portland Press”. 
conformation of this INT candidate may potentially be 
useful in the prediction or synthesis of tighter HIV-1 
PR inhibitor binders [129]. A similar observation was 
made from another crystallographic analysis [171]. The 
product segments of the HIV-1 PR—RT-RH (refined 
to 1.65 Å) was co-crystallized via standard simulated 
annealing (SA) procedures and the amplitude-based 
maximum likelihood target function [172]. The inves-
tigation also featured the observation of a LBHB be-
tween OD1 of both Asp25 and Asp25ʹ with an intera-
tomic distance of 2.30 Å. Adopting Northrop [136] 
isomechanistic hypothesis (Scheme 6), Das et al. [171] 
noted four hydrogen-bonding interactions between the 
dyad and the decapeptide substrate. From their [171] 
observations and discussions on the protonation pattern 
of the ionisable aspartates through the analysis of the 
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hydrogen bonds at the catalytic centre (Fig. 8), the re-
action proceeds with protonation model J (Fig. 4). 
Within the crystal complex, the predicted separation 
distance between the scissile amide atoms (C----N) of 
the natural substrate was 2.67 Å. These two contribu-
tions [129, 171] serve as potential answer to the ex-
perimental detection of reaction complexes along HIV-
1 PR—substrate PES. 
Another attempt to capture reacting structures along 
the PES of HIV-1 PR—substrate complex was done by 
Bihani et al. [173]. The product segments of the hydro-
lytic action of HIV-1 PR on the matrix and capsid 
(MA-CA) junction (Table 1) were elucidated with X-
ray crystallography refined to 2.0 Å resolution. Using a 
similar approach described in literature, [129, 171] they 
[173] have enabled us to summarise the hydrogen bond 
distances within the reactive Asp dyad and the natural 
substrate (Table S1; SI). Two more important observa-
tions were made with respect to hydrogen bonding 
[173] The cleavable nitrogen atom from the heptapep-
tide substrate forms no hydrogen bond with OD2 of 
Asp25ʹ and the OD1 of both catalytic aspartyl group 
forms no LBHB as seen in previous work, [171]. These 
two observations motivated the hypothesis that the 
gem-diol INT facilitates the protonation of the scissile 
nitrogen of the natural target with least ascription of 
this phenomenal hydrogen transfer to neither catalytic 
Asp [173]  
Successful crystallographic studies on the prediction 
of reacting complexes along the HIV-1 PR—substrate 
mechanistic pathway can be attributed to the dedicated 
efforts of Hosur and coworkers [129, 171, 173-176]. 
Using a solution of an undecapeptide substrate at pH 7, 
Prashar et al. [175] reported the prime observation of a 
WatC at the active site of HIV-1 PR. This was carried 
out via a crystallographic analysis, which was refined 
to 1.69 Å resolution. This dangling water molecule 
forms one H-bond with the OD2 of Asp25 and another 
H-bond with the OD1 of Asp25ʹ in the product seg-
ment. The Asp dyad was hypothesized to exhibit a pro-
tonation pattern similar to LBHB (model J, Fig. 4) in 
which the proton is shared between the OD1 of both 
Asp molecules. Fig. 9 shows the proposed mechanistic 
route for HIV-1 PR and substrate catalysis [175] based 
on 3-D crystal structures from literature. 
Also, the first X-ray snapshot of HIV-1 PR with a 
natural Gag-Pol polyprotein segment has been pre-
sented (at pH 2.5) within the reactive site of the en-
zyme [176]. The oligopeptide substrate corresponds to 
ten amino acid chain of RT-RH polypeptide subunit 
and trapped as a tetrahedral INT in the tethered HIV-1 
PR dimer refined to 1.76 Å resolution. The investiga-
tion featured the significance of accurate protonation of 
the ionic Asps at the active site [176]. Detailed litera-
ture review [34, 104, 105] and analysis with respect to 
relevant work, [90, 177, 178] were also presented 
[176]. This was followed by a thorough examination of 
the nature of the hydrogen bond and the geometry of 
the coplanar Asps. In short, protonation pattern B (Fig. 
4) was upheld to be suitable for the tetrahedral INT 
description [176]. The proposed mechanism leading to 
product formation is summarized in Scheme 3. One of 
the distinctions of this investigation [176] is the obser-
vation of a short ionic hydrogen bond (SIHB) between 
one of the hydroxyl oxygen of the neutral diol INT and 
the OD2 of Asp25ʹ which was a result of the asym-
metric binding nature of the INT structure to the reac-
tive Asps. Provided in Table S1, are preferential hy-
drogen bond distances within the active site of the 
HIV-1 PR. The SIHB presents a very sort hydrogen 
bond length at 2.2 Å. It was also reiterated that the 
separation of the INT moiety in the hydrolytic pathway 
 
Fig. (8). Hydrogen-bonding interactions at the catalytic centre are shown by dotted lines.  Picture adapted from literature[172] 
with permission “Copyright (2006) National Academy of Sciences, U.S.A”. 
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is the rate-determining step as observed in the literature 
[25, 113, 118, 176]. 
An autoproteolytic peptide sequence cleavage 
mechanism by WT, I54V, V32I and I47V HIV-1 PR 
mutants were investigated [152, 153]. To capture nota-
ble moieties along the reaction pathway of these drug-
resistant—peptide systems, Weber and coworkers [152, 
153] determined the crystal structures at high resolu-
tion (1.2–1.5 Å). In the study, the proposed mechanism 
of peptide bond cleavage is presented in Scheme 4 
whereby the protonation is on the OD1 of Asp25ʹ 
[152]. The trapped gem-diol tetrahedral INT structures 
along the PRs-catalysed peptide hydrolysis reaction 
have no contacts with the catalytic Asps. However, the 
Asp group was observed to be involved in the activa-
tion of WatC and complex stability. They therefore, 
proposed a modified mechanism (Scheme 4) of the 
substrate cleavage reaction that is devoid of the PRs 
forming a covalent bond as well as hydrogen transfer to 
the substrate. The rate-limiting step was suggested to 
be the decomposition of the gem-diol INT (step D; 
Scheme 4) [152]  
“Snapshots” of three successive steps along the re-
action coordinate of V32I and I47V—nonapeptide se-
quence were obtained through a careful X-ray crystal-
lographic analysis [153]. Unravelling these trapped 
 
Fig. (9). Proposed sequence of steps (A–F) in the cleavage of natural substrates by HIV-1 protease redrawn from litera-
ture[176] (hydrogen atoms were omitted for clarity).  Main chain atoms of substrate peptide and Asp molecules are shown in 
grey=carbon, blue=nitrogen and red=oxygen).  Each figure is based on the structure indicated: (A) Bound WatC to ligand-free 
tethered HIV-1 PR Asp dyad, PDB code 1LV1.[175]  (B) Modelled ES complex.  (C) Formation of INT, PDB code 
3MIM.[177]  (D) Breaking of the scissile bond with the product peptides bound in the active site, PDB code 2NPH.[172]  (E) 
diffusion of a unit of the separated products out of the active site and WatC into the active site, PDB code 2WHH.[176]  (F) 
Release of the other product segment and movement of WatC into its original position, PDB code 1LV1.[175] 
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conformations, the metastable diol INT, the cleaving 
C----N product segments and the C-terminus product 
complex were revealed. Both WT and mutant PRs were 
observed to exhibit conserved interactions with the 
complexed peptides, [153] a related hypothesis from 
Schramm and coworkers [146]. A reaction mechanism 
was proposed with a proton placed on OD1 of Asp25ʹ 
(to initiate reactivity) in a five-step process (similar to 
Fig. 9) for these enzymes [153]. The authors’ hypothe-
sis of the reaction path is enumerated: (1) More than 
one intermediate will be observed by simply crystalliz-
ing the protein in the presence of a peptide substrate, 
which implies that the energy barriers of the hydrolysis 
reaction of substrates by these HIV-1 PRs are similar 
[153]. (2) It is possible that the mechanistic route of the 
natural substrate hydrolysis by HIV-1 PRs does not 
include a single rate-determining step [153] as sug-
gested in a number of studies [25, 113, 118, 146, 176]. 
(3) Majority of the interactions with bound peptides are 
conserved in the wild type enzyme and the mutants in 
agreement with the report that mutants share similar 
transition states to wild type PR [146]. (4) The interac-
tions observed in these new structures [153] were 
mapped on the scheme (Scheme 6) for the reaction. (5) 
All three intermediate stages retain the short 2.3–2.4 Å 
hydrogen bond, which may be an LBHB, of the hy-
droxyl group of the peptide intermediate with one of 
the catalytic aspartates, as reported in lower resolution 
crystal structures [129, 176]  
These contributions [129, 152, 153, 171, 173, 176, 
179] appear to solve a pertinent research question men-
tioned earlier on the determination of reaction com-
plexes along the HIV-1 PR—substrate PES through in 
vitro methods. Capturing reaction complexes of the 
enzymatic process through crystallographic analyses is 
appreciably informative especially when different in-
termediate structures are discovered [179]. A clearer 
picture of the mechanism of enzyme catalysis is crucial 
to facilitate the design of new inhibitors. In addition to 
the crystallization methods mentioned so far, the use of 
theoretical/computational tools, Laue diffraction and 
neutron crystallography approach (to capture or see 
hydrogen atoms) as well as time-resolved spectroscopic 
analysis, could serve as complementing methods to-
wards the provision of a comprehensive picture of 
HIV-1 PR reaction [179].  
More recently, neutron crystallography was used to 
capture proton shift in HIV-1 PR—darunavir system at 
the reactive site of the enzyme [86]. Variations of Asp 
protonation states that were earlier proposed [34] were 
observed for the first time. The catalytic Asp dyad 
rarely maintains single protonation model throughout 
the reaction process [10, 93, 107, 112, 176, 180]. Ger-
lits et al. [86] applied neutron crystallography to detect 
two proton transfers at 2.0 and 2.3 Å resolutions within 
the acidic pH of 6.0 and 4.3, respectively. A shared 
proton between the OD1 of both Asps (an LBHB) in 
the substrate-free system moved to OD2 of Asp25 
while, the proton from OD1 of Asp25ʹ was transferred 
to the OH of darunavir [86] 
3.2.2.1.5. The Tetrahedral Intermediate 
One of the most discussed reacting complexes along 
the HIV-1 PR—substrate stepwise general acid-base 
mechanistic pathway is the tetrahedral intermediate 
(INT). X-ray crystallographic analyses have buttressed 
the existence of the gem-diol tetrahedral INT [129, 
152, 153, 176, 179] (INT1 Fig. 10) compared to the 
oxyanion INT (INT2 Fig. 10), which was proposed to 
be possible through a tunneling effect [136]. INT1 is a 
typical TS analog whose conformational mimics has 
served as the basis for the design of nearly a dozen US 
Food and Drug Administration (FDA)-approved drugs 
for HIV-1 PR inhibition [147, 181]. In addition to theo-
retical investigations [25, 119, 120, 180] attempts at 
exploring the nature of the INTs (both INT1 and 
INT2), some authors have focused their research on the 
tetrahedral the nature of the INTs using theoretical 
methods.  
Carnevale et al. [182] carried out a comparative 
analytical investigation on the nature of the INTs in-
volved in the catalysis of natural substrate segments by 
HIV-1 PR. They [182] remarked that the neutral gem-
diol INT is highly stable compared to the ionized 
oxyanion INT (Fig. 10); a similar observation noted 
here [25, 119, 120]. The applied model was the same as 
the one studied before [25] with the inclusion of the 
enzyme frame, counterion and explicit solvent to ac-
count for the entire system’s behavior in the present 
model [182]. Illustrated in Fig. 10, is the QM part in 
which DFT/B3LYP and MP2 were applied. The gem-
hydroxyl INT was predicted to be 20–30 kcal mol-1 
more stable than the negatively charged oxyanion INT. 
Even if the entropic contribution is considered, the 
likelihood of change in the instability of this later 
conformation is uncertain [182].  
Garrec et al. [10] examined the reactivity of HIV-1 
PR as a model to test the accuracy of the then latest 
DFT methods. The adopted protonation pattern was 
model D (Fig. 4) while Scheme 5 was the investigated 
mechanistic pathway. They have suggested an explicit 
model that accounts for the detailed sampling of each 
candidate structure along the reaction coordinate [10]. 
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Focusing on the nature of the tetrahedral INT and the 
geometry of the carboxyl components of the active site 
Asps, these authors investigated gem-diol versus 
oxyanion INT and dihedral angle Asp25OD2--Asp25OD1--
Asp25ʹOD1--Asp25ʹOD2, respectively. It was noted that 
the oxyanion was extremely unstable while nearly all 
the tested DFT correlation functional yielded suitable 
geometry for the Asp dyad. Using a DFT/semi-
empirical model through Our own N-layered Integrated 
molecular Orbital and molecular Mechanics (ONIOM) 
[183, 184] method, they [10] observed the model pro-
vides inaccurate geometry and reactivity description of 
the HIV-1 PR—substrate system. It appears that this 
inefficiency was due to the choice of an over-simplified 
computational model [10] involving many frozen at-
oms close to the active site (Fig. S2; SI). 
The effect of enzymatic flexibility, individual resi-
due contribution and conformational fluctuations lead-
ing to variations in the activation barrier energies on 
the PES of HIV-1 PR—p2-NC were meticulously re-
ported by Ribeirio et al. [92]. The authors applied 
QM/MM (ONIOM) and QM/MM/MD methods to de-
termine the nature of the barrier heights in the first step 
cleavage reaction of this system using protonation pat-
tern B (Fig. 4) and Scheme 7. Their observations and 
conclusions are: (1) during the reaction, structural and 
conformational fluctuations invoked by residues’ elec-
trostatic contributions lead to the disordered energy 
barrier. (2) This uneven barrier distribution was de-
noted as “instantaneous disorder”. (3) The averaged 
activation energy for the different conformations at 2 
ns time intervals was 16.5 kcal mol-1 [92] and very 
close to the experimental value of 15.9 kcal mol-1 [79]. 
(4) Variations in activation barriers are caused by dif-
ferential mechanistic routes, which the PR tends to at-
tain. (5) One of these mechanisms involved the disap-
pearance of Asp25 catalytic role. (6) Another catalytic 
route is brought by the characteristic conformational 
orientation of the active region [92] 
The influence of frozen residues on the exploration 
of the PES of HIV-1 PR reaction mechanisms was re-
cently studied [180]. The authors adopted Scheme 7 
and previously reported computational protocols [92] 
to systematically investigate the effect of freezing dif-
ferent shells of residues on the activation and free en-
ergy of the first step reaction in HIV-1 PR catalysis of 
the substrate [180]. They observed two high ∆G‡ in the 
more constrained models; 24.1 and 27.0 kcal mol-1 for 
shells of 4.00 and 5.00 Å of free residues, respectively. 
Freezing the atoms/residues closer to the active site 
often hindered the reactivity of the enzyme thereby 
producing higher energy barriers, [180] an observation 
similar to investigations from here [10, 26]. The system 
was observed to produce reasonable free energies when 
the model has a freedom of radius ≥6.00 Å away from 
the active site. 
3.1.1.2. Concerted General Acid-Base Mechanism 
The concerted general acid-base mechanism seems 
to be the least explored model amongst the mechanistic 
pathways involved in HIV-1 PR catalysis of its sub-
strates. In 1991, Jaskólski et al. put forward an experi-
mental perspective on the hydrolytic mechanism of 
HIV-1 PR and its substrate, [185] they have proposed a 
one-step catalytic model in which the nucleophilic 
WatC and the electrophilic aspartate (an acidic proton) 
 
Fig. (10). Schematic representation of the INTs; INT1 is the gem-diol intermediate [25] while INT2 is the oxyanion form[112] 
of the substrate.  Both are gas phase models in which the entire systems were partitioned into three layers.  The only structural 
difference between the neutral and the charged reaction intermediate is the position of a proton which located on the reaction 
intermediate in INT1, while the both aspartic acid residues are protonated in INT2 [183]. 
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attack the scissile bond in a synchronous manner. At 
the beginning of the reaction, the acidic proton is lo-
cated on the OD2 of the aspartate that is proximal to 
the N atom of the approaching amide [185]. The post-
reaction catalytic aspartates are still bound by the 
acidic proton, which now resides between the inner 
OD1 atoms [185] (model J; Fig. 4) We summarize this 
experimental process in Scheme 8A. It is quite puz-
zling to observe that only two theoretical research out-
puts are found with respect to this long time [185] per-
spective. Note that the 6-membered ring TS in Scheme 
8C is proposed by us.  
In 2000, Park et al. [1] gave an investigation on the 
catalytic mechanism for Asp PRs using (MP2) [124] 
and Hartree-Fock (HF) [108] theories coupled with the 
6-31G(2d) [109] basis set. They used a model reaction 
where formamide represents the substrate, while ace-
tate and acetic acid represent the catalytic Asp residues 
[1]. The studied concerted general model gave an acti-
vation free energy of 30 kcal mol-1 and featured an 8-
membered ring TS structure (Fig. S3; SI).  
The latest attempt on the concerted general catalytic 
mechanism of HIV-1 with a peptide substrate was pre-
sented by Krzemińska et al. in 2016 [120]. The study 
utilizes a model in which both electrostatic and dy-
namic contributions were accounted for. The applied 
theoretical methods (umbrella sampling method; 
QM/MM/MD) enabled these authors [120] to explore a 
4-membered ring TS model devoid of the catalytic (or 
general acid-base) function of the aspartic moieties 
(Scheme 8B) with a characteristic high free energy bar-
rier (43.5 kcal mol-1). This theoretical observation is 
quite possible as reported in related chemical and en-
zymatic reactions [27, 163-169, 186] from our group 
whereby the 4-membered cyclic TS structures rarely 
yield better results than the 6-membered models 
(Scheme 8C). 
4. GENERAL OVERVIEW  
In this section, some important concepts are high-
lighted to provide future perspectives. A careful obser-
vation of literature reveals that recognition of the sub-
strate and the reaction mechanism of the HIV-1 PR—
substrate is rather complex and the possibility of de-
scribing the process in terms of the role of water mole-
cule(s), the Asp dyad protonation state and the rate-
limiting step(s) seems uneasy. These stated conceptual 
parameters are crucial and interwoven when investigat-
ing the catalytic process of HIV-1 PR.  
 
Scheme 7. Different proposed mechanism and configurations adopted by the active centre of protease redrawn from litera-
ture.[93, 181].  A; WatC nucleophilic attack and proton transfer to Asp25ʹ, when it loses the planarity, the nucleophile can be 
more or less stabilized by the highlighted hydrogen (configurations A.1 and A.2), this is the most commonly described is 
mechanism in literature.  B; WatC nucleophilic attack and proton transfer to Asp25ʹ.  Asp25 loses its catalytic role in this 
process and this was observed to be unfavourable.   
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Scheme 8. The concerted general acid-base HIV-1 PR mechanism via Asp25ʹ OD2 protonation, (A) possible concerted 
mechanistic pathway based on Jaskólski et al. [186] hypothesis.  (B) Concerted 4-membered ring model redrawn from litera-
ture,[122] the catalytic role of the aspartate groups seems apparently loss and (C) Proposed concerted 6-membered cyclic HIV-
1 PR enzymatic mechanism. 
Based on investigations from both theoretical and 
experimental, HIV-1 PR recognizes its natural sub-
strate through; substrate modulation, substrate groove, 
conserved substrate shape, interdependence conforma-
tional adaptability of both enzyme and targets [17, 19, 
41, 42, 72, 74, 78]. A notable contrasting opinion from 
computational simulations [46] is that substrate recog-
nition of HIV-1 PR seems to be based on the conforma-
tional specificity of the protease to the Gag and Gag-
Pol polyprotein pool as opposed to the popular lock-
and-key or induced-fit model [46] 
It is generally accepted that the enzymatic mecha-
nism of HIV-1 PR requires WatC (Schemes 3–8) there-
fore the nucleophilic mechanistic route (Schemes 1-2) 
could be less realistic. The authenticity of the gem-diol 
INT (Fig. 10, INT1) is more widely accepted than the 
presence of the unstable oxyanion (Fig. 10, INT2). 
Apart from the hydrolytic function of WatC in the hy-
drolysis of the substrate peptide bond, about five addi-
tional water molecules have been highlighted to be cru-
cial to HIV-1 PR reactivity mechanism through ex-
perimental [19, 34, 153, 187] and theoretical [93, 110, 
188] techniques. The moieties along the enzyme-
substrate reaction mechanism are stabilized by these 
five water molecules through ordered orientation of 
their dipoles. However, they appear not to be credited 
for participation in the catalytic process [93]  
4.1. Stepwise Versus Concerted General Acid-Base 
Mechanism of HIV-1 PR 
The nature of the HIV-1 PR reaction mechanism has 
been more often investigated as stepwise general acid-
base rather than the concerted process. In the stepwise 
reaction pathway of HIV-1 PR—substrate showcasing 
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up to three TS moieties (Scheme 3), authors have sug-
gested that the breakdown of the gem-diol INT is the 
rate-determining step from both experimental [113, 
146] and computational [25, 113, 118, 120, 146, 176] 
methods. A contrasting opinion [153] in this regard is 
the likelihood of the existence of more than one rate-
determining step due to the possibility of more than 
two metastable intermediates along the reaction coor-
dinate (Scheme 3). Some studies [92, 180] also related 
the first step of the enzymatic reaction mechanism 
leading to INT formation as the rate-limiting step.  
For the concerted general mechanism (Scheme 8), 
Hyland et al. [125, 126] had earlier mentioned that it 
does not yield a discrete INT, therefore, the possibility 
of elucidating TS analogs necessary for inhibitor de-
sign is apparently lost. However, the concerted mecha-
nism in which the process occurs (Scheme 8C) via cy-
clic TS in our view should be revisited as proposed ex-
perimentally [185]. In the light of literature support for 
similar six-membered ring, transition structures ob-
served theoretically, [91, 163-169] a one-step concerted 
chemical process appears plausible. This could poten-
tially provide an alternative insight on the catalytic 
mechanism of HIV-1 PR. Such an investigation ap-
pears absent computationally and would be quite in-
formative if the possibility of a single rate-determining 
step could be achieved.  
FUTURE PERSPECTIVE 
Studies on updates HIV-1 PR are quite diverse and 
require distinct update directed at some specific topics. 
This overview serves as an update on recent advances 
in understanding the recognition mode and catalytic 
mechanism of HIV-1 PR and its natural targets through 
experimental and computational techniques. Theoreti-
cal approaches play a vital role in determining the rec-
ognition pattern and enzymatic mechanism of HIV-1 
PR and its natural targets, which can be expanded to 
other related aspartic proteases. Tremendous progress 
is expected in years to come through the development 
of advanced computer software and hardware, which 
would clarify the general reaction pathway for the 
HIV-1 PR—substrate/inhibitor complex. 
Future studies on the reaction mechanism of HIV-1 
PR and natural substrates should involve the applica-
tion of advanced computational techniques to provide 
plausible answers to some unresolved perspectives. In 
computational investigations, a pertinent concept to-
wards understanding the HIV-1 PR—substrate mecha-
nism is the sufficiency of inclusive (all atoms) and ex-
cluding (just the reactive parts) models to describe the 
system. Based on general observations, the use of 
model systems for the HIV-1 PR—natural substrate 
mechanism [1, 10, 25, 26, 107, 118, 146] is more popu-
lar compared to an entire representation of the en-
zyme—substrate system [94, 110]. This is the result of 
researchers preferring to simplify the model initially as 
well as historic limitations with computer software and 
hardware. It therefore, seems obvious that the correla-
tion of theoretical results with experimental data was a 
crucial outlook of most of these studies [1, 10, 25, 26, 
107, 118, 146].  
Future computational efforts should explore not 
only the energy values obtained but other properties 
such as the geometry of the system, the thermochemis-
try and the accuracy of the chosen theoretical tools. 3-
D crystal structure of unbound and bound HIV-1 PR is 
largely deposited in different databases. For example, 
RCSB PDB [18] has almost 200 wild-type HIV-1 PR 
complexed with various ligands/substrate segments at a 
resolution as low as 1.00 Å [189]. It is informative to 
note that high resolution does not necessarily mean the 
best starting geometry for computational simulation. 
For instance, 3NU3.pdb [190] was refined to 1.02 Å 
and the active site dihedral angel (Asp25OD2--Asp25OD1--
Asp25ʹOD1--Asp25ʹOD2) is 49.43º, 4HVP [137] (refined 
to 2.30 Å) gave 15.57º for this angle, while as large as 
67º have been noted for this important dihedral [10]. 
Therefore, theoretical investigations on the enzymatic 
mechanism of HIV-1 PR—natural substrate in years to 
come, would likely involve the applications of sophis-
ticated computational techniques aimed at exploring 
more than energetics of the system. The possibility of 
integrated computational algorithms which do not in-
volve partitioning/restraining/constraining/cropped 
model system of the ES mechanism would likely sur-
face in future to accurately elucidate the HIV-1 PR 
catalytic process on natural substrates/ligands.  
The protonation pattern of the Asp dyad is still a 
matter of debate, a new perspective on the protonation 
state of the active Asps should be investigated through 
advanced theoretical models. Parameters such as geo-
metric orientation, QM-based chemical properties and 
thermodynamics could be examined. The outcome of 
such studies may potentially serve as an answer to a 
query on adopting a unified protonation pattern for not 
just the natural Gag and Gag-Pol peptide segments but 
also, the HIV-1 PR inhibitors.  
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AIDS = Acquired Immune Deficiency 
Syndrome 
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∆G‡ = Activation free energy 
ANM = Anisotropic Network Model 
AVB = Approximate valence bond 
AMBER = Assisted Model Building with En-
ergy Refinement 
BSST = Biased sequence search threading 
BACE 1 = Beta-secretase 1 
CA = Capsid 
WatC = Catalytic water 
Cat D = Cathepsin D 
COBRAMM = Computations at Bologna Relating 
Ab-initio and Molecular Mechan-
ics Methods 
DEE = Dead-end elimination 
DFT = Density functional theory 
EVB = Empirical valence bond 
ES = Enzyme—substrate 
FlAsH = Fluorescein arsenical hairpin 
FDA = Food and Drug Administration 
FEP = Free energy perturbation 
HF  = Hartree-Fock 
HIV = Human Immunodeficiency Virus 
HTLV-1 = Human T-cell leukaemia virus 
IN = Integrase 
INT = Intermediate 
IRC = Intrinsic reaction coordinates 
KIEs = Kinetic Isotope Effects 
LBHB = Low barrier hydrogen bond 
MA  = Matrix 
MMFF = Merk Molecular Force Field 
MD = Molecular dynamics 
MM = Molecular mechanics 
MM-PBSA = Molecular mechanics Poisson-
Boltzmann surface area 
MP = Moller-Plesset 
MDR = Multidrug-resistant 
NMR = Nuclear magnetic resonance 
NC = Nucleocapsid 
ONIOM = Our own N-layered Integrated mo-
lecular Orbital and molecular Me-
chanics 
PME = Particle Mesh Ewald 
Plm II = Plasmepsin II  
PES = Potential energy surface 
PR = Protease 
PDB = Protein Data Bank 
QM = Quantum mechanics 
REMD = Replica-exchange Molecular Dy-
namics 
RT = Reverse transcriptase 
RH = RNAse H 
SA = South Africa 
p1 = Spacer peptide 1 
p2 = Spacer peptide 2 
S-groove = Substrate-groove 
TI = Thermodynamic integration 
3-D = Three-dimensional 
TS = Transition state 
VDW = van der Waals 
WT = Wild type 
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Scheme S1: Proposed stepwise catalytic mechanism for HIV-1 PR through protonation of OD2 in Asp.  Complex 1 involves 
the transfer of electronic charges from the deionized Asp25 to the water molecule and subsequent attack of this hydrolysis wa-
ter unit on the scissile carbonyl of the substrate.  Compound 2 is a typical oxyanion intermediate while 3 involve the breakdown 
of this tetrahedral intermediate.  Products are completely separated in 4 and thus released into the HIV life cycle. 
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Scheme S2: Proposed concerted HIV-1 PR enzymatic mechanism.  Bond breaking and forming process may occur concur-
rently (1) and products (2) are formed. 
  	  
 	  
 
Scheme S3: Proposed mechanism for HIV PR catalyzed incorporation of 18O and H2O18 into the peptide substrate.	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Figure S1: Schematic representation of the overall studied mechanisms for HIV-1 PR catalysed reaction of hexapeptide bond 
cleavage.  Activation free energies, in relation to the initial reactant state, were derived from the AM1/MM PMFs corrected at 
M06-2X:AM1/MM level.  All values are reported in kcal·mol-1.  “Adapted with permission from article.1  Copyright (2016) 
American Chemical Society." 
 
Figure S2: In ONIOM calculations, atoms in red are described at the high level.2 
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Figure S3: The concerted general acid-base mechanism involving 8-membered ring TS.3  
  
Table S1: Hydrogen bond distances (Å) in structural complexes along the PES of HIV-1 PR—substrates 
systems (Figure 8) for the general acid-base mechanism. 
 
H-Bond INT TS Prod 
OWatC—H1WatC--OD1Asp25 2.304 
2.705 
  2.656 
2.905 
OD1—HAsp25'--N 2.504     
OD2Asp25--OWatC 2.507 
2.918 
3.105 
2.569 2.456 
2.805 
OD1Asp25--OD1Asp25' 2.609 
2.487 
2.805 
2.989 2.3010 
2.766 
OD2Asp25'--N 2.80/2.907 
3.105 
  2.9010 
OD1--HAsp25 1.139 1.349   
HD1Asp25--OD1Asp25' 1.699 2.329   
HD1Asp25--OD1Asp25 1.069     
CSUB--NSUB 1.589   2.586 
2.4610 
CSUB--OWatC 1.499     
OWatC--OD1Asp25' 3.005   2.705 
OWatC--OD2Asp25' 3.005   3.005 
NSUB--OD2Asp25' 2.359     
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NSUB--H2WatC 1.149     
H2WatC--OD2Asp25' 1.189 1.579   
H2WatC--OWatC   1.309   
COSUB--OD2Asp25' 2.208     
COSUB--OD2Asp25 2.305   2.5110 
OWatC--OD2Asp25 2.918     
Values are taken from both in vitro and in silico studies.  ES = enzyme-substrate complex, INT represents tetrahedral intermediate, TS= transition state in-
volved in the breakdown process of the INT and Prod= product. 
 
Figure S3: Complexes along mechanistic pathway of HIV-1 PR—substrates system. 
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Table S2: Theoretical and experimental interatomic distances (in Å) for important complexes (Figure S3) 
along the PES of HIV-1 PR—substrates.  TS1 is obtained with ONIOM11, 12 method at 6-
31G(d)/AMBER13 level of theory in this present study. 
Distance ES TS1 INT TS2 Prod 
CSUB—NSUB 1.448 1.38 1.704 
2.2710 
  
1.5214 2.6710 
1.657 
3.506 
2.0214 
OWatC—HD2Asp25/25' 2.0015   ≥1.504     
CSUB—OSUB   1.34 1.804     
CSUB—OWatC 2.9115 1.71 1.504 1.884   
OD2Asp25'—OWatC 2.8015 2.77       
OD2Asp25—OWatC 2.6615 2.97       
OD1Asp25—OWatC 3.2815 3.73       
OD1Asp25'—OWatC 2.9615 3.24       
NSUB—HD2Asp25'     2.00–3.004 1.354 
1.2614 
  
OD2—HD2 Asp25'       1.3214   
ES is the enzyme—substrate complex, INT is the tetrahedral intermediate, TS1 and TS2 is the forming and breakdown process of the INT, respectively. 
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Abstract
We give an account of a one-step concerted catalytic mechanism of HIV-1 protease (PR) hydrolysis of its natural substrate using a
hybrid QM/MMmethod. The mechanism is a general acid–base model having both catalytic aspartate groups participating and a
water molecule attacking the natural substrate synchronously. Three different pathways were investigated: a concerted acyclic
transition state (TS) mechanistic route, a concerted 6-membered cyclic TS process involving one water molecule, and another 6-
membered ring TS pathway involving two water molecules. Activation free energies of approximately 15.2 and 16.6 kcal mol−1
were obtained for both concerted acyclic and the other possible reaction pathway involving two water molecules in the active site,
respectively. The activation free energies are comparable to experimentally derived data of 15.69 kcal mol−1. The outcome of the
present work provides a plausible theoretical benchmark for the concerted enzymatic mechanism of HIV-1 PR and can be applied
to related enzymatic processes.
Keywords HIV-1 protease . Natural substrate . QM/MM (Our own N-layered Integrated molecular Orbital and molecular
Mechanics ONIOM)method . Concerted transition states . Catalytic mechanism
Introduction
One infectious disease that has had both a profound health and
cultural impact on the human race in recent decades is the
acquired immune deficiency syndrome (AIDS) [1] caused
by the human immunodeficiency virus (HIV) [1, 2], and it
remains one of the severest health challenges [2]. HIVattacks
its host’s immune system thus making such individuals vul-
nerable to any infection; a breakthrough in the treatment of
HIV-1 is the use of drugs inhibiting specific enzymes neces-
sary for the replication of the virus [3]. Among these enzymes
is HIV-1 protease (PR), which is an important degrading
enzyme necessary for the proteolytic cleavage of the
Gag and Gag-Pol polyproteins, required for the devel-
opment of mature virion proteins [4–7]. The hydrolytic
act ion of the PR on these asymmetric natural
polyprotein substrate sequences results in the processing
of the corresponding mature virion [8, 9]. The mecha-
nism of action of PR has been a subject of research
over the past three decades [10].
The catalytic mechanism of the HIV-1 PR is one of the
most studied aspartate protease reactions. Both experimental
and theoretical techniques have been harnessed to provide a
better understanding on a number of possible reaction path-
ways for the catalytic cleavage of the natural substrate/ligand
by the PR [11–15]. The aspartate dyad of the HIV-1 PR is
most often monoprotonated [16] in such theoretical studies
(Fig. 1).
Most of the recent studies [14, 17–26] have investigated the
stepwise general acid–base mechanism involving catalytic
water (WatC) at the active site of the HIV-1 PR, whereby the
hydrolysis occurs in several steps (Scheme 1). Another possi-
ble mechanistic pathway is a nucleophilic process [19, 20, 26],
which is a variance of the stepwise general acid–base mecha-
nism without WatC. Researchers have obtained both theoretical
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and experimental rate-determining transition-state (TS) energies
[14, 17–26] that correlate with experimental energies of peptide/
substrate hydrolysis for both stepwise and nucleophilic mecha-
nisms. Despite extensive investigations on HIV-1 PR catalytic
pathways, little attention has been given to a synchronousmodel
in which the proteolytic reaction could occur as a one-step con-
certed process.
In 1991, however, Jaskólski et al. [13] proposed a one-step
concerted mechanism for the reaction; the nucleophile (water
molecule) and electrophile (an acidic proton) attack the scis-
sile bond in a concerted manner. At the beginning of the
reaction, the acidic proton is located on the OD2 atom of that
aspartate, which is proximal to the nitrogen atom of the scis-
sile amide [13]. The post-reaction catalytic aspartates are still
bound by the acidic proton, which now resides between the
inner OD1 atoms (Model E; Fig. 1). The proposed concerted
mechanism in this study was indeed derived based on the
reported experimental protocol [13] which is summarized in
Scheme S1 of the supporting information (SI).
We found only two theoretical models [14, 19] in literature
with respect to the one-step concerted perspective [13] having
cyclic TSs with activation free energies (ΔG‡) of 30 [19] and
Scheme 1 Stepwise general
acid–base catalytic mechanism of
HIV-1 PR [27]. ES is the
enzyme–substrate complex. TS1
is the first transition structure
which should be overcome before
the formation of the tetrahedral
intermediate (INT). TS2 is the
breakdown of the INT complex
while EP is the separated
products. Adapted from literature
[27]
Fig. 1 Possible monoprotonated
models for the catalytic aspartate
dyad
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43.5 [14] kcal mol−1, respectively. These values are higher
than experimental ΔG‡ values (between 14.86 and
21.03 kcal·mol−1) depending on the amino acid sequence
[11, 12, 28–33]. In light of literature support for theoretical
6-membered ring transition structures [34–41], a one-step cy-
clic concerted chemical process (Scheme 2) appears plausible
and can potentially provide a new understanding of the cata-
lytic mechanism of HIV-1 PR.
Method
System setup
TheX-raycrystal structureofMA-CAsubstrate (code:1KJ4) [42]
was obtained from RCSB PDB [43] and complexed with HIV-1
PR(code:1A30) [44].Thecatalyticwatermoleculewasmanually
inserted at the active site and thebonddistancesobserved from the
1LV1 structure were employed [45] (an apo HIV-1 PR co-
crystallizedwith awatermolecule at the active site). This complex
was subjected to classical molecular dynamics (MD) simulation
(20 ns long) as described in our previous work [46]. The lowest
energy structure from theMD runwas partitioned into two layers
andOur OwnN-layered Integratedmolecular Orbital andmolec-
ularMechanics (ONIOM) [47] (QM/MM) approachwas applied
to investigate the mechanism of the reaction. This was done after
stripping off the explicit solvation box and non-required atoms
(Cl–) inherent from the MD simulation. The catalytic active site,
natural substrate (Matrix-Capsid segment (MA-CA)), and water
were placed at a high layer (B3LYP [48, 49]/6-31++G(d,p) [50])
while the remaining residueswere at the low layer (AMBER) [51]
for geometry optimization (Fig. 2).
The rel iabi l i ty and accuracy of the B3LYP/6-
31G(d):AMBER ONIOM model has been established for a
similar study [52, 53]. In order to improve the level of accu-
racy of the results and consider the effect of diffusion and
polarization functions on the hydrogen atoms involved at the
reactive center, B3LYP/6-31++G(d,p):AMBER was used.
Given the fact that one of the aspartate residues is protonated
(Fig. 1) for a concerted mechanism where both the nucleo-
phile (water molecule) and electrophile (an acidic proton) are
expected to attack the scissile bond in a concerted manner, we
protonate OD2 of Asp25′ (Model D; Fig. 1) as proposed from
experiment [13].
Transition state modeling and energy calculations
The complex obtained (lowest energy snapshot) from MD
simulations was subjected to constraining and relaxing for
the TS QM/MM modeling. Interatomic distances for the pro-
posed cyclic transition state were constrained (Owat–Csub at
2.40 Å, Nsub–OD2 Asp25′ at 2.79 Å and Owat–OD2 Asp25′
at 2.71 Å, Scheme 2) during an optimization to find a suitable
TS starting structure. All constraints were removed for the
subsequent transition state optimization.
Calculations proceeded with a full geometry optimization
of al l s t ruc tures using the selec ted two-layered
ONIOM (B3LYP/6-31++G(d,p) :AMBER) model .
Vibrational frequencies [54] were computed for the various
species to characterize them as local minima (no negative
eigenvalues) and the TS structure having exactly one imagi-
nary frequency. Intrinsic reaction coordinates (IRCs) [55]
were computed to verify the transition structures are truly
the lowest saddle points connecting the expected reactant
and product complexes on the reaction pathway. GaussView
5.0.8 [56] was used as pre-processor and post-processor visual
interface for this study, while all calculations were executed
within the Gaussian 09 program package [57].
Results and discussion
The first attempt to find a cyclic TS (Scheme 2) gave us in fact
a concerted acyclic TS involving one water molecule
(Scheme 3). Refinement of the cyclic TS starting structures
enabled us to find them as well. The relative thermodynamic
and kinetic parameters for the concerted acyclic and cyclic
mechanistic cleavage of MA-CA by HIV-1 PR are presented
in Table 1. Generally, all the studied concerted mechanistic
pathways are exergonic with highly negative free energies at
product formation (Schemes 2, 3, and 4). The change in total
energy (ΔE), enthalpy (ΔH), and entropy (TΔS) values of the
ES and product complexes are negative. The free energy (ΔG)
values related to the difference betweenΔH and TΔS are also
Scheme 2 Proposed concerted 6-
membered cyclic enzymatic
mechanism of HIV-1 PR
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negative and ΔG of these minima seems driven by ΔH with
characteristic large negative values ranging between − 33 and
− 60 kcal mol−1.
Cleavage of the substrate by HIV-1 PR gave a significantly
large level of disorderliness as observed from the activation
entropy (TΔS‡) of the TS structures having more negative
values than the activation enthalpy, ΔH‡ (Table 1).
Activation free energies (ΔG‡) of the TS structures are thus
favored by large entropy penalties of − 16.16, − 38.71, and −
54.92 kcal mol−1 for the 6-membered cyclic, acyclic, and 6-
membered cyclic (with two water) models, respectively. The
sum of the total free energy of each mechanistic pathway gave
− 28.71, − 13.87, and − 46.48 kcal mol−1 for the 6-membered
cyclic, acyclic, and 6-membered cyclic (with two water) sys-
tems, respectively.
Based on thermodynamics (more negativeΔH) and overall
system energetics (ΔE), the two-water mechanistic pathway is
the most favorable; addition of another water molecule at the
HIV-1 PR active site essentially pulls down the activation
barrier and improves the cleavage process. However, when
the ΔG‡ of the TS structures were considered, the concerted
acyclic mechanism involving a catalytic water molecule
proved to be the most favored process (Table 1). This is a
well-established perspective from literature using both
in vitro and in silico methods [10]. The reaction rate of the
TS structures depicted by lnk follows the order C-Ac-TS > C-
6-TS > C-6-TS-TW.
Concerted acyclic general acid–base HIV-1
PR–substrate mechanistic pathway
The concerted acyclic TS (Scheme 3) leads to the expected
reactant and product complexes (from the IRC calculation,
Fig. 3) with an observed ΔG‡ of 15.21 kcal mol−1 (Table 1)
at B3LYP/6-31++G(d,p):AMBER level of theory. During this
concerted general acid–base mechanism, water donates one of
its protons to the unprotonated Asp25 and the protonated
Asp25′ loses its proton to the scissile nitrogen atom; thus,
the initial acidic Asp becomes basic and vice versa.
Meanwhile, the nucleophilic water (OH) attacks the scissile
carbon resulting in substrate cleavage (Scheme 3).
The reaction involves bond forming and breaking process-
es; the initial C–N bond increases from 1.47 to 1.67 Å, at the
TS and becomes 2.65 Å at the product complex, which is
comparable to experimental distance of 2.70 Å between these
atoms [58]. The proton transfer (to Asp25 OD2) from the
catalytic water increases in bond length from 0.96 to 1.26 Å
in the TS structure, thereby, moving closely to the OD2 of
Asp25 with a bond distance of 1.14 Å. The scissile nitrogen
atom accepts a proton from the protonated aspartate (Asp25′)
with a bond distance of 1.22 Å (Fig. 4).
For the acyclic mechanism, the ES gave ΔE, ΔH, and
TΔS values of approximately − 40, − 39, and −
22 kcal mol−1, respectively, with ΔG formation of −
17 kcal mol−1 (Table 1). This pre-ordered ES complex
Fig. 2 Schematic representation
of the two-layered ONIOM
(DFT:AMBER) model of HIV-1
PR–MA-CA complex. ONIOM
output files for the TS structures
are available in PDB format with
the SI
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Scheme 3 Concerted acyclic
enzymatic mechanism of HIV-1
PR with its substrate
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facilitates the concerted nature of the acyclic TS (Fig. 4) with
an exergonic totalΔE‡ of − 28.6 kcal mol−1,ΔH‡ value of −
23.5 kcal mol−1, TΔS‡ of − 38.7 kcal mol−1, and an activation
barrier (ΔG‡) of 15.2 kcal mol−1. C-Ac-TS is more favored
with entropy compared to enthalpy while the opposite holds
for its PC. The calculatedΔG‡ of 15.21 kcal mol−1 is in good
agreement with experimental ly deduced ΔG‡ of
15.69 kcal mol−1 [30]. The overall mechanism remained ex-
ergonic with the product complex having a ΔG of −
26.70 kcal mol−1 (Fig. 3 and Table 1) with a total ΔG value
of − 28.71 kcal mol−1 for the overall mechanistic process.
The concerted cyclic general acid–base HIV-1
PR–substrate mechanistic pathway
Subsequently, we also found the concerted 6-membered ring
TS structure facilitated by one water molecule (Scheme 2), as
well as another cyclic TS involving two water molecules
(Scheme 4). Although the mechanism closely mimics the acy-
clic model, a slight difference was observed. Unlike the acy-
clic pathway in which the aspartates participate in bond shar-
ing with the water and substrate, the 6-membered cyclicmech-
anism (involving one and two water molecules) showcased
distinct characteristics.
In the case of one water cyclic mechanism (Scheme 2), the
unprotonatedAsp25 only acts as an anchoring entity rather than a
base and a product complex is formed with Asp25′ protonated
fromwater. In other words, only Asp25′ partakes in bond sharing
and acts as an acid (donating its proton to the scissile nitrogen) as
well as a base (protonated by water) at the end of the cleavage
process. The mechanism, therefore, starts and ends with proton-
ation model D (Fig. 1). C–N scissile bond of the C-6-TS was
1.65Å and increased to 2.66Å after substrate cleavage (PC). The
interatomic distance between the scissile carbonyl (C=O) and the
nucleophilic water (OH)was 1.75Åwhile the secondH of water
was 1.43 Å away from the OD2 of Asp25 for the transition state
(Fig. S1). The scissile nitrogen and proton from the Asp25′ gave
an interatomic distance of 1.32 Å in the TS structure.
Optimization of the complexes down the reaction profile
also yielded the ES and product complexes in the 6-membered
one water cyclic mechanism with the same ES as the acyclic
model (Table 1). The calculated thermodynamic parameters
for the C-6-TS were slightly endergonic with ΔE‡ of
9.45 kcal mol−1, ΔH‡ value of 10.23 kcal mol−1, TΔS‡ of −
16.16 kcal mol−1, and ΔG‡ of 26.39 kcal mol−1. This TS
structure is largely driven by entropy contributions and the
overall mechanistic pathway remained exergonic with a
summed ΔG value of − 13.87 kcal mol−1 and the calculated
ΔG value for PC is − 23.04 kcal mol−1. Although, the activa-
tion free energy value is not perfectly comparable with exper-
iment, it is worth mentioning that this 6-membered cyclic
model is an improved model when compared to the previous
contributions from literature [14, 19]. Krzemińska et al. [14]
recently explored a 4-membered ring TS model devoid of the
catalytic (or general acid/base) function of the aspartic moie-
ties with a much higher free energy barrier of 43.5 kcal mol−1.
Scheme 4 Proposed reaction
scheme for the two-water
mediated cleavage of natural
substrate by HIV-1 PR
Table 1 Relative thermodynamic and kinetic parameters for the one-
step catalytic mechanism of natural substrate (MA-CA) using ONIOM
(B3LYP/6-31++G(d,p):AMBER)
ΔE ΔH TΔS ΔG‡ lnk
Concerted acyclic mechanism
ES −40.28 −38.88 −21.66 −17.22
C-Ac-TS −28.60 −23.49 −38.71 15.21 3.77
PC −34.71 −33.44 −10.74 −26.70
Concerted 6-membered cyclic mechanism − 13.87
C-6-TS 9.45 10.23 −16.16 26.39 −15.11
PC −43.15 −41.75 −18.71 −23.04
Concerted 6-membered cyclic mechanism with two water molecules
ES-TW −62.51 −59.66 −22.12 −37.54
C-6-TS-TW −35.82 −38.35 −54.92 16.57 1.49
PC-TW −54.63 −53.37 −27.86 −25.51
Values are reported in kilocalories per mole relative to the sum of sepa-
rated reactants. ES enzyme–substrate complex, TS transition state struc-
ture, PC product complex, TW two water, C concerted, Ac acyclic.
ONIOM output files for the TS structures are available in PDB format
with the SI
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In order to improve the 6-membered cyclic model with
catalytic water, we proposed a concerted 6-membered ring
mechanistic pathway involving two water molecules
(Scheme 4). The mechanism involves both aspartates acting
as anchoring moieties (they are not involved in bond sharing
with the substrate); however, their catalytic effect was still
obvious with ΔG‡ of 16.57 kcal mol−1 for the TS structure
(Fig. 3 and Table 1). This calculated ΔG‡ is in reasonable
a g r e emen t w i t h e xp e r imen t a l l y d e r i v e d ΔG ‡
15.69 kcal mol−1 for MA-CA (Ser-Gln-Asn-Tyr*Pro-Ile-Val-
Gln) hydrolysis by HIV-1 PR [30]. This mechanism does not
only showcase the success of a cyclic synchronous model but
also offer another perspective on the importance of water mol-
ecules at the active site of the HIV-1 PR [59–62] in which the
activation barrier was lowered by almost 10 kcal mol−1 in
comparison to the one water model (Fig. 3).
The calculated values forΔE,ΔH, and TΔS were − 62.51,
− 51.66, and − 22.12 kcal mol−1, respectively; ES complex of
the two-water model with an estimated ΔG value of −
37.54 kcal mol−1 (Table 1). C-6-TS-TW has the highest
TΔS‡ value of − 54.94 kcal mol−1 in comparison to the two
other TS possibilities; this is expected due to the increased
atomic constituent of this TS and the induced disorderliness
from an additional water molecule. This two-water mediated
mechanistic pathway also gave the highest total ΔG value of
− 46.48 kcal mol−1 for its entire process, thus establishing the
feasibility of the mechanism theoretically. The calculatedΔG
for its PC is − 25.51 kcal mol−1 while − 53.37 and −
27.86 kcal mol−1 were obtained forΔH and TΔS, respective-
ly, (Table 1).
The one-step concerted acyclic TS model provides a plau-
sible theoretical model for the enzymatic mechanism of HIV-1
PR. Unlike previous computational attempts [14, 19] for this
mechanism with higher free energy barriers for peptide hydro-
l y s i s , much lowe r ene rgy ba r r i e r s ( 15 .21 and
16.57 kcal mol−1) are obtained herein. This favorable energy
could be attributed to the studied concerted TSmodels and the
HIV-1 PR preference for large hydrophobic side chains at the
P1 position of the natural target [63]; MA-CA scissile bond is
located between Tyr-Pro (Fig. 2).
Fig. 3 Free energy profile for the
one-step concerted cyclic and
acyclic catalytic mechanism of
HIV-1 PR and MA-CA natural
substrate using ONIOM (B3LYP/
6-31++G(d,p):AMBER) method.
TS, transition state structure; TW,
two water; PC, product complex;
C, concerted; Ac, acyclic.
ONIOM output files for the TS
structures are available in PDB
format with the SI
Fig. 4 The concerted acyclic TS of HIV-1 PR–MA-CA general acid–
base mechanism using ONIOM (DFT:AMBER) method. Picture
generated with GaussView 5.0.8 [56], distances are in angstrom (Å).
ONIOM output files for the TS structures are available in PDB format
with the SI (Figs. S1 and S2)
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Conclusion
In conclusion, we have reported a new (theoretical) per-
spective on three possible concerted general acid–base
mechanisms for the HIV-1 PR catalysis of its natural sub-
strate. The mechanism that provides marginally the lowest
activation barrier involves an acyclic TS model with one
water molecule (Scheme 3) at the HIV-1 PR active site.
We also proposed a two-water model (Scheme 4) involv-
ing cyclic TS structure having an observed activation free
energy that is comparable to experiment and should be
pursued experimentally in subsequent research. This pres-
ent investigation could potentially provide a better under-
standing on achieving a single rate-limiting step for HIV-1
PR catalysis since the possibility of the existence of more
than one rate-determining step has been proposed in the
stepwise mechanistic pathway [64].
These models also provide new structural information
about the exact nature of the protonation state of the two
catalytic Asp residues, during hydrolysis of the natural
substrate for a concerted general acid–base mechanism.
The outcome of this study is quite informative and the
TS model will be applied to related homodimeric protease
and perhaps other enzymatic processes. Future studies
will attempt to obtain a better understanding of the recog-
nition phenomena of the HIV-1 PR towards natural sub-
strates with preference for the scissile amide bonds.
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ABSTRACT: The Human Immunodeficiency Virus type 1
(HIV-1) protease is a crucial target for HIV/AIDS treatment,
and understanding its catalytic mechanism is the basis on
which HIV-1 enzyme inhibitors are developed. Several
experimental studies have indicated that HIV-1 protease
facilitates the cleavage of the Gag and Gag-Pol polyproteins
and it is highly selective with regard to the cleaved amino acid
precursors and physical parameters. However, the main
theoretical principles of substrate specificity and recognition
remain poorly understood theoretically. By means of a one-
step concerted transition state modeling, the recognition of
natural substrates by HIV-1 PR subtypes (B and C-SA) was
studied. This was carried out to compare the activation free energies at varying peptide bond regions (scissile and nonscissile)
within the polypeptide sequence using ONIOM calculations. We studied both P3−P3′ and P5−P5′ natural substrate systems.
For P3−P3′ substrates, excellent recognition was observed for the MA-CA family but not for the RH-IN substrates. Satisfactory
recognition for the latter was only observed for the longer sequence (P5−P5′) after the substrate was subjected to an MD run
to maximize the interaction between the enzyme and the substrate. These results indicate that both sequence and structure are
important for correct scissile bond recognition of these natural substrates.
1. INTRODUCTION
A group of proteolytic enzymes with two aspartyl (Asp)
residues at their active sites are known as the aspartic
proteinases.1,2 This family includes renin,3,4 pepsin,3,4 pen-
icillopepsin,5 and the human immunodeficiency virus protease
(HIV-1 PR).5,6 HIV-1 PR catalyzes the hydrolysis of Gag and
Gag-Pol polyprotein precursors at specific sites (scissile
bonds). These proteins fulfill essential roles in the maturation
of the infectious virus that causes AIDS in humans.7−9 The
active form of HIV PR is a homodimer that normally contains
99 amino acids per monomer with a conserved catalytic triad
(Asp25-Thr-26-Gly27) at the active site.10−12 In the active site,
the Asp25 of both monomers are directly involved in the
catalysis and can exist in a number of protonated states.13−17
After the three-dimensional structure of the HIV-1 PR was
resolved using single crystal X-ray analysis,18,19 numerous
studies were performed to design specific and potent
inhibitors.20−22 Despite that, the detailed mechanism of
HIV-1 PR catalysis of the natural substrate is still a matter of
controversy.17 One factor that has impaired a comprehensive
analysis is the different sequence homology of the cleavage
sites on the natural substrates, making the substrate specificity
determinants difficult to identify.23 In addition, the cleavage
site sequences that occur have been compared for HIV-1
versus HIV-2 and results reveal that both enzymes do not have
a precise consensus substrate sequence.24,25 Since several
transition state analogues of the enzyme-catalyzed reaction
were found to act as excellent inhibitors, it is crucial to fully
understand the mechanism of the HIV-1 enzyme,26 so that the
design of new and improved analogues can be attempted.
Several HIV-1 PR cleavage mechanisms based on both in
vitro and in silico research have been suggested.5,6,15,20,27−29
However, there is no consensus on the most feasible
mechanistic pathway. Most of these studies classify the
mechanism into two general groups: the nucleophilic6,12,29
and the general acid−general base processes.20,30,31 The latter
is the predominant mechanism from the literature for aspartic
proteases and HIV-PR in particular.17,28,32−35 The nucleophilic
mechanism (Scheme 1) involves a direct attack on the scissile
peptide (C−N) bond by one of the protonated catalytic
aspartates that acts as the nucleophile9 yielding an anhydride
intermediate (stepwise nucleophilic reaction) or a transition
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state (TS) leading to product (concerted nucleophilic
reaction).6,26
In the general acid−base process, a catalytic water molecule
acts as the nucleophile, as proposed by Fruton30 and Suguna et
al.36 The mechanism is initiated with a nucleophilic attack on
the carbonyl atom of the scissile unit by the water molecule at
the active sites of the protease; this proceeds with the
protonated Asp donating its hydrogen to the nitrogen of the
scissile bond.37 The unprotonated Asp ionizes the catalytic
water by accepting its proton, and this process can either be a
stepwise (Scheme 2) or a concerted (Scheme 3) reaction in
which the former has been considered the most likely from the
literature.6,12,17,38 HIV-1 PR as well as their active mutants
recognize and cleave the same Gag and Gag-Pol polyprotein
precursors; hence, there remains a mutual structure−function
relationship among them that should be exploited in existing
and future drug inhibitors.39
Earlier theoretical studies that have focused on the catalytic
mechanism of the HIV-1 PR utilized molecular mechanics
(MM) and molecular dynamics (MD) modeling to explore the
enzyme−substrate and enzyme− intermediate com-
plexes.26,42−44 One of these studies used a model system that
focused mainly on the active site and the substrates,26 while
others only examined the active site with its closest
surrounding groups.43,45 The first notable limitation while
exploring the mechanistic pathway required for substrate
Scheme 1. Proposed (a) Stepwise and (b) Concerted Nucleophilic Reaction Mechanism for the HIV-1 PR−Substrate System
(Redrawn from the Literature6) Involving a Simplified Peptide and Active Site Model at the MP2/6-31G(2d)//RHF/6-
31G(2d) Level of Theorya
aThe legends are SNR = stepwise nucleophilic reactant, SNTS1 = stepwise nucleophilic transition state 1, SNINT = stepwise nucleophilic
intermediate, SNTS2 = stepwise nucleophilic transition state 2, SNP = stepwise nucleophilic product, CNR = concerted nucleophilic reactant,
CNTS = concerted nucleophilic transition state, CNP = concerted nucleophilic product. All distances are in Å.
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recognition and subsequent cleavage was the use of modified
substrate sequences similar to the natural substrate. In some
cases, six-alanine residues were used for the substrate
sequence,37 and in other investigations, one or more of the
amino acids were substituted.12,37,39 Another impediment can
be associated with the conformational difference in the active
site. Ribeiro et al.46 reported that the energy barriers are
dependent on the distances of the reactant to the transition
state conformation. Also, the electronic charge is influenced by
the residues at the active site and this contributes to the
associated energy barriers.46
Over the years, improvements have been made in the use of
theoretical methods to explore reaction processes. Density
functional theory (DFT), which is a typical quantum
mechanics (QM) method, has been considered suitable to
elucidate mechanistic pathways and obtain results close to
experimentally derived values.47−50 The reactivity of the HIV-1
PR model was examined by Garrec et al. in 2011 to specifically
test the accuracy of the latest DFT methods.47 They suggested
the combination of B3LYP51,52/6-31++G(d,p)53,54 or B3LYP/
6-311++G(d,p)53,54 for geometry optimization, and the former
theoretical level was adopted herein.
It is worth noting that two theoretical approaches6,37 with
regard to the one-step concerted mechanism for HIV PR
cleavage of natural substrates are found in the literature
(Scheme 3). In these studies, cyclic TS structures were
employed, yielding activation free energies (ΔG⧧) of 30.06 and
43.537 kcal mol−1. Most recently, the feasibility of the
concerted general acid−base model involving two 6-membered
TS, with either one or two water molecules, plus an acyclic TS
(involving one water molecule) was investigated55 (Scheme 4).
The study55 utilizes MD and the hybrid QM/MM approach in
which experimentally comparable results (ΔG⧧ = 15.2−26.4
kcal mol−1) were obtained. From experimental data, ΔG⧧
between 14.86 and 21.03 kcal mol−1 was estimated depending
on the peptide sequence.20,25,56−61
Having observed a lower energy barrier in the one-step
concerted acyclic TS reaction mechanism of the HIV-1 PR−
substrate involving one water from our previous work (Scheme
4a),55 we aimed to explore the preferential recognition and
cleavage mechanism through TS modeling. Theoretical and
experimental studies suggested that substrate modulation,
substrate groove, conserved substrate shape, interdependence
conformational adaptability of both enzyme and target, as well
as conformational specificity are crucial for recognition of
natural substrate by its HIV-1 PR.17 For theoretical studies, the
calculation of interaction and binding free energy parameters is
required to investigate the mechanism of action between the
substrate and the PR.23,62−64
To the best of our knowledge, on the basis of the latest
literature review,17 examining preferential cleavage of the
natural substrates of HIV-1 PR via a concerted TS modeling
using both MD and QM/MM methods has not been reported
elsewhere. The one-step concerted acyclic general acid−base
Scheme 2. Proposeda Concerted General Acid-Base HIV-1 PR Mechanism via Asp 25 Protonation
aStructures along the pathway are indicated as follows: (1) enzyme−substrate complex; (2) water attack TS; (3) tetrahedral gem-diol intermediate;
(4) scissile N-protonation TS; (5) protonated amide intermediate; and (6) cleavage of scissile C−N bond TS leading to a separated product
complex. Redrawn from the literature.39−41
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mechanism requires monoprotonation of one aspartate in the
active site of the enzyme (Scheme 4a).55 The water molecule
and both catalytic Asp (25/25′) are involved in the reaction
mechanism, where the acidic Asp (protonated) loses its proton
and becomes a base and the unprotonated Asp (base) becomes
acidic by gaining a proton. The acyclic TS involved in this
model for the elucidation of the concerted general acid−base
pathway55 proved to correlate well with experimental data.17
This mechanism was therefore applied to obtain a better
understanding of substrate recognition by calculating the
activation free energies at different peptide bond regions (in
addition to the scissile region) within the natural substrate
sequence.
In order to ensure the calculation is not an artifact of a single
enzyme−substrate system, two PRs, HIV-1 subtype B65 and a
popular mutant in South Africa (subtype C-SA)66 complexed
with MA-CA (Gag) and RH-IN (Gag-Pol) natural substrates
were used. Likewise, the Gag and Gag-Pol polyprotein sites
that are not normally cleaved (nonscissile domains) were also
considered. Presented in Table S1 (from the Supporting
Information) are the recognition sequences cleaved by HIV-1
PR. It is worth mentioning that the C-SA HIV-1 PR (Figure 1)
differs structurally due to the eight-point amino acid residue
mutations (R41K, L19I, T12S, H69K, I93L, I15V, L89M, and
M36I) occurring from the subtype B PR.67
By means of concerted TS modeling, the specificity of HIV-
1 PR for its natural targets was explored using constrained MD
simulations and the hybrid QM/MM (Our Own N-layered
Integrated molecular Orbital and molecular Mechanics,
ONIOM)68−71 algorithm. The modeled amino acid residues
were varied from 6 to 10 units for detailed analysis and
optimum recognition.
2. METHOD
2.1. The System Setup. Initial structure coordinates of the
subtype B and C-SA HIV-1 PR were taken at 2.1 and 2.7 Å
resolution from the Brookhaven Protein Data Bank73 (PDB
codes: 2P3B65 and 3U7166) respectively. P3−P3′ amino acid
sequence coordinates for substrates (MA-CA and RH-IN)
were drawn from PDB structures 1KJ4 and 1KJH,
respectively.74 The MA-CA crystal complex was obtained at
a 2.9 Å resolution,74 and the remaining crystal complexes used
(RH-IN and catalytic water) had a 2.0 Å resolution.74,75
For MA-CA, three cleavage domains were chosen from its
substrate sequence: Val-Ser*Gln-Asn-Tyr*Pro*Ile-Val-Gln-
Asn (-Tyr*Pro- is the scissile bond, while -Ser*Gln- and
-Pro*Ile- are the studied nonscissile domains of the same
natural substrate). From the literature, a major discrepancy was
discovered at the P2 position for RH-IN; in some cases, valine
was utilized,76,77 while other authors23,78−80 adopted Ile. In
this study, Ile was used because this is the most common
amino acid sequence established23,78−80 and the 3D structure74
is available in the PDB Bank. Hence, for RH-IN, three cleavage
domains were also chosen from this substrate: Ile-Arg*Lys-Ile-
Leu*Phe*Leu-Asp-Gly-Ile (-Leu*Phe- is the scissile bond,
and -Phe*Leu- and -Arg*Lys- are the considered nonscissile
regions within the same natural substrate). The activation
energies for each of these cases were calculated for both
subtype B and C-SA HIV-1 PR. First, a substrate model with
six amino acid residues (P3−P3′) was used, and we later
Scheme 3. Proposed Concerted General Acid−Base HIV-1 PR Mechanism via (a) Asp25′ OD2 Protonation Based on the
Jaskólski et al.28 Experimental Hypothesis and (b) the 4-Membered Ring Model Redrawn from the Literature.37
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proceed to 10 peptide sequences (P5−P5′) to improve the
(P3−P3′) recognition results for the RH-IN cleavage.
As water is an important factor for the HIV-1 PR proteolysis,
a catalytic water molecule closest to the active site was taken
from the PDB code 1LV175 and superimposed on both
enzyme−substrate complexes considered; this is represented in
Figure 2. This is necessary to ensure that the same pose is
maintained in the binding sites of the structure complexes and
serve as a starting structure for all of the investigated
complexes. The position of the substrate with the catalytic
water in the active site binds similarly to the reported HIV
PR−inhibitor complexes,81,82 and this was superimposed using
PyMOL.83 Thus, the crystallographic water molecules and ions
present within the structures of the entire enzyme−substrate
complexes were removed, leaving only the catalytic water
molecule at the active site.
The pKa values of the titratable amino acids were calculated
using the empirical PROPKA,84 and monoprotonation of
Asp25′ OD2 (Scheme 4a) at physiological pH 7 was induced
in the binding site, as supported from the literature17,28 and
our recent study55 using GaussView.85 Note that the standard
pKa values of ionizable groups can be shifted by protein
environments.86 The enzyme−substrate complexes with the
Asp proton (H+) were therefore positioned midway to the
nitrogen of the scissile bond (Scheme 4a). This position has
been shown to be stable energetically via MD simulations.45
The first results (Table 1) for the P3−P3′ RH-IN substrate
revealed lower activation free energies for some of the
nonscissile bonds. This prompted us to consider a longer
Scheme 4. Proposed Concerted General Acid−Base Reaction Schemes for the Cleavage of Natural Substrate by HIV-1 PR: (a)
an Acyclic Model; (b) a 6-Membered Cyclic Model; (c) a Two-Water Model Having a 6-Membered TS55
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substrate (P5−P5′) as well as perform a constrained MD
simulation on the substrate to find the lowest energy enzyme−
substrate complex as a starting point for the subsequent
ONIOM transition state calculation. We postulated this
approach may potentially provide improved recognition
between the substrates and the enzyme prior to the TS
calculation.
The MD simulation protocols for P5−P5′ HIV PR
complexes were employed as described by Ribeiro et al.46
This involves minimizations at 2500 cycles with the heating
stage constraint to counteract the SHAKE failure that might
result from an increase in temperature from 0 to 600 K. The
constraint allowed the enzyme to be frozen, while the substrate
was subjected to heating (MD script provided in the
Supporting Information) up to 600 K. It was demonstrated
before87 that higher temperatures are required to overcome
energy barriers of constrained molecules. Visual inspection of
the movement of the substrate during the MD simulation
revealed that extensive enzyme−substrate interactions were
achieved. A stepwise equilibration was done in three stages; 10,
5, and 2, and the constraint force was reduced at each step. In
the production stage, a 3−4 Å constraint distance between the
OH of the water (Owat) with the carbonyl of the scissile bond
(Csub) and the OH of the protonated Asp (OD2 Asp 25′)
with the nitrogen of the scissile bond (Nsub) was fixed and run
for 10 ns. Thereafter, a representative snapshot of the lowest
energy conformation was obtained and an unconstrained MD
calculation for 2 ns was performed at 300 K.
Results from the unconstrained MD for all complexes were
superimposed with the enzymes’ (B and C-SA) PDB
structures, and these complexes were taken for subsequent
ONIOM calculations. The acyclic concerted TS starting
structures55 were constructed using modred; interatomic
distances were constrained using the respective geometries
(Owat···Csub, Nsub···OD2 Asp25′, and Owat···OD2 Asp25′)
and optimized to construct a suitable starting structure for an
Figure 1. Homodimeric X-ray structure of subtype C-SA protease (PDB code: 3U7166) showing the positions occupied by the eight amino acids
R41K, L19I, T12S, H69K, I93L, I15V, L89M, and M36I. This structure was created using UCSF chimera.72
Figure 2. Schematic representation of the applied two-layered ONIOM model (B3LYP/6-31++G(d,p):AMBER) for the HIV-1 PR−MA-CA (P3−
P3′) complex (acyclic TS with one water molecule).
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unconstrained TS optimization. The active Asp25/25′
residues, catalytic water, as well as the substrate were
partitioned to a high layer (QM/B3LYP51,52/6-31++G-
(d,p)53,54), while the remaining system was put to a lower
layer (MM/AMBER88,89) for the ONIOM calculations. The
electronic embedding from the ONIOM algorithm90 was
implemented to consider the QM/MM electric field, since the
reaction center involves the transfer of protons during TS
modeling.
2.2. Free Energy Calculations. To model the cleavage
and formation of chemical bonds, electrons are included
explicitly in the energy calculations,76 and to achieve this in an
entire enzyme, a hybrid method should be employed.9 Hence,
the enzyme was divided into two regions involving one
classical model and a quantum mechanical (Figure 2) model. It
is important for the latter to describe the chemistry of the
reaction process correctly.22 A two-layer ONIOM approach
was thus applied to calculate the activation free energy of the
catalyzed reaction. Preceding studies showed hybrid QM/MM
methods are adequate for the HIV-1 PR catalytic mecha-
nism9,40,55,91 and the accuracy of the DFT/B3LYP method has
been tested for HIV-1 PR reactivity.47 All of the complex
structures for obtaining starting optimized reactant states are
prepared from energy minimization calculations using the
Amber force field.92 This allows the substrate and catalytic
water to adjust to the binding site. This was followed by a full
geometry optimization of the input structures in the gas phase
at the B3LYP/6-31++G(d,p):AMBER level of theory. Vibra-
tional frequencies93 for the different unconstrained complexes
were computed to characterize them as TS structures with one
negative eigenvalue. In this study, GaussView 5.0.885 was used
for both pre- and postprocessor graphic interface analyses with
all calculations performed within the Gaussian 0994 package.
Estimating the chemical quantities such as thermodynamics
that arises from energy, entropy contribution, and enthalpy
could be achieved computationally.93 In the context of this
study, the activation free energy, enthalpy, and temperature-
dependent (at T = 298.15 K) change in entropy are denoted as
ΔG⧧, ΔH⧧, and TΔS⧧, respectively. Provided in eqs 1−3 are
the activation free energy attained from frequency calculations
for the studied polypeptide sequences involving the scissile
bond and nonscissile bonds, as well as their difference within
the enzyme−substrate system of both subtypes B and C-SA
HIV-1 PR.
Δ = Δ − Δ − Δ⧧G G G Gscissile complex protease scissile (1)
Δ = Δ − Δ − Δ⧧G G G Gnonscissile complex protease nonscissile (2)
ΔΔ = Δ − Δ→
⧧ ⧧ ⧧G G Gnonscissile scissile nonscissile scissile (3)
3. RESULTS AND DISCUSSION
3.1. Recognition and Catalysis of Substrates with
P3−P3′ Sequence by HIV-1 PRs. By means of modeling, the
TS energy and recognition pattern of substrates by HIV-1
subtypes B and C-SA PRs was investigated. The reaction
mechanism utilized here follows a concerted general acid−base
mechanism where the unprotonated Asp25 acts as the base and
the protonated Asp25′ acts as the acid in a one-step process
(Scheme 4a). We have previously reported the acyclic
concerted theoretical mechanism,55 which corresponds well
with reported experimental results. Recall that experimental
ΔG⧧ values between 14.86 and 21.03 kcal mol−1 for natural
substrates (and peptides) were deduced from the litera-
ture.20,25,56−61
In general, the results for the polypeptide sequences reveal
that subtype C-SA has an increased rate of hydrolysis
compared to subtype B for the hydrolysis of peptides
(including natural substrates) by HIV-1 PR. All of the
calculated activation free energies reported herein (Table 1)
are in reasonable agreement with the experimental values.
Specifically, the calculated value (15.22 kcal mol−1) for the
subtype B HIV-1 PR−MA-CA natural substrate scissile bond is
in very good agreement with a reported experimental value of
Table 1. Relative Thermodynamic and Kinetic Parameters for the One-Step Concerted Acyclic TSs Involved in the Cleavage
Mechanism of the P3−P3′ Natural Substrates for Scissile and Nonscissile Bonds by HIV-1 PRs Using ONIOM [B3LYP/6-31+
+G(d,p):AMBER]a
MA-CA ΔE⧧ ΔH⧧ TΔS⧧ ΔG⧧ ΔΔG⧧
HIV-1 PR B
Gln-Asn-Tyr*Pro-Ile-Val −28.60 −23.49 −38.71 15.22
Asn-Tyr-Pro*Ile-Val-Gln −9.91 −10.49 −38.28 27.79 12.57
Gln-Val-Ser*Gln-Asn-Tyr −14.43 −18.65 −41.25 22.60 7.38
HIV-1 PR C-SA
Gln-Asn-Tyr*Pro-Ile-Val −40.19 −39.32 −52.81 13.49
Asn-Tyr-Pro*Ile-Val-Gln −17.74 −21.98 −44.69 22.70 9.21
Gln-Val-Ser*Gln-Asn-Tyr −32.74 −37.52 −55.12 17.60 4.11
RH-IN
HIV-1 PR B
Lys-Ile-Leu*Phe-Leu-Asp −9.85 −10.60 −30.00 19.40
Ile-Leu-Phe*Leu-Asp-Gly −8.96 −9.70 −29.03 19.33 −0.07
Gly-Ile-Arg*Lys-Ile-Leu −11.89 −12.92 −34.92 22.00 4.60
HIV-1 PR C-SA
Lys-Ile-Leu*Phe-Leu-Asp −25.72 −29.25 −47.28 18.03
Ile-Leu-Phe*Leu-Asp-Gly −27.71 −31.57 −49.54 17.97 −0.06
Gly-Ile-Arg*Lys-Ile-Leu −28.47 −29.05 −49.79 20.74 2.71
aValues are reported in kcal mol−1 relative to the sum of separated reactants. The peptide sequences in bold are the natural substrate scissile bonds.
ΔE⧧ = total energy, ΔH⧧ = enthalpy, TΔS⧧ = entropy change in temperature, ΔG⧧ = activation free energy, ΔΔG⧧ = activation free energy
difference.
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15.69 kcal mol−1 58 for MA-CA (Ser-Gln-Asn-Tyr*Pro-Ile-Val-
Gln) hydrolysis by HIV-1 PR. Also, the calculated ΔG⧧ values
of 18.03 and 17.97 kcal mol−1 for the cleavage of the HIV-1 PR
subtype C-SA−RH-IN scissile domain and the Ile-Leu-
Phe*Leu-Asp-Gly nonscissile region respectively agree with
the observed experimental ΔG⧧ values of 18.2420 and 17.6057
kcal mol−1 for RH-IN hydrolysis by HIV-1 PR.
It is interesting to note that the scissile bond for MA-CA
systems gave the lowest activation energies (compared to the
nonscissile bonds) as expected. This is not the case for the RH-
IN systems, suggesting the model substrates (P3−P3′) are
likely too short for proper recognition. This observation could
be akin to a recent (experimental and computational) study64
in which it was suggested that an increase in the peptide
sequence has a substantial effect on the protease selectivity of
cleavage sites. In an earlier theoretical investigation by Perez et
al.,62 it was concluded that many nonscissile peptide
sequences, despite their high affinity, do not cleave because
they are suppressed inside the polyproteins.62 Also, the
recognition of substrate by HIV-1 PR is based on the
geometric specificity of the exposed Gag and Gag-Pol
polyprotein precursors.25,62 However, in this present study
whereby the nonscissile domains were modeled in proximity
with the PRs, they did not necessarily yield lower activation
free energies than the default scissile bonds (Table 1) despite
being exposed to the enzymes’ active region.
The overall mechanistic pathway is a synchronous process55
with negative values for ΔE⧧, ΔH⧧, and TΔS⧧ for the natural
substrate and nonsubstrate transition states. The large negative
values of the TΔS⧧ indicate that the mechanistic process is
largely driven by entropy contributions due to the concerted
reaction process (Scheme 4a) for both HIV-1 PR B and C-
SA−peptide complexes. On the basis of the accepted notion
that a more negative entropy indicates greater restrictions of
the inhibitor in the active site,82,95 it is therefore likely that the
calculated TΔS⧧ values seem to have arisen from restriction of
substrate movement in the active site.
The P3−P3′ calculated energetics also revealed that subtype
C-SA has more negative ΔE⧧ and ΔH⧧ values than subtype B.
To further understand the specificity of the PRs for the peptide
sequences, activation free energy profiles were computed for
both scissile and nonscissile regions of the Gag and Gag-Pol
polyprotein segments (Table S1).
3.2. MA-CA Substrate Specificity and Analysis of the
Complexes Involving the P3−P3′ Unit. The subtype B−
MA-CA natural substrate complexes have activation free
energy differences (ΔΔG⧧) of approximately 12.57 kcal
mol−1 (Asn-Tyr-Pro*Ile-Val-Gln) and 7.38 kcal mol−1 (Gln-
Val-Ser*Gln-Asn-Tyr) compared to the scissile domain (Gln-
Asn-Tyr*Pro-Ile-Val). This outcome is feasible, as observed by
Boross et al.25 where HIV-1 substrates show preference for
small residues such as Asn or Cys at the P2 position and Ile or
Val at the P2′ position for HIV-1 PR. For the Tyr-Pro*Ile-Val
nonscissile sequence with Val at the P2′ position, a higher
activation free energy of 27.79 kcal mol−1 was computed. This
can be attributed to the presence of the large hydrophobic
chains of proline at the P1 position, while the nonscissile bond
with small residues (Ser*Gln) has a better affinity. Although
subtype B PR correctly recognizes and cleaves the nonscissile
peptide bonds, the effect of the Pro side chain in the Asn-Tyr-
Pro*Ile-Val-Gln sequence gave a ΔΔG⧧ value of 5.19 kcal
mol−1 compared to the scissile bond domain (Gln-Val-
Ser*Gln-Asn-Tyr). It is quite fascinating to note that the
calculated ΔG⧧ value (15.22 kcal mol−1) for the subtype B
HIV-1 PR−MA-CA natural substrate scissile bond is in very
good agreement with a reported experimental value of 15.69
kcal mol−1 for MA-CA (Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln)
hydrolysis by HIV-1 PR.58
For the subtype C-SA−MA-CA complex, a ΔG⧧ value of
13.49 kcal mol−1 was obtained for the cleavage of the scissile
bond (Gln-Asn-Tyr*Pro-Ile-Val), with a decreased ΔΔG⧧
value of −1.73 kcal mol−1 in comparison with the subtype
B−MA-CA complex. The rate of hydrolysis for subtype C-SA−
MA-CA is faster, and this could be a result of the mutations
that occur in the protease, which also contributes to the less
effective inhibition of the FDA approved drugs.81,96 This lower
ΔG⧧ value could also be related to the HIV-1 PR preference
for hydrophobic amino acid side chains (Tyr*Pro) at the P1
and P1′ positions of the natural target. Furthermore, the
nonscissile bond domain that contains Pro*Ile has a ΔG⧧ value
of 22.70 kcal mol−1, that is 9.21 kcal mol−1 higher than its
natural substrate and 5.09 kcal mol−1 lower than the subtype B
complex for the same cleavage site (Asn-Tyr-Pro*Ile-Val-Gln).
These results suggested that the proposed concerted general
acid−base acyclic cleavage mechanism (Scheme 4a) involving
HIV-1 PR and its substrates (plus nonsubstrates) accurately
predicts the recognition and specificity phenomena of the
HIV-1 PR enzyme for its MA-CA substrates. Also, the
recognition of the studied peptides is dependent on their
geometry orientation, which was proposed earlier78 plus their
amino acid sequence length as recently reported.64 From our
observation, the model RH-IN (P3−P3′) system seems too
Table 2. Relative Thermodynamic and Kinetic Parameters for the One-Step Concerted Acyclic TSs Involved in the Cleavage
Mechanism of the P5−P5′ Natural Substrates for Scissile and Nonscissile Bonds by HIV-1 PRs Using ONIOM [B3LYP/6-31+
+G(d,p):AMBER]a
RH-IN ΔE⧧ ΔH⧧ TΔS⧧ ΔG⧧ ΔΔG⧧
HIV-1 PR B
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile −9.35 −10.62 −30.31 19.69
Arg-Lys-Ile-Leu-Phe*Leu-Asp-Gly-Ile-Asp −9.96 −10.80 −30.60 19.80 0.11
Ser-Ala-Gly-Ile-Arg*Lys-Ile-Leu-Phe-Leu −11.99 −12.96 −37.25 24.29 4.60
HIV-1 PR C-SA
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile −25.64 −29.34 −47.68 18.34
Arg-Lys-Ile-Leu-Phe*Leu-Asp-Gly-Ile-Asp −27.56 −30.59 −49.03 18.44 0.10
Ser-Ala-Gly-Ile-Arg*Lys-Ile-Leu-Phe-Leu −29.17 −31.22 −52.26 21.04 2.70
aValues are reported in kcal mol−1 relative to the sum of separated reactants. The peptide sequences in bold are the natural substrate scissile bonds.
ΔE⧧ = total energy, ΔH⧧ = enthalpy, TΔS⧧ = entropy change in temperature, ΔG⧧ = activation free energy, ΔΔG⧧ = activation free energy
difference.
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short for effective recognition; hence, we decided to study a
P5−P5′ model for this substrate.
3.3. RH-IN Substrate Specificity and Analysis of the
Complexes Involving the P5−P5′ Unit. The relative
thermodynamic parameters for the HIV-1 PR−RH-IN catalysis
of the P5−P5′ substrates are presented in Table 2. In all cases,
the scissile bonds exhibited lower activation energies (albeit
marginal) than the nonscissile bonds. An activation free energy
of 19.69 kcal mol−1 was observed for the scissile bond cleavage
of the subtype B−RH-IN natural substrate complex, which is
0.11 kcal mol−1 lower than the considered nonscissile domain
(Arg-Lys-Ile-Leu-Phe*Leu-Asp-Gly-Ile-Asp). Likewise, the
subtype C-SA−RH-IN natural substrate system was observed
to follow this trend with a ΔΔG⧧ difference of 0.10 and 2.70
kcal mol−1 compared to the nonscissile peptide sequences Arg-
Lys-Ile-Leu-Phe*Leu-Asp-Gly-Ile-Asp and Ser-Ala-Gly-Ile-
Arg*Lys-Ile-Leu-Phe-Leu, respectively (Table 2).
For both proteases, HIV-1 PR complexed with the
nonscissile domain Ser-Ala-Gly-Ile-Arg*Lys-Ile-Leu-Phe-Leu,
activation free energies of 24.29 and 21.04 kcal mol−1 were
obtained, respectively. Although a slight increase for the
activation energy of the scissile bonds was observed in the P5−
P5′ calculation, the longer peptide sequences provide better
recognition.
4. CONCLUSION
In this study, we have investigated the mechanistic route of
substrate recognition between subtype B and C-SA HIV-1 PR,
using constraint MD simulations and a two-layered ONIOM
B3LYP/6-31++G(d,p) method, and found that the substrate
pattern recognition is similar for both wild type and mutated
enzymes. The cleavage mechanism follows a concerted acyclic
TS model leading to product and activation free energies that
are in reasonable agreement with experimental values for
peptide hydrolysis by HIV-1 PR. It needs to be emphasized
that the recognition specificity of the enzyme depends on the
Gag and Gag-Pol sequence as well as the number of amino
acid residues in the substrate polypeptide sequence. The
results obtained herein demonstrate that optimum recognition
depends on both the length of the amino acid sequence and
the structural details of the substrates. For example, the P3−
P3′ MA-CA substrate provides suitable recognition, while a
P5−P5′ sequence is required for effective recognition of the
RH-IN substrates.
It is evident from the present results that the rate of
hydrolysis for HIV-1 subtype C-SA PR is faster for both MA-
CA and RH-IN (scissile-bond) complexes compared to the
subtype B HIV-1 PR−substrate (scissile bond) complexes.
This phenomenon could justify the inhibition of the enzyme in
which the approved FDA HIV-1 PR inhibitors relatively inhibit
the subtype B better than the subtype C-SA PR as reported in
our previous work.81 On the basis of accepted theory that the
HIV-1 PR inhibitors mimic the transition state analogue of the
enzyme-catalyzed reaction, we therefore propose that future
potent inhibitors could be developed to mimic the RH-IN
substrate for both subtype B and C-SA HIV-1 PR on the basis
of its mechanism of reaction. Note that a higher activation free
energy has been associated with a diminished hydrolytic
ability.49,50 Future research would be directed toward
increasing the activation energy of these natural substrates
through electronic effects, resulting in higher activation free
energy. If that can be achieved, new natural substrate based
inhibitors may be unveiled.
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Section S1
Table S1: The nine recognition sequences cleaved by HIV-1 PR.1-2
Cleavage sites in Gag Cleavage domain
Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-Asn MA-CA
Lys-Ala-Arg-Val-Leu*Ala-Glu-Ala-Met-Ser CA-p2
Pro-Ala-Thr-Ile-Met*Met-Gln-Arg-Gly-Asn p2-NC
Glu-Arg-Gln-Ala-Asn*Phe-Leu-Gly-Lys-Ile NC-p1
Arg-Pro-Gly-Asn-Phe*Leu-Gln-Ser-Arg-Pro p1-p6
Cleavage sites in Gag-Pol
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile
Val-Ser-Phe-Asn-Phe*Pro-Gln-Ile-Thr-Leu
RH-IN
TF-PR
   Cys-Thr-Leu-Asn-Phe*Pro-Ile-Ser-Pro-Ile PR-RT
Gly-Ala-Glu-Thr-Phe*Tyr-Val-Asp-Gly-Ala RT-RH
The asterisk (*) denotes the cleavage sites and are named after the proteins that are released.  Matrix-
capsid; MA-CA, capsid-p2; CA-p2, p2-nucleopsid; p2-NC, nucleopsid-p1; NC-p1, trans frame peptide-
protease; TF-PR, protease-reverse transcriptase; PR-RT, reverse transcriptase-RNAseH; RT-RH, 
RNAseH-integrase; RH-IN.  
S2
Section S2
Distance Restraint/Constraint Molecular Dynamics3 
1. Create a pdb file using the prmtop/inpcrd files of the simulation you are intended to do. 
This .pdb file will order the atoms according to prmtop file. This is a very crucial step!
ambpdb -aatm -p prmtop <inpcrd> structure.aatm.pdb
ambpdb -aatm -p com_solvated.top <com_solvated.crd> structure.pdb
2. Locate the atoms to be restrained e.g restraining two atoms SG of cys and C13 of your 
ligand.
NB: You can get the atoms and residue details of the atoms to be restrained from 
complex_gas.pdb as well.
3. To create the RST.dist file, you need a 7/8 column format file for the distance restraints 
like this; 
124 ASP OD2 199 LIG N1 3.0 4.0 
025 ASP 0D2 199 UNK N5 3.0 4.0
Create 8col.in file having one line from RST.dist file e.g 025 ASP 0D2 199 UNK N5 3.0 4.0
4. Use makeDIST_RST command to run the 8col.in
makeDIST_RST -ual 8col.in -pdb com_solvated.pdb -rst dist.RST
5. If (4) works properly, you should generate the dist.RST.
Repeat for each distance restrain. So, you will have dist1.RST dist2.RST and so on
You can now merge all the dist.RST files in one dist.RST file;
#
# 199 UNK C19 199 UNK O12 2.0 2.5
 &rst
  ixpk= 0, nxpk= 0, iat=3170,3295, r1= 1.50, r2= 2.00, r3= 2.50, r4= 3.00,
      rk2=20.0, rk3=20.0, ir6=1, ialtd=0,
 &end
# 
# 124 ASH OD2 124 ASH HD2 1.0 1.2
 &rst
  ixpk= 0, nxpk= 0, iat=1986,1987, r1= 0.50, r2= 1.00, r3= 1.20, r4= 1.70,
       rk2=20.0, rk3=20.0, ir6=1, ialtd=0,
 &end
#
S3
# 025 ASP OD2 199 UNK H82 3.0 4.0
 &rst
  ixpk= 0, nxpk= 0, iat= 417,3296, r1= 2.50, r2= 3.00, r3= 4.00, r4= 4.50,
      rk2=20.0, rk3=20.0, ir6=1, ialtd=0,
 &end 
6. Run partial and full minimization, do heating with ibelly=1 to desired temperature in the 
input file.
7. MD Run looks like;
Production Step of MMP3 (MMMM): stage-1
 &cntrl
  imin= 0,
  irest=1,
  ntx=7, 
  ntb=2,
  ntp=1,
  PRES0=1.0,
  TAUP=2.0,
  NTPR=500,
  NTWX=500,
  ntr=0,
  Tempi=300.0, 
  Temp0=300.0,
  ntt=3,
  gamma_ln=1.0, 
  ntc=2,
  ntf=2, 
  cut=12.0,
  nstlim=1000000,
  dt=0.002,
  nmropt=1,
/
  &wt type='END' /
  DISANG=dist.RST 
  DUMPAVE=chi_vs_t.170
8. Analyzing the results
We will start our analysis of the results by plotting temperature, total energy, kinetic energy and 
potential energy from the output file. Examining these properties will allow us to check that 
S4
nothing strange happened during the MD. We can check that the temperature rose smoothly and 
equilibrated at 300 K. Similarly changes in the kinetic energy and potential energy should be 
smooth and should level off at equilibrated values. Any sudden spikes in the temperature or 
energy plots are indicative of a problem with our simulation protocol, bad starting structure, too 
long a time step, inappropriate parameters etc.
In order to extract the data from the output files we can use the following perl script that 
automates the process (process_mdout.perl). We can then process the output files in one go by 
listing them all on the command line as follows:
chmod u+x process_mdout.perl
To analyze the data output files now copied to the analysis folder the following was then entered:
process_mdout.perl Data_01.out Data_02.out Data_03.out Data_04.out Data_05.out
Ensure you are in the directory of the Data_**.out 
The next step is to locate the structure with the lowest energy, we can locate the lowest energy 
by looking at the summary.EPTOT file that process_mdout.perl produced. But first we need to 
strip off the first 50ps of the data as this represents the heating phase. Here is the file with this 
section removed. (summary_EPTOT_stripped.dat.gz). The following awk script will quickly find 
the lowest value in the file for us. It will print a value every time it finds a new minimum value, 
the last value printed will be the lowest energy found.
Move to the next step:
cat summary.EPTOT | awk '{if($2<min) {min=$2;print $1"   "min}}'
Gly the results were as follows:
the time in ns and the energy in kj cal-1 in the columns below respectively 
2081.000   -124399.4246
2082.000   -124489.0763
2094.000   -124590.8692
2142.000   -124623.6573
2154.000   -124654.6174
2180.000   -124660.1580
2181.000   -124749.1681
S5
So, the lowest energy is -124749.1681 kcal/mol and it occurred 2.181 ns into our simulation. We 
can find out where this is in our output files by using grep:
grep 2181.000 *.out using this command however only points to the binary file. To get actual 
output file: Gly- grep -a 2181.000 *.out
grep 324.000 *.out
Data_01.out: NSTEP =    50500   TIME(PS) =    2181.000 TEMP(K) =   300.18 PRESS =    48.9
It occurred on step 50500 of our Data_01 production step. We wrote to the mdcrd file every 500 
steps (ntwx=500) (found by vi Data_01.in) during the production so this should represent frame 
101 (50500/500) of data_01.mdcrd. Extract that structure using ptraj and look at it.
Simulation time= ntslim x dt= picoseconds x data files
Convert new rst file to pdb
ambpdb -p new1.top <new1.rst> new1.pdb
and view the pdb structure.
Section S3
Structure S1: The 3D ONIOM output files for the TS structures of the enzyme—substrate 
complexes
Sub_recog_pdb_structures.zip
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Concerted hydrolysis mechanism of HIV-1 natural
substrate against subtypes B and C-SA PR: insight
through molecular dynamics and hybrid QM/MM
studies†
Zainab K. Sanusi,a Monsurat M. Lawal,a Thavendran Govender, b
Sooraj Baijnath, a Tricia Naicker, a Glenn E. M. Maguire, ac
Bahareh Honarparvar *a and Hendrik G. Kruger *a
It is well known that understanding the catalytic mechanism of HIV-1 PR is the rationale on which its inhibitors
were developed; therefore, a better understanding of the mechanism of natural substrate hydrolysis is important.
Herein, the reaction mechanism of HIV-1 natural substrates with subtypes B and common mutant in South
Africa (subtype C-SA) protease were studied through transition state modelling, using a general acid–general
base (GA–GB) one-step concerted process. The activation free energies of enzyme–substrate complexes were
compared based on their rate of hydrolysis using a two-layered ONIOM (B3LYP/6-31++G(d,p):AMBER) method.
We expanded our computational model to obtain a better understanding of the mechanism of hydrolysis as well
as how the enzyme recognises or chooses the cleavage site of the scissile bonds. Using this model, a potential
substrate-based inhibitor could be developed with better potency. The calculated activation energies of natural
substrates in our previous study correlated well with experimental data. A similar trend was observed for
the Gag and Gag-Pol natural substrates in the present work for both enzyme complexes except for the
PR-RT substrate. Natural bond orbital (NBO) analysis was also applied to determine the extent of charge
transfer within the QM part of both enzymes considered and the PR-RT natural substrate. The result of
this study shows that the method can be utilized as a dependable computational technique to rationalize
lead compounds against specific targets.
Introduction
It has been well known since the first clinical report in the 80’s1,2
that the causative agent of AIDs (acquired immunodeficiency
syndrome) and its related disease is the Human immunodeficiency
virus (HIV).3,4 This HIV virus encodes an aspartic protease (Asp-PR)
known as the HIV PR which promotes the replication of functional
viral progeny.5,6 HIV protease cleaves and processes the viral Gag
and Gag-Pol polyprotein precursors that are required as building
blocks for the final stage of the maturation process of the HIV life
cycle. Blocking this action by mutagenesis or inhibitors results
in the production of noninfectious, immature viral particles.7–10
Faced with this information, potent inhibitors against the HIV PR
were developed and are commercially available drugs.10,11 Due to
long-term use of the FDA approved protease inhibitors, drug
resistance; polymorphisms/mutations have occurred within the
PR.12–16 It is therefore necessary to develop new potent inhibitors.
The HIV protease is a dimeric aspartic protease with two
identical subunits that normally contain 99-amino acids per
monomer (100 and 101-amino acids were reported by our
group).17,18 There is a conserved catalytic triad (Asp25–Thr26–
Gly27) at the active site,19,20 which usually cleaves up to nine
specific substrate sites,21 each having a different amino acids
sequence in the Gag and Gag-Pol polyproteins.5,8,22 Knowledge
of the HIV PR structure and function has led the successful
development of a wide range of efficient drugs designed using
structure-based and substrate mechanistic methods.23 Hence,
an accurate computational transition state model is necessary to
provide a better understanding of the recognition mechanism of
the HIV-1 PR with regard to the cleavage of the scissile bonds.
Although, there is no consensus yet on the most feasible
mechanistic pathway for the HIV protease cleavage reaction,
most studies have classified the mechanism into two major
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groups; the nucleophilic process and the general acid–general
base (GA–GB).22,24,25
As described in our recent literature review,26 the GA–GB
model is the most upheld mechanism from literature for aspartic
proteases, in particular the HIV PR.27–29 This mechanism involves a
catalytic water that acts as the nucleophile and attacks the carbonyl
atom of the scissile peptide (C–N) bond at the active site of the
Asp-PR.25,30 The reaction proceeds with the nitrogen of the
scissile bond accepting a hydrogen atom from the protonated
Asp, while the unprotonated Asp ionizes the catalytic water by
accepting its proton, and this process can either be a step-wise or
concerted mechanism.22,31
The catalytic mechanism of the enzyme–substrate and
enzyme–intermediate complexes of HIV PR have been theoretically
studied using molecular mechanics (MM) and molecular dynamics
(MD) modelling.32–34 The application of QM/MM methods in
studying the HIV-1 PR mechanism have entailed the use of hybrid
Car–Parrinello (QM) and MM,35,36 classical QM/MM MD,9,24
enhanced QM/MM MD umbrella sampling,30 QM/MM interface
algorithm37 and ONIOM QM/MM approach.38,39
The reactivity of the HIV-1 PR model was examined in 2011
by Garrec et al., to specifically validate the accuracy of the latest
density functional theory (DFT) methods.40 DFT method has
been considered suitable to elucidate mechanistic pathways
and obtain results closer to estimated experimental values,40–43
and the combination of B3LYP44,45/6-31++G(d,p)46,47 or B3LYP/
6-311++G(d,p) was implemented. The hybrid approach of Our
own N-layered Integrated molecular Orbital and molecular
Mechanics (ONIOM)48,49 method using the DFT functional
has been used to study the inhibition mechanisms of matrix
metalloproteinase 2,50 L,D transpeptidase51,52 and recently, in
our group, the concerted catalytic mechanism of HIV PR.38,39
This multi-layered approach allows treatment of large molecular
systems in different research areas. Herein, the catalytic active
site was treated at a high DFT level of theory, while the rest of the
system is treated with MM (AMBER)53 level of theory.
Literature support exits for a concerted hydrolysis reaction
mechanism for similar chemical reactions41,43,51,54–56 and enzymatic
reactions. We previously39 calculated theoretical transition structures
involving a 6-membered ring and an acyclic model in a one-step
concerted reaction process for HIV-1 PR (Scheme 1). The
activation free energies for hydrolysis of the Abz-Arg-Val-Nle-
Phe(NO2)-Glu-Ala-Nle-NH2 substrate (which mimics the CA/p2
natural substrate) by both subtypes B/C-SA HIV-1 PR was
determined experimentally.18,57–59 In which, cyclic transition
states (TSs)25,30 with activation free energies (DG‡) of between
3025 and 43.530 kcal mol1 were reported, showing higher values
comparable to the experimental data (14.9–21.0 kcal mol1 depend-
ing on the peptide sequence).27,60–65 It should also be noted that
two theoretical models25,30 were found in literature for the HIV-1
PR cleavage of peptide with respect to the one-step concerted
mechanism.
In our earlier studies,38,39 the one-step concerted acyclic
reaction mechanism of HIV-1 PR (Scheme 1b) provided an
optimal basis for substrate recognition and cleavage. From
our most recent work where only two substrates (MA–CA and
RH–IN) were considered with subtypes B/C-SA, respectively,
DG‡ values of 15.2/13.5 kcal mol1 and 19.7/18.3 kcal mol1
were obtained, respectively.38 It was also realized that a longer
natural substrate sequence (P5–P50) was required for favorable
recognition; hence a 10-amino peptide sequence was used in
the present investigation.
Herein, seven of the remaining Gag and Gag-Pol natural
substrate polyproteins are complexed with two HIV-1 enzymes;
Scheme 1 The one-step concerted enzymatic mechanism of HIV-1 PR with an idealised amide precursor.38,39 (a) Proposed concerted 6-membered
cyclic HIV-1 PR enzymatic mechanism. (b) Proposed acyclic HIV-1 PR enzymatic mechanism.
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subtype B11 and a common mutant in South Africa (subtype C-SA).66
This study was designed to expand our understanding of the
reaction mechanism of the HIV-1 PR, since its mutants as well as
the active enzyme recognize and cleave the same polypeptide
precursor. The HIV-1 PR cleavage sites in the Gag and Gag-Pol
polyproteins are represented in Fig. S1 (ESI†) and Table 1.
HIV-1 protease hydrolysis of the natural substrate involves
cleavage and formation of chemical bonds;25 hence we employed
the use of ONIOM,48,69,70 a hybrid QM/MM approach for this study.
The catalytic process follows a concerted, general acid–general base
mechanism, with a mono-protonation of the Asp at the active site,
the same as the model adopted in our previous work.17,71,72 Also,
to provide more in-depth knowledge of the enzyme–substrate
reactivity, the natural bond orbital73 was used to identify the
charge transfer between the QM region of the enzyme proteases
(subtype B and C-SA) and PR-RT natural substrate.
In this study, the relative thermodynamics and kinetics of
the concerted acyclic cleavage mechanism of the natural sub-
strates by HIV-1 subtypes B and C-SA PRs was studied using
ONIOM (B3LYP/6-31++G(d,p):AMBER) model and energetics
are reported in kcal mol1.
Computational methodology
The X-ray structural coordinates of the natural substrates were
taken from the Protein Data Bank (PDB) with the following
codes; 1KJF (p1–p6),68 1KJ7 (p2-NC),68 1KJG (RT-RH),68 1F7A
(CA-p2),67 1TSU (NC-p1),74 3OU4 (TF-PR),75 3OU3 (PR-RT).75
The initial structural models for subtype B and C-SA HIV-1 PR
were taken at 1.8 and 2.7 Å resolution from PDB bank (codes:
2P3B11 and 3U7166) respectively. The 3D structures for all the
selected enzyme–substrates complexes were constructed by
superimposing the available crystal structure of the natural
substrates with subtype B (details provided in the ESI†) and
C-SA PR, using the same overlay method described in our
previous papers.17,72 Since the involvement of water is an
important aspect for the HIV-1 PR proteolysis, a catalytic water
molecule (PDB code: 1LV176) closest to the active site is also
superimposed on the generated enzyme–substrate complexes
using PyMOL.77 PyMOL measures the root mean square (RMS),
which is helpful to evaluate how well the enzyme–substrate
complexes were overlaid, and an optimal superimposition is
considered satisfactory if the RMS is less than 2 Å.78–80 The
RMS values of the superimposed enzyme–substrate complexes
were in the range of 1.5–1.7 Å for all 14 systems (7 substrates
with two HIV strains). In this strategy, the substrate maintains
the same pose in the active binding sites of the complexes and
serve as a consistent starting structure for all complexes. Thus,
the structures of all enzyme–substrate complexes were refined
by removing the ions and crystallographic waters from the
complexes except for the catalytic water in the active site.
An area of contention in modelling of HIV PR is the protonation
state of the catalytic aspartate (Asp25/250) at the active site and this
has been extensively discussed in literature.40,81,82 Both in vivo and
in vitro studies show that the catalytic process of HIV PR functions
at a pH of 2–7.26,81,83,84 Hence, several different protonation states
at the active site have been proposed in literature.26 Using
PROPKA85 in assigning the protonation state for the catalytic Asp,
a mono-protonation model at Asp250 was adopted and this
approach is supported by the majority of studies.25,27,71,84,86,87
The empirical PROPKA server85 was used to calculate the pKa
values of the titratable amino acids in assigning protonation to
both enzymes. A mono-protonated catalytic Asp25/250 was induced
in the active site at a physiological pH 7, using GaussView.88 It is
notable that the standard pKa values of ionizable groups can be
shifted due to protein environments.89 The proton (H+) of the
protonated Asp in the enzyme–substrate complexes is positioned
midway to facilitate its donation to the nitrogen of the scissile
bond, this position has been measured to be energetically stable via
molecular dynamics (MD) simulations.34
The MD simulations follows a similar protocol as described
by Ribeiro et al.,90 and explained in our previous paper.38 It
should be noted that MD simulations was carried out to explore
all the possible conformational space to obtain a stable starting
structure for subsequent ONIOM TS calculations. The initial
stage involves minimizations at 2500 cycles which was followed
by the heating stage at an increasing temperature from 0 K to
600 K. Constraint was applied to counteract the SHAKE failure
that might occur because of the increase in temperature at the
heating steps. It has been established before that higher
temperatures are necessary to overcome energy barriers of
constrained molecules.87 This is required to explore all possible
enzyme–substrate conformations, the constraint allows only
the enzyme to be frozen and the substrate (10 amino acid
sequence) was subjected to heating for up to 600 K. Visual
inspections of the substrate during the MD simulation shows
that an extensive enzyme–substrate interactions were achieved.
As was done in our previous work,38 a 3-stage stepwise equili-
bration was performed at 10, 5 and 2 ns, and the constraint
forces was reduced at each step. While at the production stage,
Table 1 Recognition sequences for natural substrates cleaved by the
HIV-1 protease67,68
Peptide sequences cleavage domain Cleavage domain
Cleavage sites in Gag
P5 P4 P3 P2 P1 * P10 P20 P30 P40 P50
Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-Asn MA-CA
Lys-Ala-Arg-Val-Leu*Ala-Glu-Ala-Met-Ser CA-p2
Pro-Ala-Thr-Ile-Met*Met-Gln-Arg-Gly-Asn p2-NC
Glu-Arg-Gln-Ala-Asn*Phe-Leu-Gly-Lys-Ile NC-p1
Arg-Pro-Gly-Asn-Phe*Leu-Gln-Ser-Arg-Pro p1–p6
Cleavage sites in Gag-Pol
Val-Ser-Phe-Asn-Phe*Pro-Gln-Ile-Thr-Leu TF-PR
Cys-Thr-Leu-Asn-Phe*Pro-Ile-Ser-Pro-Ile PR-RT
Gly-Ala-Glu-Thr-Phe*Tyr-Val-Asp-Gly-Ala RT-RH
Ile-Arg-Lys-Ile-Leu*Phe-Leu-Asp-Gly-Ile RH-IN
The asterisk (*) denotes the scissile bond. Matrix-capsid; MA-CA,
capsid-p2; CA-p2, p2-nucleopsid; p2-NC, nucleopsid-p1; NC-p1, trans
frame peptide-protease; TF-PR, protease-reverse transcriptase; PR-RT,
reverse transcriptase-RNAseH; RT-RH, RNAseH-integrase; RH-IN. The
P1, P2. . .Pn to P10, P20. . .Pn0 represents the amino acid residues of the
substrate and are counted from the cleavage point. N. B.: the activation
free energies of the substrates in bold has been determined in our
previous paper.38
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a constraint distance of 3–4 Å was applied between the OH of
the water (Owat) with carbonyl of the scissile bond (Csub) and the
OH of the protonated Asp (OD2 Asp250) with the nitrogen of the
scissile bond (Nsub) was fixed and run for 10 ns. An unconstrained
MD calculation at 300 K was later performed for 2 ns and a
representative snapshot of the complex with lowest energy
conformation was attained. Subsequently, the lowest energy
conformation for all complexes were overlaid with the enzymes
(B and C-SA PR respectively) that did not undergo constraint MD
and was taken for further ONIOM calculations for an uncon-
strained acyclic concerted TS optimization. TS starting structures
were generated constraining the interatomic distances where
bond breaking/formation takes place, as described before.38,91
Due to the different trend found in the theoretical data versus
experimental results for two of the substrates (PR-RT and TF-PR),
triplicate MD92 runs were also performed. This was done by (a)
varying the random seed to create a new starting MD simulation
with a different atomic velocity of 10 Å water box, (b) then
creating another starting MD simulation with different atomic
coordinates as well as different atomic velocities and changing
the size of solvent/water box to 12 Å. As aforementioned, an
unconstrained MD calculation at 300 K was performed for 2 ns
for all the three cases and a representative snapshot of the
complexes with the lowest energy was attained. These were used
for subsequent ONIOM transition state calculations.
The active Asp25/250 residues, catalytic water, and all the
substrates used were considered at a high quantum mechanics
(QM) layer; (DFT/B3LYP44,45/6-31++G(d,p)46,47), while the rest of
the system were considered at a molecular mechanics (MM)
layer; (AMBER53) for the ONIOM calculations (Fig. 1). The
electric field is taken into consideration as the reaction centre
involves the transfer of protons due to transition state modelling,
therefore an ONIOM electronic embedding conformation was
specified during the calculations.70
ONIOM free energy calculations
The inclusion of explicit electrons in energy calculations is
necessary to model the breaking and formation of chemical
bonds,21 hence a multi-layered method is adopted for the entire
enzyme.9 A two-layer ONIOM48,93 method was applied to calculate
the activation free energies of the catalysed reaction by defining the
systems into two regions, one classical and the other quantum
mechanical.86,94,95 Previous studies have shown that the hybrid
QM/MM methods are adequate for the HIV-1 PR catalytic
mechanism and the accuracy of the DFT/B3LYP level of theory
has been tested for HIV-1 PR reactivity.9,94–96
The enzyme–substrate complex structures for obtaining starting
optimized reactant states are prepared from energy minimization
calculations using the Amber forcefield,97 this is necessary to allow
both the substrates and catalytic water to adjust to the active
binding site. The lowest energy conformation taken from the
constrained MD that was initially performed for all complexes were
superimposed with an unconstrained subtype B and C-SA HIV-1 PR
and this was further used for ONIOM calculations to obtain an
unconstrained acyclic concerted TS optimization. A full uncon-
strained geometry optimizations of the input structure complexes
in gas phase using ONIOM (B3LYP/6-31++G(d,p):AMBER) model
were carried out, vibrational frequencies98 for the different
complexes were computed to assess the TS structures with one
negative eigenvalue. The TS models were determined by having
only one negative frequency, the atomic vibrations associated
with the negative eigenvalue were visually inspected to ensure
the expected bond cleavage and formation within the enzyme–
substrate complex. GaussView 5.0.888 was used for both pre and
post-processor graphic interface analyses in this study, and the
Gaussian 16 package99 was used for all calculations.
The chemical properties such as thermodynamics, that com-
prises of energy, entropy contribution and enthalpy can be estimated
computationally.100 Herein, the activation free energy, enthalpy and
temperature-dependent change in entropy (T = 298.15 K) is repre-
sented as; DG‡, DH‡ and TDS‡, respectively. The following equation
gives the activation free energy attained from frequency calculations
for the natural substrate polypeptide sequences:
DG‡substrate = DGcomplex  DGprotease  DGsubstrate (1)
Natural bond orbital (NBO) analysis
The natural bond orbital101 offers a robust mathematical
method for investigating charge transfer that occur between
hydrogen bond atoms through a set of occupied Lewis and
unoccupied non-Lewis localized structural orbitals.102–104 The
second-order perturbation between the proton donor (i) and
Fig. 1 Schematic representation of the applied two-layered ONIOM model (B3LYP/6-31++G(d,p):AMBER) for HIV-1 PR-natural substrate (P5–P50)
complex (acyclic TS with one catalytic water molecule). The model includes 77 atoms at the QM region and 1512 atoms at the MM region. All the 3D
structures of the enzyme–substrate complexes considered are provided with the ESI† (Gaussian input file format).
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proton receptor ( j) is used to predict the stabilization energy also
known as the delocalization strength E2 and this is measured by
eqn (2)105,106 as:
Eð2Þ ¼ DEij ¼ qi
Fði; jÞ2
ej  ei
(2)
where qi is the occupancy number of the donor orbital, ej and ei are
orbital energies (diagonal elements) and F(i,j)2 is the off-diagonal
elements of Fock matrix.
Results and discussion
Our previous protocol of transition state modeling38 on the
inhibition mechanism of HIV PR and the activation energies of
the scissile versus non-scissile bonds was utilized to demon-
strate the recognition pattern of different natural substrates
against HIV-1 subtypes B and C-SA. The HIV-1 PR cleaves at
nine different sites of the Gag and Gag-Pol protein leading to
different amino acid sequence. Earlier, the MA-CA and RH-IN
domain have been investigated38 and it was discovered that the
HIV-1 PR specifically cleaves at the scissile region of its natural
substrates. This prompted us to investigate all the remaining
natural substrates of PR and determine the rate of their
hydrolysis and cleavage process using the P5–P50 sequence.
A concerted general acid–base mechanism as described in our
previous work38,39 was applied, where the protonated catalytic
Asp250 acts as the acid and the unprotonated Asp25 acts as
the base in a one-step acyclic reaction process (Scheme 1b).
The catalytic function of the Asp25/250 groups as well as the
nucleophilic attack of the water molecule on the scissile (C–N)
bond and other amide bonds occurred simultaneously. The
concerted acyclic reaction proceeds with an attack from the
catalytic water (OH) on the carbonyl atom of the scissile bond
to form COOH, meanwhile Asp250 donates a proton to the
nitrogen atom of the scissile bond which then becomes a base.
Subsequently Asp25 accepts a proton from the nucleophilic
water yielding OH to become acidic.
The free energy values were computed for the enzyme–
substrate complexes and are ranked in terms of their activation
free energies for the Gag and Gag-Pol polyproteins for subtypes
B and C-SA HIV-1 PR (Tables 2 and 3). The calculated activation
energies for MA-CA and RH-IN substrates from our previous
paper38 were included to get an overall view. The theoretical
results (Table 2) are in reasonable agreement with the available
experimental results (within experimental error). Note that
the standard deviation of the theoretical activation energies
for PR-RT and TF-PR were as high as 1.0 and 0.7 kcal mol1
respectively (see ESI,† Table S1).
The computed results for the Gag polyproteins (Table 2)
have the MA-CA natural substrate with the smallest activation
energy (DG‡ of 15.2 kcal mol1), and that of NC-p1 the largest
(20.0 kcal mol1). This largest DG‡ for NC-p1 is expected based
on the study carried out by Moses et al.,91 where the NC-p1
natural substrate processing is not only the slowest, but also
the rate-limiting cleavage step in the maturation of the Gag
polyprotein.91
Cleavage of the scissile bonds of the aforementioned sub-
strates by both subtype B and C-SA HIV-1 PR gave a significant
entropy variation as seen from the results of the TS structures
(Tables 2 and 3). It should be noted that more negative entropies
(higher entropy penalty) is an indication of greater restriction of
movement for the substrate in the active site.72,107 This could be
attributed to steric restrictions and strong non-covalent inter-
actions for certain parts of the substrate.77,104
Even though the scissile bond of both substrates (PR-RT and
TF-PR) consists of hydrophobic amino acids (Phe*Pro), for TF-PR
Table 2 Relative thermodynamics and kinetic parameters for the one-
step concerted acyclic TSs involved in the cleavage mechanism of the
P5–P50 natural substrates for scissile bonds by subtype B HIV-1 PR using
ONIOM [B3LYP/6-31++G(d,p)]
HIV-1 PR B DE‡ DH‡ TDS‡ DG‡ DGa‡
Gag
MA-CA 28.6 23.5 38.7 15.2 15.7
CA-p2 30.0 31.0 47.7 16.8 17.0
p2-NC 22.5 24.0 43.1 19.2 —
p1–p6 23.8 24.6 44.3 19.7 17.6
NC-p1 19.6 20.3 40.4 20.0 18.7
Gag-Pol
RH-IN 9.4 10.6 30.3 19.7 18.42
RT-RH 23.3 24.3 39.1 14.7 —
TF-PR 29.0 32.1 48.6 16.5 15.4
PR-RT 36.0 39.0 53.4 14.5 15.6
Values are reported in kcal mol1 relative to the sum of separated
reactants. DE‡ = total energy, DH‡ = enthalpy, TDS‡ = entropy change in
temperature, DG‡ = calculated activation free energy, DGa‡ = experimental
activation free energies taken from literature for subtype B HIV-1 PR.62,64 All
the 3D structures of the enzyme–substrate complexes considered are provided
with the ESI (Gaussian input file format). N. B.: the activation free energies of
the substrates in bold has been determined in our previous paper.38
Table 3 Relative thermodynamics and kinetic parameters for the one-
step concerted acyclic TSs involved in the cleavage mechanism of the P5–P5
natural substrates for scissile bonds by subtype C-SA HIV-1 PR using ONIOM
[B3LYP/6-31++G(d,p)]
HIV-1 PR C-SA DE‡ DH‡ TDS‡ DG‡ DGa‡
Gag
MA-CA 40.2 39.3 52.8 13.5 15.7
CA-p2 42.2 49.1 65.9 16.8 17.0
p2-NC 45.3 53.4 74.0 20.6 —
p1–p6 45.0 53.6 74.6 21.0 17.6
NC-p1 26.1 29.5 52.1 22.6 18.7
Gag-Pol
RH-IN 25.6 29.3 47.7 18.3 18.4
RT-RH 34.6 39.1 53.4 14.8 —
TF-PR 39.1 44.9 60.7 15.8 15.4
PR-RT 44.1 49.7 66.1 16.4 15.6
Values are reported in kcal mol1 relative to the sum of separated
reactants. DE‡ = total energy, DH‡ = enthalpy, TDS‡ = entropy change in
temperature, DG‡ = activation free energy, DGa‡ = experimental activa-
tion free energies taken from literature for subtype B HIV-1 PR.62,64 All
the 3D structures of the enzyme–substrate complexes considered are
provided with the ESI (Gaussian input file format). N. B.: the activation
free energies of the substrates in bold has been determined in our
previous paper.38
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(16.51 kcal mol1), a hydrophilic amino acids Asn and Gln is found
at the P2–P20 position of the scissile bond, which may slow down
the hydrolysis. While, for PR-RT a polar amino acid (Asn) at P2
precedes the phenylalanine (P1 position) and the Pro (P10 position)
is followed by a hydrophobic amino acid (Ile) at P20. Although,
the PR-RT and TF-PR complexes gave a reversed order for the
theoretical activation energies (compared to the experimental
results), the results are within the experimental error.
While both subtype B and C-SA HIV-1 PR recognize and
cleave these natural substrates, the rate of proteolysis of the
enzymes are different as can be seen from their activation free
energies. This could be because of the eight-point mutations in
C-SA compared to the subtype B (Tables 2 and 3). The theoretical
results (Table 2) for the activation energies of the natural substrates
with subtype C-SA are also in reasonable agreement with the
available experimental results (within experimental error).
Similar to the subtype B–substrate complexes, the MA-CA
and NC-p1 (Gag polyproteins) complexed with the subtype C-SA
HIV-1 PR also gave the smallest and largest activation energies
(DG‡ of 13.5 and 22.6 kcal mol1, respectively). The computed
data for the Gag polyproteins of subtype C-SA follow the same
trend than for subtype B HIV-1 PR.
While the same trend was observed for both HIV-1 PR subtype B
and C-SA–substrate complexes, an outlier was observed for the Gag-
Pol substrates. A reduced activation energy was found for PR-RT in
the subtype B complex (14.5 kcal mol1) compared to a much-
increased activation energy in the C-SA complex (16.4 kcal mol1).
Hence, NBO analysis was carried out on the PR-RT substrate to
further understand the electronic factors contributing to the reac-
tivity of the both proteases.
Natural bond orbital analysis
To further explore the hydrogen bond stabilization energies of both
subtype B and C-SA complexed with PR-RT natural substrate, NBO
analysis was performed at the DFT B3LYP/6-31++G(d,p) for the QM
region and this is reported in Table 4. The hydrogen bond
formation in the studied complexes indicates that certain transfer
of electronic charge occurs during the transition state modelling
(Fig. 2). The intensive interactions of the hydrogen bonds are
directly proportional to the second-order perturbation (E2) value,
hence the higher the E2 value the greater charge transfer and
consequently more stable the interaction. The charge transfers
particularly from lone pair (LP) to unoccupied lone pair orbital
(LP*) of the subtype B–PR-RT complex gave a higher E2 value, which
provides stability to the transition state (TS) model structure with a
reduced activation energy of 14.5 kcal mol1 (Table 2).
This clearly indicates that intermolecular interactions in the
concerted acyclic mechanism of the PR-RT substrate in the
subtype B enzyme are greater compared to the intermolecular
interactions of the PR-RT substrate in the subtype C-SA PR.
These results explain the anomaly for the theoretical results
that we have obtained.
Conclusion
This study employs a two-layered ONIOM (B3LYP/6-31G++(d,p):
AMBER) model to calculate the TS energies via a concerted
mechanism of hydrolysis. It examines the subtype B and C-SA
HIV-1 PR recognize their scissile bonds. Based on experimental
results and our previous paper a longer peptide is required to
recognize the substrate effectively and thus obtain a more
accurate model for hydrolysis. Therefore, a P5–P50 amino acid
sequence was used to compute the free energy profiles of the
complexes. The reaction mechanism follows a concerted acyclic
TS model leading to product and activation free energies that are
in close proximity with experimental values for hydrolysis by
HIV-1 PR. It is evident from the computed results that both
proteases complexed with the natural substrate follow a similar
activation energy trend at the Gag and Gag-Pol. The exception is
with the PR-RT substrate, the extent of charge transfer between
the natural substrate (PR-RT) and the active residues in close
contact with the substrate (derived by second-order perturbation
theory of NBO analysis) supports the observation of the varying
activation energies of the PR-RT substrate against both HIV-1 PR
subtypes. While the CA-p2 substrate gave a lower calculated DG‡
than the experimental results, RT-RH substrate had a lower calcu-
lated value of DG‡ at the Gag-Pol for both subtypes considered. The
NC-p1 substrate gave an increase DG‡ (at Gag and Gag-Pol) for both
PR subtypes compared to the experimental results. The catalytic
Table 4 Second-order perturbation E2 in kcal mol1 conforming to the
most important charge transfer in the reaction coordinate (donor -
acceptor) at the B3LYP/6-31++G(d,p) level of theory in the QM region of
the PR-RT enzyme complexes
Complex Donor NBO Acceptor NBO E2 (kcal mol1)
Subtype B–PR-RT LP(O8) LP*(H7) 122.4
LP(N6) LP*(H7) 213.6
LP*(H7) BD*(C9–O8) 2.5
Subtype C–PR-RT LP(O8) LP*(H7) 14.3
LP(N6) LP*(H7) 181.0
LP*(H7) BD*(C9–O8) 2.4
LP = lone pair, LP* = unoccupied lone pair, BD* = anti-bonding orbital.
Fig. 2 Molecular plot of the interaction in the QM region (catalytic Asp25/
250 with PR-RT natural substrate) conforming to the most important
charge transfer in the reaction coordinate.
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mechanism of HIV-1 PR is the rationale on which its inhibitors were
developed. It is expected that an increase in the activation energy of
the natural substrate will retard the rate of hydrolysis and thus serve
as an improved model for a competitive inhibitor. Thus, it is
important to understand which of the HIV-1 natural substrates best
binds to both subtype B and C-SA PRs in finding potential lead
compounds, necessary for drug discovery. We therefore, propose
that future potent inhibitors could be developed to mimic the NC-p1
substrate for both subtype B and C-SA HIV-1 PR based on its
mechanism of reaction. This could be related to not only the slow
rate of its hydrolysis (NC-p1) but also its rate-limiting cleavage step in
the maturation of the Gag, as seen from the compiled results and
related experimental data. This model can also potentially provide
information on how electronic and steric effects will change the
activation energies and the reaction rate of natural substrates.
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Montgomery and K. Morokuma, et al., Combining quantum
mechanics methods with molecular mechanics methods in
ONIOM, J. Chem. Theory Comput., 2006, 2(3), 815–826.
71 M. Jaskolski, A. G. Tomasselli, T. K. Sawyer, D. G. Staples,
R. L. Heinrikson and J. Schneider, et al., Structure at 2.5-.
ANG. resolution of chemically synthesized human immu-
nodeficiency virus type 1 protease complexed with a
hydroxyethylene-based inhibitor, Biochemistry, 1991,
30(6), 1600–1609.
72 Z. Sanusi, T. Govender, G. Maguire, S. Maseko, J. Lin and
H. Kruger, et al., Investigation of the binding free energies
of FDA approved drugs against subtype B and C-SA HIV PR:
ONIOM approach, J. Mol. Graphics Modell., 2017, 76, 77–85.
73 A. E. Reed, L. A. Curtiss and F. Weinhold, Intermolecular
interactions from a natural bond orbital, donor-acceptor
viewpoint, Chem. Rev., 1988, 88(6), 899–926.
74 M. Prabu-Jeyabalan, E. A. Nalivaika, N. M. King and
C. A. Schiffer, Structural basis for coevolution of a human
immunodeficiency virus type 1 nucleocapsid-p1 cleavage
site with a V82A drug-resistant mutation in viral protease,
J. Virol., 2004, 78(22), 12446–12454.
75 Z. Liu, Y. Wang, J. Brunzelle, I. A. Kovari and L. C. Kovari,
Nine crystal structures determine the substrate envelope of
the MDR HIV-1 protease, Protein J., 2011, 30(3), 173–183.
76 M. Kumar, K. Kannan, M. Hosur, N. S. Bhavesh,
A. Chatterjee and R. Mittal, et al., Effects of remote muta-
tion on the autolysis of HIV-1 PR: X-ray and NMR investi-
gations, Biochem. Biophys. Res. Commun., 2002, 294(2),
395–401.
77 W. L. DeLano, The PyMOL molecular graphics system, 2002.
78 J. C. Cole, C. W. Murray, J. W. M. Nissink, R. D. Taylor and
R. Taylor, Comparing protein–ligand docking programs is
difficult, Proteins: Struct., Funct., Bioinf., 2005, 60(3),
325–332.
79 H. Gohlke, M. Hendlich and G. Klebe, Knowledge-based
scoring function to predict protein-ligand interactions,
J. Mol. Biol., 2000, 295(2), 337–356.
PCCP Paper
Pu
bl
is
he
d 
on
 0
9 
Ja
nu
ar
y 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f 
K
w
az
ul
u-
N
at
al
 o
n 
6/
26
/2
02
0 
10
:5
2:
33
 A
M
. 
View Article Online
This journal is©the Owner Societies 2020 Phys. Chem. Chem. Phys., 2020, 22, 2530--2539 | 2539
80 M. Kontoyianni, L. M. McClellan and G. S. Sokol, Evalua-
tion of docking performance: comparative data on docking
algorithms, J. Med. Chem., 2004, 47(3), 558–565.
81 F. Sussman, M. C. Villaverde, J. L. Dominguez and
U. H. Danielson, On the active site protonation state in
aspartic proteases: implications for drug design, Curr.
Pharm. Des., 2013, 19(23), 4257–4275.
82 A. Tripathi, M. Fornabaio, F. Spyrakis, A. Mozzarelli,
P. Cozzini and G. E. Kellogg, Complexity in modeling
and understanding protonation states: computational
titration of HIV-1-Protease–inhibitor complexes, Chem.
Biodiversity, 2007, 4(11), 2564–2577.
83 A. Brik and C.-H. Wong, HIV-1 protease: mechanism and
drug discovery, Org. Biomol. Chem., 2003, 1(1), 5–14.
84 S. Piana and P. Carloni, Conformational flexibility of the
catalytic Asp dyad in HIV-1 protease: an ab initio study on the
free enzyme, Proteins: Struct., Funct., Bioinf., 2000, 39(1), 26–36.
85 H. Li, A. D. Robertson and J. H. Jensen, Very fast empirical
prediction and rationalization of protein pKa values,
Proteins: Struct., Funct., Bioinf., 2005, 61(4), 704–721.
86 H. Liu, F. Müller-Plathe and W. F. van Gunsteren, A
combined quantum/classical molecular dynamics study
of the catalytic mechanism of HIV protease, J. Mol. Biol.,
1996, 261(3), 454–469.
87 B. Honarparvar, T. Govender, G. E. Maguire, M. E. Soliman and
H. G. Kruger, Integrated approach to structure-based enzymatic
drug design: molecular modeling, spectroscopy, and experi-
mental bioactivity, Chem. Rev., 2013, 114(1), 493–537.
88 R. Dennington, T. Keith and J. Millam, GaussView, Version,
Semichem Inc., Shawnee Mission KS, 2009, vol. 5.
89 J. Antosiewicz, J. A. McCammon and M. K. Gilson, Predic-
tion of pH-dependent properties of proteins, J. Mol. Biol.,
1994, 238(3), 415–436.
90 A. J. Ribeiro, D. Santos-Martins, N. Russo, M. J. Ramos and
P. A. Fernandes, Enzymatic flexibility and reaction rate: a
QM/MM study of HIV-1 protease, ACS Catal., 2015, 5(9),
5617–5626.
91 M. Prabu-Jeyabalan, E. A. Nalivaika, K. Romano and
C. A. Schiffer, Mechanism of substrate recognition by
drug-resistant human immunodeficiency virus type 1 pro-
tease variants revealed by a novel structural intermediate,
J. Virol., 2006, 80(7), 3607–3616.
92 T. Masuda, Molecular dynamics simulation for the
reversed power stroke motion of a myosin subfragment-
1, BioSystems, 2015, 132, 1–5.
93 S. Humbel, S. Sieber and K. Morokuma, The IMOMO
method: Integration of different levels of molecular orbital
approximations for geometry optimization of large sys-
tems: test for n-butane conformation and SN2 reaction:
RCl+ Cl, J. Chem. Phys., 1996, 105(5), 1959–1967.
94 M. J. Field, P. A. Bash and M. Karplus, A combined
quantum mechanical and molecular mechanical potential
for molecular dynamics simulations, J. Comput. Chem.,
1990, 11(6), 700–733.
95 D. Wei and D. Salahub, A combined density functional and
molecular dynamics simulation of a quantum water mole-
cule in aqueous solution, Chem. Phys. Lett., 1994, 224(3–4),
291–296.
96 N. Heinrich, K. B. Lipkowitz and D. B. Boyd (ed.), Reviews
in computational chemistry, VCH Verlagsgesellschaft,
Weinheim, New York, 1990, ISBN 3-527-27845-1, 419 Seiten,
Preis: DM 176, Berichte der Bunsengesellschaft für Physikalische
Chemie, 1992, 96(2), 224.
97 J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman and
D. A. Case, Development and testing of a general amber
force field, J. Comput. Chem., 2004, 25(9), 1157–1174.
98 J. W. Ochterski, Vibrational analysis in Gaussian help@
gaussian com, 1999.
99 M. Frisch, G. Trucks, H. Schlegel, G. Scuseria, M. Robb,
J. Cheeseman, et al., Gaussian 16 Revision B. 01, Gaussian
Inc., Wallingford CT, 2016.
100 J. W. Ochterski, Thermochemistry in Gaussian, Gaussian
Inc., 2000, pp. 1–19.
101 J. Foster and F. Weinhold, Natural hybrid orbitals, J. Am.
Chem. Soc., 1980, 102(24), 7211–7218.
102 F. Weinhold and C. R. Landis, Valency and bonding: a
natural bond orbital donor–acceptor perspective, Cambridge
University Press, 2005.
103 I. Majerz, Directionality of inter-and intramolecular OHO
hydrogen bonds: DFT study followed by AIM and NBO
analysis, J. Phys. Chem. A, 2012, 116(30), 7992–8000.
104 R. Behjatmanesh-Ardakani, NBO–NEDA, NPA, and QTAIM
studies on the interactions between aza-, diaza-, and triaza-
12-crown-4 (An-12-crown-4, n= 1, 2, 3) and Li +, Na +, and
K+ ions, Comput. Theor. Chem., 2015, 1051, 62–71.
105 A. M. Priya, L. Senthilkumar and P. Kolandaivel, Hydrogen-
bonded complexes of serotonin with methanol and ethanol:
a DFT study, Struct. Chem., 2014, 25(1), 139–157.
106 Z. M. Kotena, R. Behjatmanesh-Ardakani, R. Hashim and
V. M. Achari, Hydrogen bonds in galactopyranoside and
glucopyranoside: a density functional theory study, J. Mol.
Model., 2013, 19(2), 589–599.
107 U. Ryde, A fundamental view of enthalpy–entropy compen-
sation, MedChemComm, 2014, 5(9), 1324–1336.
Paper PCCP
Pu
bl
is
he
d 
on
 0
9 
Ja
nu
ar
y 
20
20
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f 
K
w
az
ul
u-
N
at
al
 o
n 
6/
26
/2
02
0 
10
:5
2:
33
 A
M
. 
View Article Online
1
Concerted hydrolysis mechanism of HIV-1 natural substrate against subtypes B and C-SA 
PR: Insight through Molecular Dynamics and Hybrid QM/MM studies
Zainab K. Sanusi,a Monsurat M. Lawal,a Thavendran Govender,b Sooraj Baijnath,a Tricia 
Naicker,a Glenn E. M. Maguire,a, c, Bahareh Honarparvar,a* and Hendrik G. Kruger.a* 
aCatalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, 
Durban 4041, South Africa.
bAnSynth PTY LTD, 498 Grove End Drive, Durban 4001, South Africa.
cSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban 4041, South Africa.
*Corresponding authors: Prof. H. G. Kruger; kruger@ukzn.ac.za and Dr B. Honarparvar, 
baha.honarparvar@gmail.com; Catalysis and Peptide Research Unit, School of Health Sciences, 
University of KwaZulu-Natal, Durban 4041, South Africa.
Table of Contents
The HIV-1 PR cleavage sites in the Gag and Gag-Pol polyproteins. ............................................................2
Figure S1. Schematic representation of the Gag and Gag-Pol polyproteins..................................................2
Table S1. The relative thermodynamics of the three ONIOM (QM/MM) optimized MD run of PR-RT and 
TF-PR enzyme—substrate complexes as well as the lowest conformation using ONIOM [B3LYP/6-
31++G(d,p)]. ..................................................................................................................................................3
Figure S2. Superimposed QM/MM optimized TS geometries of PR-RT natural substrate (average RMSD 
of 0.82 Å) taken from triplicate MD runs showing movement and flexibility at the subtype B HIV-1 PR 
active site. …………………………………………………………………………………………………. 4
Figure S3a.  Hydrogen bond interactions plot of HIV subtype B PR complexed with PR-RT natural 
substrate. These plots were created after ONIOM optimization of the lowest conformation (case 1) using 
Ligplot. ……………………………………………………………………………………………………. 5
Figure S3b.  Hydrogen bond interactions plot of HIV subtype B PR complexed with PR-RT natural 
substrate. These plots were created after ONIOM optimization of the changed simulation box to 12 Å 
using Ligplot. ……………………………………………………………………………………………... 6
Appendix: The 3D structures of all the enzyme—substrate complexes considered......................................6
Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics.
This journal is © the Owner Societies 2019
2
The HIV-1 PR cleavage sites in the Gag and Gag-Pol polyproteins.
Figure S1. Schematic representation of the Gag and Gag-Pol polyproteins.
We determined (a) the standard deviation for these calculations and (b) explored whether the MD 
method to find starting structures for these calculations will give rise to potential conformational 
effects of the HIV-1 PR—substrate complexes.  In order to achieve this, we performed a triplicate 
MD run for the PR-RT and TF-PR complexes, since these two substrates gave a reversed order for 
the theoretical activation energies, compared to the experimental results.  We employed a random 
seed to create a new starting MD simulation with different atomic velocities, creating a new 
starting MD run with different atomic coordinates as well as different atomic velocities and 
changing the simulation box.1  This was followed by a ONIOM (QM/MM) geometry optimization 
on the three different starting structures from the MD calculation (Table S1).  The optimized 
ONIOM (QM/MM) TS structures for PR-RT and TF-PR enzyme—substrate complexes taken 
from the triplicate MD runs as well as the lowest substrate conformation taken from the restrained 
MD (described earlier) exhibit a similar geometry overall.  Note that the standard deviation for 
both substrates PR-RT and TF-PR were as high as 1.0 and 0.7 kcal mol-1 respectively.  The 
differences in distances are small (Figure S2) with an average RMSD of 0.82 Å, this suggests that 
3
the reversed orders for the activation energies is not a result of different poses for the starting 
structures.  It also gives assurance that the method to create starting structures produces consistent 
minimum conformations for the substrates.  
Table S1. The relative thermodynamics of the three ONIOM (QM/MM) optimized MD run of PR-RT and 
TF-PR enzyme—substrate complexes as well as the lowest conformation using ONIOM [B3LYP/6-
31++G(d,p)]. 
HIV-1 PR B—PR-RT ΔG‡ Average value Standard deviation
1. ONIOM after lowest conformation 14.5
2. ONIOM after random seed in MD 14.5
3. ONIOM after creating a different 
atomic coordinates and velocities in 
MD
15.7
15.3 1.0
4. ONIOM after changing the size of 
simulation box in MD
16.6
HIV-1 PR B—TF-PR
1. ONIOM after lowest conformation 16.5
2. ONIOM after random seed in MD 16.6
3. ONIOM after creating a different 
atomic coordinates and velocities in 
MD
17.5 17.1 0.7
4. ONIOM after changing the size of 
simulation box in MD
17.9
Values are reported in kcal mol-1, ΔG‡ =Activation free energy
The ONIOM calculation after changing the size of the simulation box1, 2 from 10 to 12 Å should 
not have a drastic effect on the interaction between the natural substrate and the active sites.  As 
mentioned earlier the average RMSD is less than 1 Å which shows good pose for the natural 
substrate.3, 4  
4
Figure S2. Superimposed PR-RT natural substrate (average RMSD of 0.82 Å) taken from triplicate MD 
runs showing movement and flexibility at the subtype B HIV-1 PR active site. 
However, the structural characteristic of the complexes may have been altered as a result of the 
increase in the water residues resulting from the change in the simulation box.5  Therefore, a virtual 
inspection and analysis was performed for the PR-RT and TF-PR for cases 1 and 4 (Table S1) 
using LigPlot6 (see Figure S3a and S3b).  As can be seen more hydrogen bond intermolecular 
interactions was observed for case 1 (Table S1), while case 4, after changing the size of simulation 
box in MD complex shows fewer hydrogen bond intermolecular interactions between the substrate 
and active sites.  This explains why case 1 has a much lower activation energy compared to case 
4 for both natural substrates Figure S3a and S3b.
5
Figure S3a.  Hydrogen bond interactions plot of HIV subtype B PR complexed with PR-RT natural 
substrate. These plots were created after ONIOM optimization of the lowest conformation (case 1) using 
Ligplot6.
6
Figure S3b.  Hydrogen bond interactions plot of HIV subtype B PR complexed with PR-RT natural 
substrate. These plots were created after ONIOM optimization of the changed simulation box to 12 Å 
using Ligplot6. 
Appendix: The 3D structures of all the enzyme—substrate complexes considered.
3D structures of the enzyme substrate complexes.zip
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Abstract 
The HIV-1 protease (HIV-1 PR) is an essential enzyme for the replication process of its virus 
and it is therefore considered an important target for the development of drugs against the 
acquired immunodeficiency syndrome (AIDs).  In this paper, the concerted acyclic hydrolysis 
reaction catalytic mechanism by subtype B/C-SA HIV-1 PR is explored by means of enhanced 
sampling technique using the umbrella method.  The free activation energy results were 
computed in terms of potential mean force (PMF) analysis within hybrid QM(DFTB)/MM 
approach.  The theoretical findings suggest that the proposed mechanism corresponds in 
principle with experimental data.  Given our observations, we suggest that the QM/MM MD 
method can be used as a reliable computational technique to rationalize lead compounds against 
specific targets such as the HIV-1 protease. 
Keywords 
HIV-1 subtypes B and C-SA PR; HIV-1 PR cleavage mechanism; Umbrella sampling method; 
Steered molecular dynamics (SMD); Natural substrates; Activation free energy; Concerted 
transition state.  
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1 Introduction 
In the quest for potential antiviral drugs for acquired immune deficiency syndrome (AIDs), the 
crystal structures of the active human immunodeficiency virus type 1 protease (HIV-1 PR) and 
its mutants have been investigated possibly more than any other protein structures.(Rick, 
Erickson, & Burt, 1998; Wlodawer & Erickson, 1993)  The HIV virus encodes an aspartic 
protease (Asp-PR) known as the HIV PR which is essential in the replication of the infectious 
virus that causes AIDs.(Kohl et al., 1988; Navia et al., 1989; Veronese, DeVico, Copeland, 
Oroszlan, Gallo, & Sarngadharan, 1985)  This enzyme catalyzes the cleavage of the viral Gag 
and Gag-Pol polypeptides, which are necessary for the final maturation process for the HIV life 
cycle.(Kohl et al., 1988; Navia et al., 1989; Veronese et al., 1985)  The inhibition of this process 
results in the production of immature, noninfectious viral particles.(Chatfield, Eurenius, & 
Brooks, 1998; Roberts et al., 1990; Weber, Cavanaugh, & Harrison, 1998; Wlodawer & 
Erickson, 1993)  Earlier experimental(Coates et al., 2006; Hyland, Tomaszek Jr, & Meek, 1991; 
Northrop, 2001; Rodriguez, Angeles, & Meek, 1993) and theoretical(Bjelic & Åqvist, 2006; 
Park, Suh, & Lee, 2000; Piana, Bucher, Carloni, & Rothlisberger, 2004; Piana, Carloni, & 
Parrinello, 2002; A. M. Silva, Cachau, Sham, & Erickson, 1996; Trylska, Grochowski, & 
McCammon, 2004) studies of the HIV-1 PR have found that transition state (TS) analogues of 
this enzyme-catalyzed reaction act as good inhibitors.  Nevertheless, over the past decades there 
is yet no consensus on the mechanistic pathway for the HIV-1 PR cleavage reaction.  The 
structure of the catalytic aspartate dyad as well as its protonation is ultimately linked to the 
uncertainty of the HIV-1 PR mechanism and both are still a source of many scientific 
discussions.(Krzemińska, Moliner, & Świderek, 2016; Lawal, Sanusi, Govender, Maguire, 
Honarparvar, & Kruger, 2019)  However, the reaction mechanism has been classified into two 
major groups; the nucleophilic(Hsu, Delbaere, James, & Hofmann, 1977; Stanton, Hartsough, & 
Merz Jr, 1993) and the general acid-general base (GA-GB)(Antonov, Ginodman, Kapitannikov, 
Barshevskaya, Gurova, & Rumsh, 1978; Jaskolski et al., 1991; Lapatto et al., 1989; Park et al., 
2000; Trylska et al., 2004) process, with the latter being the most upheld mechanism for aspartic 
proteases, especially for HIV-1 PR (Scheme 2).(Antonov et al., 1978; Fruton, 1976; Hyland et 
al., 1991)  These proposed mechanisms have been elaborated in our reported work.(Lawal et al., 
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2019; Lawal et al., 2018; Z. K. Sanusi, Lawal, Govender, Maguire, Honarparvar, & Kruger, 
2019)  
Generally, in the nucleophilic mechanism, the protonated catalytic aspartate act as the 
nucleophile(Weber et al., 1998) which attacks the carbonyl atom of the scissile peptide (C—N) 
bond yielding either an anhydride intermediate (stepwise nucleophile reaction, Scheme 1a) or a 
transition state that leads to the product (concerted nucleophilic reaction, Scheme 1b).(Boross, 
Bagossi, Copeland, Oroszlan, Louis, & Tözsér, 1999; Hsu et al., 1977)  The general acid-base 
mechanism (Scheme 2) involves a catalytic water acting as the nucleophile, which attacks the 
carbonyl atom of the scissile peptide (C—N) at the active site of the Asp-PR.(Krzemińska et al., 
2016; Park et al., 2000)  The reaction mechanism proceeds with the nitrogen atom of the scissile 
unit that accepts a hydrogen from the protonated Asp and the catalytic water is ionized by 
donating its proton to the unprotonated Asp, this phase of the mechanism can either be a step-
wise (Scheme 2a) or a concerted process (Scheme 2b).(Lawal et al., 2019; Trylska, Bała, Geller, 
& Grochowski, 2002; Trylska et al., 2004)  
 
In 1991, Jaskólski et al(Jaskolski et al., 1991) put forward an experimentally backed perspective 
on the hydrolytic mechanism of HIV-1 PR and a substrate.  They proposed a concerted catalytic 
model in which the nucleophilic water and the electrophilic aspartate (an acidic proton) attack 
the scissile bond in a synchronous manner.  The reaction started with the acidic proton at the 
OD2 aspartate proximal to the N atom of the approaching scissile unit. The post-reaction 
catalytic aspartates are still bound by the acidic proton, which now resides between the inner 
OD1 atoms.(Jaskolski et al., 1991)  Based on our understanding, we have summarized this 
experimental process in Scheme 2b. 
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Scheme 1. Proposed (a) stepwise and (b) concerted general acid-base reaction mechanism for HIV-1 
PR—substrate system, redrawn from literature.(Lawal et al., 2019) Structures along the pathway of the 
stepwise are indicated as follows: (1) enzyme—substrate complex; (2) water attack TS; (3) tetrahedral 
gem-diol intermediate; (4) scissile N-protonation TS; (5) protonated amide intermediate; and (6) cleavage 
of scissile C-N bond TS leading to separated product complex.  
With regards to the concerted cleavage mechanism of HIV-1 PR two theoretical investigations 
have reported transition states with activation free energies of 30(Park et al., 2000) and 
43.5(Krzemińska et al., 2016) kcal mol-1. However, these are higher values in comparison to 
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similar experimental data found in literature. (Boross et al., 1999; Hyland et al., 1991; Kipp, 
Silva, & Schramm, 2011; Rodriguez, Debouck, Deckman, Abu-Soud, Raushel, & Meek, 1993; 
Tözsér, Bagossi, Weber, Copeland, & Oroszlan, 1996)  The feasibility of the concerted general 
acid-base model which involves a 6-membered ring TS with either one or two water molecule(s), 
and an acyclic TS involving one water molecule was reported in our previous ONIOM based 
study.(Lawal et al., 2018)  It was observed that the concerted acyclic reaction mechanism 
(Scheme 3) of HIV-1 PR gave an optimal basis for substrate cleavage,(Lawal et al., 2018) 
likewise, a longer peptide sequence was necessary for favorable recognition.(Z. K. Sanusi et al., 
2019)  The calculated activation free energy values from these studies(Z. K. Sanusi et al., 2020; 
Lawal et al., 2018; Z. K. Sanusi et al., 2019) were found to be within the experimental range. 
 
Scheme 2. Proposed concerted acyclic general acid-base reaction mechanism for HIV-1 PR—substrate 
system.  The main difference between Scheme 2b and our proposed TS is that the acidic Asp became 
basic while the de-protonated Asp becomes acidic. 
Studies of the HIV-1 PR structures show conformational variances in the apo enzyme and a 
variety of substrate/ligand-bound enzymes,(Rick et al., 1998; Schulz, 1991) hence the energy 
difference between the different conformational states is an important factor.  Umbrella 
sampling,(G. Torrie & Valleau, 1977; G. M. Torrie & Valleau, 1974) an enhanced sampling 
technique has been applied to study reaction rates from free-energy barriers by establishing an 
appropriate reaction pathway.(Rick et al., 1998)  Once the path is known the potential mean 
force (PMF)(Hazel & Gumbart, 2017) can be determined through a series of windows and are 
finally combined with either umbrella integration(Kästner & Thiel, 2005) or the weighted 
histogram analysis method (WHAM).(S. Kumar, Rosenberg, Bouzida, Swendsen, & Kollman, 
1992; Souaille & Roux, 2001) 
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The application of the hybrid quantum mechanics/molecular mechanics (QM/MM) combined 
with molecular dynamics (MD) simulations has been used to study the catalytic mechanism of 
enzyme—substrate and enzyme—intermediate complexes of the HIV-1 PR(Krzemińska et al., 
2016) and other related biological systems.(Di Martino, Masetti, Cavalli, & Recanatini, 2014; Di 
Palma, Bottaro, & Bussi, 2015; J. R. A. Silva et al., 2015; J. R. r. A. Silva, Roitberg, & Alves, 
2014; Tsukamoto, Sakae, Itoh, Suzuki, & Okamoto, 2018; Yildirim, Park, Disney, & Schatz, 
2013)  This method provides improved sampling in atomistic simulations by biasing potentials 
(one or more dimensional) along a reaction coordinate to drive a system from one 
thermodynamic state to another (reactant to transition state or product).(Kästner, 2011; Rick et 
al., 1998) 
Similarly, the protonation state of the catalytic aspartate (25/25ʹ) has been extensively 
studied,(Meek et al., 1989; Northrop, 2001; Piana & Carloni, 2000; Piana, Sebastiani, Carloni, & 
Parrinello, 2001; Smith, Brereton, Chai, & Kent, 1996) in fact, all ten possibilities (mono-
protonation at different O2 of the Asp, di-protonation, un-protonated, low barrier hydrogen) have 
been considered in the past.(Lawal et al., 2019)  Nevertheless, the choice of protonation herein 
was influenced by Meek et al(Hyland et al., 1991; McGee, Edwards, & Roitberg, 2014) who 
demonstrated that the pKa of one of the catalytic Asp increases to 5.2, while the other is 3.1 
when bound to a substrate/inhibitor.  This suggests that the catalytic aspartate group at the active 
site is mono-protonated.(Adachi et al., 2009; Wang et al., 1996) 
The HIV-1 PR hydrolysis of the Gag and Gag-Pol polypeptide involves the cleavage and 
formation of chemical bonds,(Park et al., 2000) and the catalytic process in this study follows a 
concerted general acid-base mechanism with a mono-protonation of the catalytic aspartate at the 
active site.(Z. K. Sanusi et al., 2020; Z. Sanusi et al., 2017; Z. K. Sanusi et al., 2018; Z. K. 
Sanusi et al., 2019)  Herein, a concerted acyclic TS reaction mechanism of the HIV-1 PR—
substrate involving one water molecule as well as a longer natural substrate sequence (P5-P5ʹ) 
from our previous ONIOM report was employed,(Z. K. Sanusi et al., 2020; Lawal et al., 2018; Z. 
K. Sanusi et al., 2019)  the present work is aimed at providing more information of the 
mechanistic landscape of the HIV-1 PR system.    Both the catalytic Asp (25/25ʹ) as well as a 
water molecule are involved in the reaction mechanism, where the protonated Asp becomes basic 
by losing its proton and the unprotonated Asp gains a proton and becomes acidic.   
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We applied hybrid QM/MM MD simulations and umbrella sampling approaches to study the 
details of the concerted acyclic catalytic mechanism of the HIV-1 PR.  In the QM/MM 
methodology, a part of the system (active site and the natural substrate) is described by quantum 
mechanics while the remaining part (the whole system) is described by classical mechanics.  The 
SCC-DFTB(Elstner et al., 1998) method is used to describe the QM region of the system, this 
method has not only demonstrated an accurate level of theory for describing the energetics of 
chemical reactions,(Woodcock, Hodošček, & Brooks, 2007) but also established for large 
biological systems yielding minimum energy path results in good agreement with high level of 
theory such as MP2.(Barnett & Naidoo, 2010)  To ensure that the calculation is not an artefact of 
a single enzyme—substrate system, two PRs, HIV-1 subtype B complexed with a natural 
substrate (NC-p1) is set as the standard/control and subtype C-South Africa (C-SA) HIV-1 PR 
complexed with three natural substrates Matrix-capsid (MA-CA), nucleopsid-p1 (NC-p1) and 
protease-reverse transcriptase (PR-RT) were used.  Since the active enzyme as well as its 
mutants recognizes and cleaves the same polypeptide precursors, this study was aimed at 
exploring the proposed mechanism of proteolysis catalyzed by HIV-1 PR via QM/MM umbrella 
sampling technique using an adequate reaction coordinate.  Figure 1 demonstrates the structure 
of the HIV-1 PR, showing graphical details of the catalytic Asp (25/25ʹ) at the active site and a 
natural substrate.  The recognition sequences cleaved by the HIV-1 PR is provided in Table S1 
of the supporting information (SI).  
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Figure 1. Graphical structure of the HIV-1 PR, showing the direction of the hydrogen at the catalytic active site, which 
includes the aspartates and peptide substrate. The circled-out part is the area of the system treated at QM (DFTB) level of 
theory, while the rest of the system is treated at the MM level of theory. All histogram and free-energy plots are provided 
in the supporting information (SI). The ES, TSs and PC structures are also provided in PDB format and these are listed in 
the table of content in the SI. 
2 Computational methods 
2.1 Structure preparation of the HIV-1 natural substrate complexes 
The initial X-ray coordinates of the subtypes B and C-SA HIV-1 PR were obtained from the 
Protein Data Bank (PDB code: 2P3B(Kempf et al., 1990) and 3U71(Naicker et al., 2013) 
respectively) which contain a bound inhibitor fragment.  These bound-inhibitors were exchanged 
for three of the HIV-1 natural substrates (MA-CA, PR-RT and NC-p1) derived also from PDB 
bank code: 1KJ4,(Prabu-Jeyabalan, Nalivaika, & Schiffer, 2002) 3OU3,(Z. Liu, Wang, 
Brunzelle, Kovari, & Kovari, 2011) 1TSU(Prabu-Jeyabalan, Nalivaika, King, & Schiffer, 2004) 
(Table S1) respectively.  The contribution of water is an important aspect for the HIV-1 PR 
proteolysis, therefore, a catalytic water molecule close to the active binding site of HIV-1 PR 
was taken from PDB code:1LV1.(M. Kumar et al., 2002)  Our model complexes used in this 
study were obtained by overlaying the crystal structures of both subtypes B and C-SA HIV-1 PR 
with the natural substrates and catalytic water using the same superimposition method explained 
in our previous papers.(Z. Sanusi et al., 2017; Z. K. Sanusi et al., 2018)  The root mean square 
(RMS) values of the enzyme—substrate systems after superimposition is at the range of 1.2-1.5 
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Å, this was measured using PyMOL,(DeLano, 2002) which is helpful in evaluating how well the 
substrates are overlaid in the complex systems.  An optimal superimposition is considered 
satisfactory if the RMS is less than 2 Å,(Cole, Murray, Nissink, Taylor, & Taylor, 2005; Gohlke, 
Hendlich, & Klebe, 2000; Kontoyianni, McClellan, & Sokol, 2004) hence the natural substrates 
considered maintain the same position at the active binding sites of the subtype B/C-SA HIV-1 
PR as the substituted inhibitors.  The structures of the entire enzyme—substrate systems are 
refined by removing any present ions and crystallographic waters from the complexes except for 
the catalytic water at the active site.  These enzyme—substrate (ES) models serve as a starting 
structure for all calculations carried out in this study.   
A major area of debate in modelling the HIV PR is the protonation state of the catalytic Asp 
(25/25ʹ) at the active binding site and this has been discussed at length in literature.(Garrec, 
Sautet, & Fleurat-Lessard, 2011; Kontoyianni et al., 2004; Sussman, Villaverde, L Dominguez, 
& Danielson, 2013)  An accurate assignment of the protonation states for the catalytic aspartates 
and other residues at pH 7 was performed using the empirical propKa(Li, Robertson, & Jensen, 
2005)  server by recalculating the standard pKa values of titratable amino acids.  A mono-
protonation model of the catalytic aspartate at the binding site was adopted and this approach is 
braced by the majority of related studies.(Jaskolski et al., 1991; Krzemińska et al., 2016; H. Liu, 
Müller-Plathe, & van Gunsteren, 1996; Park et al., 2000; Piana & Carloni, 2000)  To prepare the 
enzyme—substrate complexes for MD simulations and the free energy calculations, the proton 
(H+) of the protonated Asp in the ES system complexes is positioned midway to facilitate its 
donation to the nitrogen atom of the scissile peptide bond.  This position has been measured to be 
energetically stable via MD simulations.(Fakhar, Govender, Lamichhane, Maguire, Kruger, & 
Honarparvar, 2017) 
The charge of the natural substrate was determined using the restrained electrostatic potential 
(RESP) method by applying the HF/6-31G* level of theory using the Gaussian16 
package.(Frisch et al.)  Subsequently, missing atoms were added to the system complexes using 
the Leap module as implemented in AMBER 18 molecular dynamics package.(Case et al.)  All 
the enzyme—substrate systems considered were solvated in an octahedral box of 
TIP3P(Jorgensen, Chandrasekhar, Madura, Impey, & Klein, 1983) water molecules, extending 
12 Å outside the protein on all sides.  Chlorine ions (Cl-) were positioned around the protein to 
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make sure the system is neutralized, the protein and natural substrate were described using the 
AMBER force field 99SB.(Hornak, Abel, Okur, Strockbine, Roitberg, & Simmerling, 2006)  The 
ES system complexes were initially energy-minimized by performing minimization at 5000 steps 
(of each steepest descent and conjugate gradient method) with a 20 kcal mol-1.Å-2 restraint 
applied to only the backbone of the protein and natural substrate peptide residues.  The system is 
then gradually heated from 100 to 300 K using the Langevin thermostat(Pastor, Brooks, & 
Szabo, 1988) at a constant volume, with a restraint of 10 kcal mol-1.Å-2, over 1000 ps, and 
followed with 5 kcal mol-1.Å-2 restraints on the backbone atoms.  This system is followed by 
1000 ps of constant pressure equilibration at 300 K with 2 kcal mol-1.Å-2 restraints.  All 
minimizations, heating and equilibration simulation steps utilized a nonbonded cutoff of 8 Å.  
The long-range Coulomb forces was calculated by using the particle mesh Ewald (PME) method, 
the time step was set to 2 fs and the SHAKE algorithm(Ryckaert, Ciccotti, & Berendsen, 1977) 
was used to restrain the backbone of the protein and natural substrate peptide residues during the 
MD simulations. 
2.2 Umbrella sampling and free energy calculations   
For the hybrid QM/MM MD calculations, the system was optimized where the catalytic Asp 
25/25ʹ, one water molecule at the active site and two amino acid residues of the peptide at the 
scissile bond were selected as the QM region that contains 62 atoms for the ES complexes, 
except MA-CA (63 atoms).  The QM region is described using the self-consistent charge density 
functional tight binding (SCC-DFTB) Hamiltonian,(Seabra, Walker, Elstner, Case, & Roitberg, 
2007) as implemented in AMBER18.(Case et al.)  To satisfy the valence of the QM/MM 
boundary atoms, link atoms were placed in the substrate peptide and the catalytic aspartates’ 
residues (Figure 1).  The rest of the system (protein and water molecules) are described using the 
AMBER ff99SB(Hornak et al., 2006) and TIP3P(Jorgensen et al., 1983) force fields 
respectively, as mentioned earlier.   
The free energy profile for the reaction mechanism catalyzed by HIV-1 PR (subtypes B/C-SA) 
was first evaluated with steered molecular dynamics (SMD) (Jarzynski, 1997a, 1997b) to drive 
the reaction process to completion and sample the reaction path, after which the QM/MM MD 
umbrella enhanced sampling was performed.  The SMD method is very similar to the umbrella 
sampling in which the restraint center is time-dependent, and by integrating the force over 
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distance or time, a generalized simulation can be performed.(Case et al., 2018)  In order to set up 
this feature for the SMD method, the NMR-specific options (nmropt=1) in the umbrella run is 
replaced with jar=1, which are used for generating the distance restraints based on the reference 
coordinates in both instances.  The reaction coordinate (RC) for the acylation step that was 
chosen came from our previous study,(Z. K. Sanusi et al., 2020; Lawal et al., 2018; Z. K. Sanusi 
et al., 2019) having observed a lower energy barrier in the concerted acyclic TS reaction 
mechanism involving one water molecule. The RC involves the breaking of the C-N and Oasp-
Hasp bonds, and the formation of HOwat-C and N-Hasp bonds, hence, the acyclic TS step is 
defined as; RC = d(C-N) + d(Oasp-Hasp) – d(HOwat-C) – d(N-Hasp) (see Figure 2, scheme 3).   
The simulation was started by performing SMD calculation from the initial state (RC=-4.00 Å) 
to the final state (RC=+4.00 Å) for 50 ps.  The initial configuration was generated for each 
window by fetching the structure every 0.75 ps.  Later, we perform an umbrella sampling of 100 
ps in steps of 0.12 Å on each window from the structure generated with the SMD simulation.  
The outputs of each MD in the sampled umbrella window serves as the initial/starting structure 
to perform the next one for which the value of the RC is restrained to the next position.  All the 
QM/MM MD simulations were carried out restraining the reaction coordinate distance at a 100 
kcal mol-1.Å-2 force constant of harmonic potential.  The free energy curve was obtained by 
unbiasing the system along the reaction coordinate through variation free energy profile (vFEP) 
developed by Lee et al.(Lee, Radak, Huang, Wong, & York, 2013; Lee, Radak, Pabis, & York, 
2012)  
3 Results and discussion 
3.1 The concerted acyclic general acid-base catalytic mechanism of HIV-1 PR 
Recent computational research(Z. K. Sanusi et al., 2020; Lawal et al., 2019; Lawal et al., 2018; 
Z. K. Sanusi et al., 2019) from our group has buttressed the feasibility of the earlier 
suggested(Jaskolski et al., 1991) existence of the concerted process (Scheme 2b).  Based on our 
previous theoretical investigations,(Z. K. Sanusi et al., 2020; Lawal et al., 2018; Z. K. Sanusi et 
al., 2019) we have applied umbrella sampling algorithm to explore the proposed concerted 
process (Scheme 3).  The outcome of which follows the general acid-base model in a 
synchronous mechanism in which water donates one of its protons to the unprotonated Asp25 
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and the protonated Asp25 loses its proton to the scissile nitrogen atom; thus, the initial acidic 
Asp becomes basic and vice versa. Meanwhile, the nucleophilic water (OH) attacks the scissile 
carbon resulting in substrate cleavage (Scheme 3).  In the concerted acylation mechanism 
(Scheme 3, Figure 2), generally, three major types of conformational state occurred.  One is the 
formation of the HOwat-C bond, the d(HOwat-C) decreases considerably from 3.40 Å in ES to 
2.61 Å in TS, and then to 1.30 Å in product complex (PC).  This indicates the possibility of the 
nucleophilic attack of the OH group of water to the carbonyl carbon (C) of the peptide at the 
scissile bond. 
 
Figure 2. Proposed concerted acyclic general acid-base reaction mechanism for HIV-1 PR—substrate system. Showing the 
distances in the chosen reaction coordinates, from the ES to TS and product complex for one of the enzymes—substrate complex. 
Values are reported in Å. 
Another important conformational change is the cleavage of the C-N bond, the d(C-N) increases 
from 1.38 Å in ES to 1.50 Å in transition state model, and then to 2.83 Å in PC, which indicates 
the breaking of the natural substrate’s peptide bond.  The last event is the proton transfer from 
the protonated aspartate (Hasp) to the nitrogen atom (N) of the substrate at the scissile bond, the 
d(N-Hasp) and d(Oasp-Hasp) respectively changes from 3.02 and 1.03 Å in ES to 1.30 and 1.48 Å 
in TS, and then to 1.07 and 2.22 Å in PC.  The measured distances are summarized in Table 1, 
S2, S3, and S4 for all the enzyme—substrate complexes considered.  
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Table 1. Averaged distances for ES, TS and PC structures for the 
concerted mechanism obtained by DFTB/MM 1D-PMF (Umbrella 
sampling) for subtype C-SA—MA-CA complex. 
DFTB/MM ES TS PC 
d(HOwat-C) 3.40 2.61 1.30 
d(C-N) 1.38 1.50 2.83 
d(N-Hasp) 3.02 1.30 1.07 
d(Oasp-Hasp) 1.03 1.48 2.22 
Values are reported in Å. Provided in the supplementary information is the table 
for the average distances for ES, TS and PC of the remaining considered 
complexes. All histogram and free-energy plots are provided in the supporting 
information (SI). The ES, TSs and PC structures are also provided in PDB format 
and these are listed in the table of content in the SI. 
The plausibility of this mechanistic process was evaluated by calculating the activation free 
energy (ΔG‡) value associated with each transition state (TS) structure (Table 2) of the respective 
complex systems.  It was noticed that the ΔG‡ obtained from the umbrella sampling approach are 
between 14.2 and 24.7 kcal mol-1.  The calculated values follow the same trend as experimental 
results(Fehér et al., 2002; Lawal et al., 2019; Maschera et al., 1996) and previously calculated 
values(Z. K. Sanusi et al., 2020) in which an ONIOM approach was used.  The overall reaction 
process (Figures 3a and 4a) is exergonic with negative free energy values for the product 
complexes (PC). 
Table 1. Free energy value of the concerted acyclic general acid-base cleavage mechanism 
of natural substrate by HIV-1 PR (subtypes B and C-SA) using QM(DFTB)/MM MD 
(Umbrella sampling) 
 B—NC-p1 C-SA—MA-CA C-SA—NC-p1 C-SA—PR-RT 
ΔG‡ 18.3 14.2 24.7 15.5 
PC -8.0 -18.0 -4.6 -2.5 
ΔGo‡ 19.7 13.5 22.6 16.4 
ΔGe‡ 18.7 15.7 18.7 15.8 
Values are reported in kilocalories per mole (kcal mol-1).  
ΔG‡ = calculated activation free energy (Umbrella sampling), PC product complex, ΔGo‡ = calculated 
activation free energy from previous paper using ONIOM approach,(Z. K. Sanusi et al., 2020) ΔGe‡ = 
experimental activation free energy from literature for subtype B HIV-1 PR.(Fehér et al., 2002; Lawal et al., 2019; 
Maschera et al., 1996)  All histogram and free-energy plots are provided in the supporting information (SI). The 
ES, TSs and PC structures are also provided in PDB format and these are listed in the table of content in 
the SI. 
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3.2 Free energy analysis 
It should be noted that since the active enzyme cleaves the same scissile precursor as its mutant, 
the computed results (Table 2) were compared with respect to the activation free energies of the 
HIV-1 PR found in literature.(Fehér et al., 2002; Lawal et al., 2019; Maschera et al., 1996)   For the subtype B—NC-
p1 system, ΔG‡ of 18.3 kcal mol-1 was obtained for the cleavage of the scissile bond Phe*Asn 
(Table 2, Figure 3b), which is -0.4 kcal mol-1 lower than experimental HIV-1 PR hydrolysis data 
of the same substrate.(Fehér et al., 2002; Lawal et al., 2019; Maschera et al., 1996)   
However, the subtype C-SA—NC-p1 system gave a higher value of 24.7 kcal mol-1, 
approximately 6 and 2.1 kcal mol-1 greater than experimental (subtype B HIV-1 PR) and 
previously calculated data(Z. K. Sanusi et al., 2020) respectively.  This could be as a result of the 
eight-point mutation that occurs in the subtype C-SA HIV-1 PR.   Likewise, NC-p1 natural 
substrate has been suggested to have the slowest mechanistic process as well as being the rate-
limiting cleavage step in the maturation of Gag.(Prabu-Jeyabalan, Nalivaika, Romano, & 
Schiffer, 2006)  It is noticeable from all components in Table 2 that this system (C-SA—NC-p1) 
produced the highest ΔG‡ values for both calculated theoretical methods.  Hence, it could be that 
our calculated result is accurate but needs experimental verification for HIV-1 subtype C-SA PR.  
From the analysis of the calculated ΔG‡ obtained through enhanced sampling approach herein, it 
is tenable to say that the calculated values are comparable with experimental results and the 
theoretical method describes the proposed concerted mechanism reasonably.    
134 
 
 
 
 
Figure 3. (a) Free energy profile for the concerted acyclic mechanism of subtype B HIV-1 PR with NC-p1 natural substrate. (b) 
3D structures of enzyme—substrate (ES), transition state (TS), and product complex (PC) for the acyclic mechanistic process 
taken from trajectories. All histogram and free-energy plots are provided in the supporting information (SI). The ES, TSs and PC 
structures are also provided in PDB format and these are listed in the table of content in the SI. 
The product complexes gave free energy values within -18 to -2.5 kcal mol-1 (Table 2), thus 
indicating that the entire mechanism is energetically favorable.  Provided in Figure 3a is the free 
energy pathway involving subtype B catalysis of NC-p1 indicating the scanned reaction 
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coordinates for the acyclic TS model.  The zoomed in structural details of the reaction center is 
provided in Figure 3b.  The free energy profile for the concerted acyclic mechanism of subtype 
C-SA HIV-1 PR cleavage of MA-CA natural substrate is also provided in Figure 4a with the 3D 
moieties along its reaction path in Figure 4b.  
 
 
Figure 4. (a) Free energy profile for the concerted acyclic mechanism of subtype C-SA HIV-1 PR with MA-CA natural substrate. 
(b) 3D enzyme—substrate (ES), transition state (TS), and product complex (PC) for the acyclic mechanistic process taken from 
trajectories. All histogram and free-energy plots are provided in the supporting information (SI). The ES, TSs and PC structures 
are also provided in PDB format and these are listed in the table of content in the SI. 
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4 Conclusion 
The enzymatic mechanism catalyzed by HIV-1 PR in the presence of its natural substrate is the 
focus of this study, and this is described by means of enhanced umbrella sampling calculations 
using a hybrid DFTB/MM level of theory.  We envisaged that the QM/MM MD method would 
provide detailed information on the proposed concerted mechanism and based on the results 
obtained we were able to compute a complete profile of the possible reaction pathway that 
corresponds to the concerted acylation mechanism.  The reaction process starts with a 
nucleophilic attack from the catalytic water on the carbonyl atom of the scissile bond, which is 
synchronously followed by a proton transfer from the protonated catalytic Asp25 to the nitrogen 
atom of the scissile bond.  The cleavage of the peptide bond as a result of the nucleophilic attack 
from the water and hydrogen transfer from the water molecule to the unprotonated aspartate also 
occurs concurrently.  The present investigation provides a single rate-limiting step with 
computed free energy barrier of 14.2, 24.7 (18.3 for subtype B—NC-p1) and 15.5 kcal mol-1 for 
the cleavage of MA-CA, NC-p1 and PR-RT by subtype C-SA, respectively.  These calculated 
energies correspond well with the experimental data for the above natural substrates catalyzed by 
HIV-1 protease.  Since these calculations require moderately high computational cost (long MD 
simulations), we were restricted to performing a 1-dimensional calculation, however, the 
accuracy of the results (in comparison with experimental results) is reasonable.  From our work 
the QM/MM MD umbrella sampling is a viable method for calculating accurate results.  The 
approach requires fewer parameters, convergence is easy to achieve with minimal or no error and 
the reaction pathway can be easily determined.  However, the system set-up, appropriate choice 
of the RC along which the simulation is biased and can be difficult to ascertain.  While the 
ONIOM calculation in principle has a straightforward calculation setup, the number of input 
parameters and errors makes achieving convergence more difficult and time consuming.  
Nevertheless, both theoretical techniques have proved to give results that are comparable to 
experimental data.  
Most HIV-1 PR inhibitors are developed to resemble the molecular structure that occur during 
the chemical process, particularly the transition state model.  We believe electronic modification 
of the amide bond is possible (for example via N-methylation)(Rauf et al., 2015) and the 
QM/MM MD umbrella sampling technique will be useful to determine if the activation energy 
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for hydrolysis increases.  If the activation energy of the “scissile” bond of a natural peptide can 
be sufficiently increased, it may potentially be used as substrate-based inhibitors (with limited 
toxicity and side effects) for HIV-1 PR and other enzymes. 
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The HIV-1 PR cleavage sites in the Gag and Gag-Pol polyproteins. 
Table S1. Recognition sequences for natural substrates cleaved by the HIV-1 protease.1, 2  
Peptide sequences cleavage domain Cleavage domain 
                  P5   P4   P3   P2   P1 * P1ʹ  P2ʹ  P3ʹ P4ʹ  P5ʹ  
145 
 
Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-Asn MA-CA 
Glu-Arg-Gln-Ala-Asn*Phe-Leu-Gly-Lys-Ile NC-p1 
Cys-Thr-Leu-Asn-Phe*Pro-Ile-Ser-Pro-Ile PR-RT 
The asterisk (*) denotes the scissile bond.  Matrix-capsid; MA-CA, NC-p1, trans frame peptide-protease; PR-RT, 
reverse transcriptase-RNAseH.  The P1, P2…P5 to P1ʹ, P2ʹ…P5ʹ represents the amino acid residues of the substrate 
and are counted from the cleavage point.  
 
The free energy plot for the concerted acyclic mechanism for all considered enzyme—substrate 
and 3D structures of reactant (RC), transition state (TS), and product complex (PC) for the 
acylation step of the HIV-1 PR enzyme.  
 
 
Subtype C—NC-p1 complex 
RC= d(C1-N1) + d(Oasp-Hasp) – d(HOwat-C1) – d(N1 -Hasp) (Å) 
 
(a) 
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Figure S1. (a) Free energy profile for the concerted acyclic mechanism of subtype C HIV-1 PR with NC-p1 natural substrate. (b) 3D 
structures of enzyme—substrate (ES), transition state (TS), and product complex (PC) for the acylation step of the HIV-1 PR enzyme 
taken from trajectories.  
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Subtype C—PR-RT complex 
RC= d(C1-N1) + d(Oasp-Hasp) – d(HOwat-C1) – d(N1 -Hasp) (Å) 
 
(a) 
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Figure S2. (a) Free energy profile for the one-step concerted acyclic mechanism of subtype C HIV-1 PR with PR-RT natural 
substrate. (b) 3D structures of enzyme—substrate (ES), transition state (TS), and product complex (PC) for the acylation step of the 
HIV-1 PR enzyme taken from trajectories.  
 
The averaged distances for reaction complex (RC), transition states (TSs) and product complex 
(PC) structures for the concerted mechanism is given below. 
 
Table S2. Averaged distances for RC, TS and PC structures for the 
concerted mechanism obtained by DFTB/MM 1D-PMF for subtype 
B—NC-p1complex 
DFTB/MM RC TS PC 
d(HOwat-C1) 2.81 2.06 1.31 
d(C1-N1) 1.36 1.75 3.09 
d(N1 -Hasp) 3.23 1.10 1.06 
d(Oasp-Hasp) 1.00 1.47 2.85 
Values are reported in Å. 
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Table S3. Averaged distances for RC, TS and PC structures for the  
concerted mechanism obtained by DFTB/MM 1D-PMF for subtype 
C—NC-p1 complex 
DFTB/MM RC TS PC 
d(HOwat-C1) 2.75 2.43 1.35 
d(C1-N1) 1.32 1.93 3.88 
d(N1 -Hasp) 3.20 1.10 1.03 
d(Oasp-Hasp) 1.02 1.48 2.34 
Values are reported in Å. 
 
 
Table S4. Averaged distances for RC, TS and PC structures for the  
concerted mechanism obtained by DFTB/MM 1D-PMF for subtype 
C—PR-RT complex 
DFTB/MM RC TS PC 
d(HOwat-C1) 2.98 2.20 1.42 
d(C1-N1) 1.42 1.62 3.28 
d(N1 -Hasp) 3.52 1.20 1.02 
d(Oasp-Hasp) 0.99 1.32 2.12 
Values are reported in Å. 
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CHAPTER EIGHT 
CONCLUSION 
The HIV-1 virus is among the most investigated infection globally, and the discovery of 
zidovudine in the 80s was the breakthrough that led to the development of many other antiretroviral 
drugs.  These antiretroviral drugs inhibit certain developmental phase/enzymes in the life circle of 
the human immune virus and have remained a well-known method of therapeutic treatment, as a 
result, HIV-1 PR is still a therapeutic target enzyme.  The mechanism of action of proteases on the 
cleavage of the natural polypeptides has been a focus of research for the past decades.  Despite 
important contributions on understanding the recognition and reaction mechanism of the HIV-1 
PR with respect to its natural substrates across the globe, some important gaps in knowledge are 
yet to be addressed by researchers.  
The introductory chapter focuses on the main topic which provides a background discourse 
necessary for the rest of the thesis.  The different theoretical techniques accessible, computational 
methods and tools used are highlighted in chapter two.  Presented in chapter three is a literature 
review on the recognition and hydrolysis of the natural substrate by HIV-1 PR.  The mechanism 
of hydrolysis of the natural substrates by the HIV-1 PR enzyme at the molecular level (using an 
enzyme—substrate system and a hybrid QM/MM method) was presented in chapter four.  Chapter 
five analyzed the recognition pattern of two asymmetric natural substrates in the scissile and non-
scissile bond by homodimeric subtypes B and C-SA HIV-1 PR using a hybrid QM/MM (ONIOM) 
method.  This study was then broadened (Chapter six) to understand the cleavage mechanism of 
all the nine asymmetric natural substrates by subtypes B and C-SA HIV-1 PR with the application 
of a hybrid QM/MM (ONIOM) technique.  Finally, umbrella sampling was employed to ascertain 
our proposed model in the recognition pattern and hydrolysis of the natural substrates by HIV-1 
PR in chapter seven.   
The HIV-1 PR reaction mechanism has frequently been studied as a stepwise and/or general acid-
base process rather than a concerted reaction.  However, debates such as the exact rate-limiting 
step seems to occur with the stepwise reaction process of HIV-1 PR—substrate.  Likewise, the 
protonation pattern of the catalytic aspartates at the active site which is responsible for the 
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hydrolytic cleavage of the natural substrates remains a topic of discussion and was addressed in 
the literature review (Chapter three). 
An identifiable gap from the literature review incited the design of a concerted six-membered 
general acid-base mechanism of HIV-1 PR—substrate model, which occurs through cyclic 
transition state (TS) as proposed from experiment.  Based on previous theoretically investigations 
for similar six-membered ring transition state structures, a concerted chemical process was studied 
with the aim of providing alternative insight into the catalytic mechanism of HIV-1 PR and 
inhibitor design through computational methods. It was observed that the mechanism that provides 
a marginally lower activation energy involves an acyclic TS model (Chapter four) with one water 
molecule at the HIV-1 PR active site.   
A follow up investigation using the proposed concerted acyclic TS modeling via a hybrid QM/MM 
ONIOM approach to account correctly for the scissile bond cleavage (recognition pattern) of the 
natural substrates by subtypes B and C-SA HIV-1 PRs was presented in chapter five.  It was 
observed that optimum recognition and specificity depends on the length of the amino acids 
sequence as well as the structural detail of the substrates.  Both subtypes B and C-SA HIV-1 PR 
recognize and cleave at the scissile and non-scissile bond of the natural substrate sequence with a 
lower activation free energy than the non-scissile region.  Subsequent investigation (Chapter six) 
was dedicated to a more broadened study of all the remaining natural substrates as described 
earlier, using a longer amino acid sequence (P5-P5ʹ).  It was observed that one of the natural 
substrates (NC-p1) has a characteristic slower rate of hydrolysis and is the rate-limiting cleavage 
step in the maturation of the Gag and Gag-pol substrate, this was observed in experimental work 
also.  It was concluded that our computational model also provides excellent results for 
biologically active mutants of HIV-1 PR in that it correctly recognizes and cleaves its natural 
substrate polypeptides. 
Umbrella sampling was explored by applying a QM/MM MD method to investigate and ascertain 
our proposed theoretical model for substrate recognition and reaction mechanism of mainly the C-
SA HIV-1 PR (Chapter seven).  The theoretical findings suggest that the proposed concerted 
acyclic TS modeling corresponds in principle with experimental data with lower activation 
energies.  This method complimented our previous mechanistic studies of the HIV-1 PR, 
presenting the overall free energy profile of the HIV-1 PR potential energy surface.  
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Studies on the HIV-1 PR are quite diverse and theoretical approaches have played a vital role in 
determining the recognition pattern and enzymatic mechanism of HIV-1 PR and its natural target.  
The present work is dedicated to the study of the entire HIV-1 PR system considered and its exact 
Gag and Gag-pol polypeptide sequence.  Tremendous improvement is expected in years to come 
through more advanced computer soft and hardware development, which would elucidate the 
general reaction pathway for the HIV-1 PR—substrate/ligand complex.  This computational 
technique can be utilized to rationalize lead compounds against specific target. The possibility of 
integrated computational algorithms which do not involve 
restraining/partitioning/constraining/cropped model system of enzyme—substrate (ES) 
mechanism would likely surface in future to perfectly model the HIV-1 PR catalytic process on 
natural substrates/inhibitors. 
 
 
 
 
